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ABSTRACT 
 
Paul Michael Himes: Studies toward Understanding the Biosynthesis of Sactipeptides and the 
Creation of Peptide Natural Product Libraries through mRNA Display 
 (Under the direction of Albert A. Bowers) 
 
 
Ribosomally-synthesized and post-translationally modified peptides (RiPPs) are a class 
of natural products that are an attractive starting point for new antibiotics due to their wide range 
of structural diversity and biological activities.  The post-translational modifications imparted 
upon the peptide substrate are carried out by promiscuous RiPP enzymes.  Sactipeptides are 
members of the RiPPs family that are made through radical-mediated cysteine sulfur to α-carbon 
coupling reactions. The resulting thioether linkages give rise to sactipeptides defined structures 
and concomitant biological activities. The research presented here focuses on the biochemical 
and structural characterization of CteB, a radical SAM enzyme that imparts a single sactionine 
bridge, the development of an E. coli heterologous expression system for sactipeptides and the 
combination of RiPPs and mRNA display for the production of modified peptide libraries. 
We have biochemically and structurally characterized CteB, a radical SAM enzyme that 
imparts a sactionine bridge on its corresponding peptide substrate.  A crystal structure was 
obtained at 2.04 Å and showed a RiPPs recognition element connected to a (β/α)6-TIM barrel 
fold, followed by an SPASM domain that houses two auxiliary [4Fe-4S] clusters, one of which 
contains a free coordination site for potential peptide ligation.  
We have developed an E. coli heterologous expression system for the production of 
sactipeptides based on subtilosin A from Bacillus subtilis 168.  In the system, both the peptide 
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substrate and radical SAM enzyme (AlbA) are expressed together and the modified sactipeptide 
is produced and isolated.  This system was used to probe the substrate promiscuity of AlbA, and 
determine what changes it can tolerate.  Additionally, an unnatural amino acid, O-Me-tyrosine, 
was able to be incorporated into the peptide substrate while also forming a thioether bridge at 
that position. 
We have also worked on combining the natural promiscuity of RiPPs enzymes with 
mRNA display to generate modified peptide libraries on a large scale (~5 x10
6
).  Using two 
previously described and characterized RiPPs systems, pantocin A and thiomuracin, we have 
used their respective RiPPs enzymes, PaaA and TbtF, to create RiPP peptide libraries to find 
elements important for binding and to further characterize the promiscuity of these modifying 
enzymes.  
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PREFACE 
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Chapter 2 represents a submitted journal article for which I was one or two co-first authors.  My 
contributions to the work focused on the cloning, expression, and reconstitution of activity of the 
sactionine synthase, CteB.  I also characterized all activity of the enzyme by mass spectrometry 
while performing bioinformatic analysis of the enzyme and related proteins.  These results are 
shown in Tables 2.1-2.2, Figures 2.2, and 2.5-2.6 and Appendix Figures A.1-A.3 and A.11-A.16.  
Dr. Tyler Grove performed all the crystallography on both the apo and peptide bound forms of 
CteB, structural comparisons to other known enzymes in the same class, as well as size exclusion 
chromatography.  These experiments are shown in Figures 2.3, 2.4, 2.8 and Appendix Table A.1, 
Figures A.4-A.10.  With the help of Dr. Bowers and Dr. Almo, the co-first authors designed 
experiments, communicated and divided the work, and then wrote the paper.  This work has been 
submitted as a full article to JACS and has been through two rounds of review and resubmission: 
Grove, T.L., Himes, P.M., Hwang, S., Yumerefendi, H., Bonanno, J.B., Kuhlman, B., Almo, 
S.C., Bowers, A.A.  Structural Insights into Thioether Bond Formation in the Biosynthesis of 
Sactipeptides. JACS, 2017, resubmission 
Dr. Tyler Grove and Dr. Steve Almo, co-first author on the paper and his PI respectively, have 
given permission for me to include this work in my dissertation. 
 Chapter 3 represents work done solely in the Bowers lab.  I am the lead author on the 
paper but other members of the Bowers lab helped me to complete it.  Dr. Scott Allen provided 
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helpful discussion, experimental design and mass spectrometry analysis.  Sungwon Hwang 
helped me clone the library of peptides into the system I had developed for the production of 
sactipeptides in E. coli.  The paper was published previous to the writing of this thesis with the 
following citation:  
Himes, P.M., Allen, S.E., Hwang, S., Bowers, A.A. Production of Sactipeptides in Escherichia 
coli: Probing the Substrate Promiscuity of Subtilosin A Biosynthesis.  ACS Chem Biol. 2016, 11, 
1737-1744  
Permission to include the article in its entirety in this dissertation was retained from ACS 
Publications.  Copyright (2016) American Chemical Society 
Chapter 4 represents unpublished research that was designed and preformed primarily by 
myself with help from Steven Fleming also of the Bowers lab. 
All copyrighted material included in this dissertation is used with permission from the 
relevant copyright holders. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 The Promiscuity of RiPPs Biosynthesis and the Potential for Natural Product Libraries 
Natural products, for more than a century, have advanced the understanding of biology 
and have been at the forefront of the development of novel medicines for the world’s most 
pressing diseases.
1
  From the discovery of penicillin and use of Chinese herbal medicine, to the 
use of more complicated molecules for the treatment of cancer, diabetes, parasitic and bacterial 
infections, natural products have been used as medication or the first step in the development of 
life-saving medicines.
2-6
 These natural products house privileged scaffolds that convey their 
unique activities but are very difficult to produce synthetically due to their large size and very 
specific combinations of stereochemistry found within the molecule.
7,8
  The natural products, 
however, come with their own drawbacks.  To harness the power of these natural products, the 
producer (bacteria, fungi, etc.) needs to be cultivated in specific conditions to facilitate the 
production of the natural product and in sufficient enough quantity.  This can be extremely 
difficult due to laboratory conditions not resembling the native environments of microbial 
communities and their constant fight for resources where the production of the natural product 
would give an advantage.
9
  Thus a method to produce enough fully formed, biologically active 
natural products is required to meet this pressing need.       
2 
 
Ribosomally-synthesized and post-translationally modified peptides (RiPPs) are a class 
of natural products defined by their unique biosynthetic pathways as well as their modifying 
enzymes (Figure 1.1).
1
  Unlike polyketide synthases (PKS) or non-ribosomal peptide synthases 
(NRPS), both of which use separate active module-like assembly to create their natural products, 
RiPPs use the ribosome to create the precursor peptide.
10,11
  This precursor peptide can house up 
to three domains, termed the leader, core, and follower peptides respectively.  The leader peptide 
is used by the RiPPs modifying enzymes to recognize the peptide substrate, while the core 
peptide is where the modifications are imparted by the enzyme.  The follower, if the peptide has 
one, can play the same role as the leader peptide in terms of recognition.  After the modifications 
are imparted, the leader and/or follower sequence is removed by a peptidase and the modified 
core is released to give the biologically active product.
1,12
  RiPPs modifying enzymes impart 
extensive post-translational/co-translational modifications that give these peptides structures that 
are not directly accessible by natural ribosomal synthesis or by the modular synthesis related to 
PKS or NRPS.  These modifications, which are typically conformationally constraining, allow a) 
better target recognition and higher binding affinity, b) metabolic and chemical stability, and c) a 
change in chemical functionality by altering the side chains of the canonical amino acids.
1
 Due to 
their structural diversity, wide range of biological activities, and conformational constraining 
structures, RiPPs are an attractive starting point for novel therapeutics for anti-cancer and 
antibiotic therapies. 
A member of the RiPPs family of natural products is a class of diverse modified peptides 
known as sactipeptides.  Sactipeptides are characterized by their unique thioether bridges that 
form intramolecular bridges between the sulfurs of cysteine residues and the unreactive α-carbon 
of a bridging residue amino acid.  This forms a new quaternary carbon because of the bridging 
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partner’s amino acid side chain. Therefore, sactipeptides tend to have highly defined regions of 
secondary structure due to the distribution and number of thioether or sactionine bridges as well 
as the stereochemistry at the α,α-disubstituted bridging partner residues.13-20  Subtilosin A, a 
founding member of sactipeptides, adopts a 310 helix within its structure while other sactipeptide 
can adopt α-helical structures. The amphipathic helicity of these regions within sactipeptides is 
thought to grant subtilosin A and others narrow spectrum activity through the ability to interact 
and disrupt bacterial cell walls resulting in cell death through membrane disruption 
16,21,22
  This 
activity, as well as their added stability to heat and proteases due to their thioether bridges, make 
sactipeptide an attractive biological scaffold for the development of novel therapeutics and 
chemical probes.  Previously in our lab, a system was developed to predict and estimate these 
highly defined secondary structures using analyses generated from replica exchange molecular 
dynamics (REMD) trajectories using AMBER 14 and various constraints and implicit solvent 
conditions.
23-25
 In REMD, multiple molecular dynamic simulations are run simultaneously at 
varying temperatures, and these temperatures are exchanged between replicas at set intervals 
over the course of the entire simulation. This exchange of temperatures can allow the simulation 
to overcome energy wells and barriers that cannot be overcome at lower temperatures.  After the 
simulation, the likelihood of each residue adopting a particular secondary structure over the 
course of the simulation will be identified by hydrogen bonding patterns and angles of that 
residue.  We did this simulation for subtilosin A and found it agreed well with the NMR structure 
reported by Vederas and co-workers in 2004 (Figure 1.2).
19
 Using these simulations, we found 
that continuous stereochemistry (all D or all L) is required to propagate helicity (either α or 310) 
through subtilosin A, an important finding due to subtilosin A switching stereochemistry in the 
thioether bridges (L, D, D).  We therefore hypothesize that this simulation tool for sactipeptides 
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can be used to help design and predict highly defined secondary structures that could be used as 
biologically active scaffolds for the grafting of known epitopes for desired function and 
biologically activity (i.e. inhibition, binding, cell-death, etc.) if it could be paired with a robust 
expression system. 
 
Figure 1.1. Overview of ribosomally synthesized and post-translationally modified peptides 
(RiPPs). 
 
 
Figure 1.2.  Sactipeptide secondary structure. a) Pictorial representation of fully modified and 
cyclized Subtilosin A. b)NMR structure showing the helix at the C-terminus.
19
 c) Secondary 
structure of each residue of Subtilosin A over the entire simulation. Para = parallel β-sheet; Anti 
= anti-parallel β-sheet; 3-10= 310 helix; alpha = α-helix; pi = π-helix; turn = some other 
hydrogen bonding pattern. 
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RiPPs machinery, including the radical SAM enzymes in sactipeptide biosynthesis, that 
impart the modifications necessary for biological activity have only recently been isolated and 
studied in a way that sheds light on how the RiPPs modifying enzyme recognizes and imparts the 
aforementioned modifications.  Through crystallography of these enzymes as well as mutational 
analysis (in vitro and in vivo), it has been determined there is a specialized recognition domain 
termed the RiPPs recognition element (RRE) that allows the RiPPs enzymes to recognize and 
coordinate to their intended peptide substrate.
26
  This RRE recognizes sequences at either the 
leader or follower sequence of the precursor peptide.  This gives RiPPs one of their most 
impressive abilities, their promiscuity within their own biosynthesis.  It has been shown that as 
long as the recognition element within the leader peptide is intact, the core peptide can be 
mutated and the RiPPs modifying enzymes can still impart their modification on this “new” core 
peptide.
27-32
 While not every change is allowed, this system houses much more flexibility in the 
identity of its substrates than most enzymes could tolerate.  This gives RiPPs the advantage of 
creating a wide range of distinct, yet similar peptides that can be tested and altered for specific 
activities or properties. 
With the promiscuity of RiPPs biosynthesis, comes a method to test these libraries of 
compounds for the desired efficacy and activity toward a therapy.  mRNA display happens to be 
uniquely compatible with RiPPs due to a) RiPPs being encoded genetically in the genome, b) 
RiPPs being translated by the ribosome, c) mRNA display can tolerate chemical post-
translational modifications, and d) mRNA display houses the capability to be performed in vitro 
and test libraries on the order of 10
12-13 
unique members
33-41
, giving a comprehensive study of the 
promiscuity of a certain RiPPs enzyme related to its substrate.  Utilizing the power of mRNA 
display, RiPPs biosynthetic promiscuity can be tested and unique RiPPs can be made with 
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differing activities (Figure 1.3) than its natural counterpart giving promising new leads for 
potential therapeutics against cancer and bacterial infections. 
 
Figure 1.3. Overview of natural product peptide libraries. a) By using the same leader peptide 
and the innate promiscuity of RiPPs biosynthesis, a natural compound library can be created. b) 
Proposed workflow for the modification and selection of RiPPs natural products by mRNA 
display. 
New antibiotics are desperately needed due to the rise of antibiotic resistance and the 
severe lack of new antibiotics.  A recent study by the PEW Charitable Trust reported that there 
has not been a new class of antibiotics registered since 1984.
42
  A potential work-around would 
be to use RiPPs as a starting point and using the power of mRNA display, test on the order of 
trillions molecules for activity against bacterial species.  This can give rise to novel therapeutics 
in a high-throughput manner. 
In the presented work, the promiscuity of RiPPs biosynthesis has been probed and its 
potential for natural product peptide libraries through mRNA display has been tested.  We have 
studied the biosynthesis of sactipeptides and probed the promiscuity in specialized heterologous 
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expression system.  More specifically, we have biochemical and structural characterized CteB, a 
radical SAM enzyme that imparts a single sactionine bridge in its corresponding sactipeptide 
thermocellin.  We also describe the development of an E. coli heterologous expression system 
for sactipeptides based on subtilosin A.  Using this system, we probe the promiscuity of 
sactipeptide biosynthesis related to subtilosin A and its sactionine synthase AlbA.  Lastly, we 
will report the progress that has been made with combining RiPPs and mRNA display for the 
production of modified peptide libraries. We used the pantocin A and thiomuracin biosynthetic 
pathways that have been previously characterized in our mRNA display studies as cases to study 
both a) binding affinity and b) RiPP biosynthetic enzyme modification.
43-46
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CHAPTER 2 
STRUCTURAL INSIGHTS INTO THIOETHER BOND FORMATION IN THE 
BIOSYNTHESIS OF SACTIPEPTIDES 
 
2.1 Introduction 
Enzymes that belong to the S-adenosylmethionine (SAM) radical superfamily are capable 
of catalyzing a wide array of radical mediated reactions utilizing the 5’-deoxyadenosyl radical 
(5’-dAdo•) as a radical intermediate.  These reactions include modification to not only DNA and 
RNA, but also complex peptide modifications such as the formation of carbon-carbon bonds and 
quaternary carbon-sulfur bonds.
1,2
 These radical SAM (RS) enzymes (rSAMs) contain conserved 
domains and motifs that unite the family.  rSAMs bind several [4Fe-4S] clusters that carry out 
the chemistry of the enzyme.  One [4Fe-4S] cluster is bound by a CX3CXφC motif where φ is an 
aromatic residue.  This motif is present in a conserved partial ()6 triose-phosphate isomerase 
(TIM) barrel and provides three cysteines to coordinate with the iron atoms in present in the 
cluster, while the fourth iron atom is ligated by the amine-nitrogen and carboxyl oxygen from the 
methionine present in SAM.
1,3,4
 This direct ligation of SAM to the [4Fe-4S] cluster allows 
reductive cleavage of the C-S bond upon electron transfer to the σ*-antibonding orbital of the 
SAM sulfonium group leading to the formation of methionine and the5’-dAdo• intermediate.  
This radical abstracts a hydrogen atom from the enzyme substrate and facilitates the particular 
chemical transformation carried out by the enzyme.
5
 The [4Fe-4S] cluster is then typically 
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regenerated by a chemical reductant such as dithionite, or, in some cases, by the enzymatic 
NADPH/flavodoxin-flavodoxin reductase system.
1
 Sequence homology suggests that many 
rSAMs contain a unique C-terminal extension, termed a SPASM domain in addition to a 
conserved RS domain.
2,3,6-9
 The SPASM domain (named for the biochemically characterized 
members, AlbA, PqqE, anSME, and MftC which are involved in subtilosin A, pyrroquinoline 
quinone, anaerobic sulfatase, and mycofactocin maturation respectively) is involved in the 
coordination of auxiliary [4Fe-4S] clusters by cysteine residues, which are thought to expand and 
enhance the range of chemistries accessible by the RS domain.
2,7,8
 All known SPASM domain-
containing enzymes catalyze overall oxidation of their respective substrates by two electrons, yet 
there appears to be significant sequence and structural variation among SPASM domains, 
namely in the state and arrangement of cysteine residues that coordinate to the auxiliary iron-
sulfur clusters.
7,8
 The crystal structure of anSME was solved in 2013 and showed that the 
SPASM domain housed two additional, fully ligated auxiliary [4Fe-4S] clusters that were 
important for the enzymatic reaction of anSME.  anSME co-translationally catalyzes the formal 
2-electron oxidation of a cysteine residue found in the active site of its sulfatase substrate to yield 
a formyl glycine residue (Figure 2.1b).
9-11
 To date this is the only modifying enzyme belonging 
to the rSAM superfamily, with a full SPASM domain, whose structure has been solved. 
Some of the founding members of the SPASM domain, AlbA and PqqE, and thus their 
peptide substrate products, subtilosin A and pyrroquinoline quinone respectively, also belong to 
the natural product class known as ribosomally synthesized and post-translationally peptides 
(RiPPs).   RiPPs, which are peptides that are first synthesized by the ribosome and then modified 
later by tailoring enzymes, have gained attention due to their structural diversity and biological 
activities.
12-15
 The modifications involve leader peptide-directed, enzymatic transformations by 
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promiscuous enzymes that are readily exploited for combinatorial biosynthesis as well as other 
applications.
16-20
 The leader peptide is responsible for binding to the post-translational modifying 
enzymes while the chemical modification is done on the core peptide.  Recently it has been 
shown that leader peptide interacts with a conserved motif present in RiPPs enzymes known as a 
RiPP precursor peptide recognition element (RRE).  These RREs have been found in a wide 
variety of RiPPs enzymes such as LynD, a cyclodehyratase involved in cyanobactin biosynthesis, 
and NisB, a dehydratase involved in the biosynthesis of the lantibiotic nisin.
21
 These domains are 
based on the structure of PqqD which associates with the rSAM PqqE to allow the formation of 
the carbon-carbon bond between a glutamic acid and tyrosine residues. 
 
Figure 2.1. Introduction to sactipeptides. a) Formation of sactionine thioether linkages found in 
sactipeptides. b) Formation of formyl glycine from cysteine by anSME c) Comparison of known 
sactipeptides to the bridge formed in CteA. d) Gene clusters of some known sactipeptide 
producers. 
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Not only can rSAMs catalyze the formation of carbon-carbon bonds such as those found 
in PQQ biosynthesis by PqqE and the recently characterized StrB from streptide biosynthesis
22-
25
, they can also form sulfur to α-carbon bonds to form thioether (sactionine) bridges, a 
characteristic of the subclass of RiPPs known as sactipeptides.  Sulfur-to-α-carbon-antibiotics 
(sactibiotics), also known as sactipeptides, are in the family of sulfur bridged bacteriocins, but 
unlike their lantipeptide cousins, sactipeptides are formed by making sulfur to α-carbon bonds 
(sactionine bridges) through the use of rSAMs, termed sactionine synthases.
26-28
 These sactionine 
bridges impart conformational strain on the peptide, giving rise to unique secondary structures 
forming natural “stapled” helices.  Sactipeptide may contain one or more of these sactionine 
linkages that form their constrained macrocyclic peptide backbones, making them resistant to 
heat, proteolysis and degradation.
29,30
 These sactipeptides have been shown to have broad 
spectrum activity against gram positive bacteria.  Thuricin CD, a particular two component 
sactipeptide, has even shown nanomolar activity against Clostridium difficile, a common hospital 
secondary infection.
30-36
 These properties make sactipeptides attractive scaffolds for antibiotic 
development.  Recent work has shown that sactionine synthases cleave SAM to generate 5’-dA•, 
which is used to catalyze thioether bond formation by an incompletely understood and not well-
defined mechanism (Figure 2.1a).
4,37-42
 Elegant work by Marahiel and co-workers characterized 
the first member of sactionine synthases from the biosynthesis of the sactipeptide subtilosin A.  
Marahiel demonstrated that the sactionine synthase AlbA radically cleaves SAM and 
subsequently catalyzes the formation of three sactionine linkages on its precursor peptide.
37
 By 
means of an in vivo engineered expression system, we recently showed that AlbA exhibits broad 
substrate promiscuity and that SboA cysteines and their attendant cross ring bridging partners 
can be repositioned within the precursor peptide sequence while still undergoing enzymatic 
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modification to sactionine linkages.
43
 These efforts are limited to substrates that fortuitously 
undergo modification by the native enzyme, but engineering and rational design of sactipeptide 
libraries will require better understanding of both sactisynthase structure and mechanism of 
thioether bond formation.  Not only are these rSAMs predicted to hold SPASM domains (only a 
few of which has been structurally characterized)
2,3,6-9
, but they are also RiPPs enzymes and 
predicated to hold RRE domains attached to, not separate, of the active site of the enzyme.  That 
makes any structural information on these thioether bond forming sactionine synthases extremely 
important.  A crystal structure of a sactionine synthase can shed light on a) how the SPASM 
domain of a peptide modifying enzyme compares to known SPASM domains, b) how the RRE 
domain interacts with the peptide substrate, c) insights into the mechanism of sactionine bond 
formation, and d) what this can tell us about other known sactionine synthases. 
Recent bioinformatic efforts predicted a number of sactipeptide clusters in a wide array 
of bacterial genomes, including several from thermophiles.
7,8,44
 We anticipated that sactionine 
synthases from thermophilic bacteria might have the desired stability for efficient heterologous 
expression and crystallization.  In particular, the sactionine synthase from Clostridium 
thermocellum ATCC 27405, Cthe_0906, here referred to as CteB, looked to be a member of the 
newly defined family of sactipeptides being called SCIFF (or six cysteines in forty-five residues) 
peptides.
7
 CteB is co-located with the short peptide Cthe_0907, here referred to as CteA, in the 
C. thermocellum ATCC 27405 genome and is therefore predicted to chemically modify CteA to 
form its SCIFF peptide known as thermocellin (cte).  Although no native natural products 
belonging to this family have been isolated to date, Bandarian and co-workers reconstituted 
enzymatic activity of Tte1186 from a putative SCIFF pathway in Caldanaerobacter 
subterraneus subsp. tengcongensis MB4.
41
 We therefore considered CteB a strong candidate for 
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enzymatic reconstitution and potential crystallographic investigation aimed at understanding the 
mechanism of sactionine synthases.  In this study, we reconstitute the activity of the 
sactisynthase, CteB and through a combination of chemical modification and tandem mass 
spectrometry, we demonstrate that CteB installs a single sactionine thioether linkage between 
Cys32 and Thr37 of its precursor peptide, CteA, and that the remaining five cysteines in CteA go 
unmodified. We also report two structures of CteB: a 2.70-Å-resolution structure of CteB with 
SAM bound and a 2.04-Å-resolution structure of CteB with both SAM and the leader peptide of 
CteA bound. These structures define all three [4Fe-4S] clusters predicted by bioinformatics, one 
of which, auxiliary cluster I (Aux I), displays a novel open coordination site on one of its 
constituent iron ions. These structures, together with substrate binding assays and a 
computational model based on the crystal structure, provide insights into the mechanism of 
thioether bond formation for CteA and other members of the sactisynthase family. 
2.2 In vitro reconstitution of CteB: a sactionine synthase 
The genes that encode CteB and its peptide substrate CteA were codon optimized for 
expression in E. coli and separately cloned into different expression vectors. Previously we had 
reported improved yields of peptide when co-expressed with its sactisynthase, presumably due to 
added protection from proteolysis.
43
 Therefore, the precursor peptide, CteA, co-expressed with 
CteB in a pETDuet vector in multiple cloning sites 1 and 2 respectively. Only CteA was 6xHis-
tagged in the construct and could be readily purified from inclusion bodies formed during 
expression at 18°C with generous aeration. No modification of CteA was observed under these 
aerobic conditions, making recombinant CteA obtained in this manner suitable for an in vitro 
enzymatic assay. CteB could be expressed and purified in a manner similar to other radical SAM 
enzymes and sactisynthases (see Experimental section 2.7.2).
45
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Using Fluhe et al. as a basis
37
, we ran a series of anaerobic assays to determine a) 
whether CteB could reductively cleave SAM to generate 5’-deoxyadenosine or 5’-dA and b) 
if/how it modified CteA.  When there is no peptide substrate for a sactisynthase, the 5’-dA• 
abstracts a hydrogen from nearby solvent, forming 5’-dA.  The production of 5’-dA is a clear 
indication of proper folding, redox state, and activity of the enzyme.  When CteB was incubated 
in the presence of SAM and the strong non-physiological reductant sodium dithionite, we 
observed a distinctive mass (252.1108) corresponding to 5’-dA (within <10 ppm error) in LC-
MS traces of the assay supernatants (see Appendix Figure A.1).  This product mass was not 
observed in control reactions without CteB or SAM, suggesting that reconstituted CteB carries 
out this characteristic reductive cleavage of radical SAM enzymes. 
The next step was to confirm whether or not CteB was in fact a sactionine synthase, 
capable of forming sactionine bridges within its peptide substrate CteA.  With this positive 
result, we went forward with the peptide modification assay.  We ran a series of assays 
incubating CteB together with CteA, SAM and dithionite followed by analysis of the products by 
HPLC coupled to an Agilent 6520 Accurate-Mass Q-TOF spectrometer.  In the presence of 
stoichiometric amounts of enzyme, we observed complete conversion of CteA to a mass that was 
2.0 atomic mass units (amu) lower than the starting mass, consistent with the loss of two 
hydrogen atoms corresponding to the formation of a single sactionine thioether bond.  Figures 
2.2a and 2.2b show examples of the mass shift in the envelope corresponding to the +6 charge 
state of CteA.  To confirm that the 2.0 amu loss resulted from a thioether linkage and not a 
disulfide bond (also a 2.0 amu loss) , we quenched the reactions under reducing conditions and 
reacted with N-ethylmaleimide (NEM), in order to alkylate all free cysteines (Figures 2.2a and 
2.2c). In a control reaction, where CteA was not treated with CteB but treated with NEM, the 
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m/z values for the various charge states corresponded to the mass of the peptide plus six 
molecules of NEM (Figure 2.2c, black trace and Table 2.1). In contrast, CteA that was 
modified by CteB before being quenched with NEM exhibited masses corresponding to m/z for 
peptide with five alkylated cysteine residues and a loss of two hydrogens (Figure 2.2c, red trace 
and Table 2.1), confirming that a single thioether had been installed by CteB under these 
conditions. 
In order to identify the location of the single sactionine thioether linkage, we used tandem 
mass spectrometry.  CteA that was modified with CteB and treated with NEM (CteA-mod-
5NEM) was fragmented by collision induced dissociation (CID).  Based on the pattern of b- and 
y- ions, the newly formed thioether bridge was found to reside between residues Cys32 and 
Thr37 of CteA (Figure 2.2d).  We found that the b- and y- ions for fragments containing Cys32 
lack one NEM group and two hydrogens corresponding to the formation of the sactionine 
thioether linkage at this position. A full table of observed masses and the residues to which they 
correspond is provided in Table 2.2. 
As mentioned before, as we were working on our system, Bandarian and co-workers 
reconstituted the activity of a sactisynthase, Tte1186, from a SCIFF pathway in 
Caldanaerobacter subterraneus subsp. tengcongensis MB4.
41
 Upon comparison to our system, 
we found that the peptide substrates (CteA and Tte1186a) had 65.2% shared identity and 76.1% 
consensus sequences while the enzymes (CteB and Tte1186) had 55.0% shared identity and 
70.0% consensus sequences.  Thus when comparing our tandem MS-MS spectra for CteB-
modified CteA to their corresponding tandem MS-MS spectra for Tte1186-modified Tte1186a, it 
was interesting that we found the same pattern of b- and y- ions that they had seen, further giving 
credence to the sactionine linkage placement between Cys32 and Thr37.  To further corroborate 
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the assignment of the sactionine linkage, the Cys32Ala mutant of CteA was prepared via Gibson 
Assembly mutagenesis, and purified similar to wild type. Assays with CteA-C32A in presence of 
CteB and SAM yielded only the unmodified precursor peptide, consistent with thioether 
formation at this position (see Appendix Figure A.3).  Peptide products with only one sactionine 
bridge were observed regardless of whether CteB was limited or used in large excess. It cannot 
be completely ruled out that multiple thioether bridges may be formed in the cellular 
environment of the native producer with the native reductant. Whether this is the active form of 
CteA in vivo remains to be determined.  
Table 2.1. Mass Spec. table for peptide modification assays treated with NEM 
 
Table 2.2. Tandem MS/MS table for peptide modification assays treated with NEM 
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Figure 2.2.  MS analysis of CteA modified by CteB. a) Expected masses of CteA modified by 
CteB or alkylated with NEM. b) MS of CteA product modified by CteB. In red is 1 eq. of CteA 
treated with 1 eq. of CteB while in black is CteA unmodified. The difference between the 
corresponding charge states is that of one sactionine bridge or two hydrogen atoms. c) MS of 
CteA product alkylated with NEM after first being modified by CteB. In red is 1 eq. of CteA 
treated with 1 eq. of CteB then NEM, while in black is CteA treated with just NEM. The 
difference between the corresponding charge states is that of one sactionine bridge and one NEM 
modification See Table 2.1 for expected exact masses. d) MS/MS analysis (+7 charge state) of 
where the sactionine bridge is forming in modified CteA. 
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2.3 Crystal structure of CteB 
We solved the crystal structures of CteB, from anomalous iron edge datasets, in two 
different states: CteB bound to SAM and no substrate was solved at 2.7 Å resolution while CteB 
bound to both SAM and a 21-residue N-terminal fragment of CteA (M1-C21) at 2.04 Å 
resolution.  We attempted co-crystallization with the full-length CteA precursor peptide, but 
were unable to obtain diffraction quality crystals. As of the time of writing, there have been no 
structures reported for any RiPP enzyme and its full-length precursor peptide substrate bound, 
presumably due to the dynamic nature of the interactions between the core peptide and the RiPP 
enzyme.   
The two CteB structures, CteA-bound and unbound, superimpose with a root mean 
square deviation (RMSD) of 1.3 Å
2
 based on 415 Cα atoms (see Appendix Figure A.11). 
Because of this close structural similarity, our discussion focuses mainly on the higher resolution 
structure, CteB+SAM+CteA-M1-C21 (Pep-Bound-CteB), with reference to the unbound structure 
where relevant. Crystals of the enzyme-peptide complex exhibit diffraction consistent with the 
orthorhombic space group P21212, with a monomer in the asymmetric unit (Figure 2.3a). The 
final model consists of CteB residues 1 to 449 (out of 450), residues 1 – 9, and 20- 21 of the 
CteA-M1-C21 peptide, 12 iron ions and 12 sulfide ions which correspond to 3-[4Fe-4S] clusters, 2 
calcium ions, 1 SAM molecule and 146 water molecules. CteB residues 115-121 are not defined 
by electron density, and reside in a disordered loop immediately following the RS [4Fe-4S] 
cluster binding motif. A similar disordered loop was also seen in the structure of anSME.
9
 In 
addition, CteB residues 334-336 are not defined in a disordered loop that joins α6 in the RS 
domain to the SPASM domain. This region lies on a symmetry axis and is difficult to model (see 
Appendix Figure A.8). This region contains a conserved cysteine (Cys336) found in SCIFF 
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maturases (Appendix A.15), which may form a disulfide bond with the adjacent Cys336 from a 
symmetry mate (see Appendix Figure A.8).  In addition, this entire region (CteB residues 330-
341) is disordered in the CteB+SAM structure. Interestingly, the crystallization solution 
contained about 500 μM dithiothretol (DTT) that carried over with the CteB added to the 
solution and all predicted [4Fe-4S] clusters are intact in the crystals indicating a lack of oxidative 
damage. To determine if a disulfide exists in the crystalline state, crystals of CteB+SAM+CteA-
M1-C21 were dissolved in buffer and the solution chromatographed on a size exclusion column 
equilibrated in buffer that did not contain reductants (see Appendix Figure A.4). The majority 
(~ 65 %) of protein in this sample migrated with an apparent molecular weight of ~ 95 kDa, 
which is consistent with a dimer of CteB, while the remaining protein migrated as a monomer. 
The monomer fraction of this solution is likely CteB protein that was present in the 
crystallization drop but did not form crystals. We next tested the oligomeric state of CteB in 
solution, both in presence and absence of full-length CteA substrate, under reducing conditions 
by size exclusion chromatography (SEC). Under these conditions, CteB migrates with an 
apparent mass of 42 kDa, consistent with a monomer (see Appendix Figure A.5). In the 
presence of CteA, the apparent mass of CteB increases by ~ 4 kDa, consistent with a CteA-CteB 
complex. Thus, in solution, under reducing conditions CteB does not seem to form a dimer.  
Next, we removed the reductant, DTT, from CteB and mixed protein with varying ratios of 
reduced glutathione (GSH)/oxidized glutathione (GSSG) to survey the redox potential of the 
mixture from – 377 mV to – 223 mV. These mixtures were subsequently electrophoresed on a 
non-reducing SDS-PAGE gel (see Appendix Figure A.6). Importantly, increasing the redox 
potential by increasing the ratio of GSSG to GSH does not lead to significant intermolecular 
disulfide bond formation in solution as can be seen by the lack of a dimer band at ~100 kDa in 
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the non-reducing SDS-PAGE gel. With these results, we concluded that this disulfide is most 
likely an artifact of crystallization.  Due to the weak electron density and the evidence that in 
solution, the enzyme behaves as a monomer, we have decided not to model this disulfide bond 
forming a dimer (see Appendix Figure A.8). 
However this leaves the question of what is the role of this highly conserved cysteine in 
SCIFF maturases?  We set out to answer this by mutating Cys336 to an alanine and testing its 
ability to cleave SAM radically and modify CteA.  Shown in Appendix A.1 and A.2, CteB-
C336A cleaves SAM radically on par with that of CteB.  However, unlike CteB, CteB-C336A 
does not modify CteA to form a single sactionine bridge, implicating this conserved residue 
plays a role in the activity of CteB on the substrate.  Looking at the structure, we hypothesized 
that the cysteine rich CteA substrate could form a disulfide with CteB at Cys336.  Using the 
same conditions to prove that CteB did not form a dimer in solution, we were able to show that 
CteB-CteA complex forms under oxidizing conditions (see Appendix A.7) indicating the 
presence of a disulfide bond formed between the enzyme and substrate.  We hypothesize that 
Cys336 in CteB may form a disulfide with one of the other N-terminal cysteines (Cys21, Cys24, 
Cys28) in CteA and orient the peptide substrate within the active site for modification at Cys32.  
Therefore, we made the individual cysteine to alanine mutants of CteA (C21A, C24A, and 
C28A) and tested whether CteB could modify each substrate.  Shown in Appendix A.3, all 
cysteine to alanine mutants (except for C32A) were modified to a single sactionine bridge by 
CteB indicating that a single residue change did not affect the ability of CteB to form a disulfide 
complex with CteA and form the sactionine bridge.  A possible explanation for this observation 
is that the possible cysteines, within CteA,  to form a disulfide bond with Cys336 in CteB are all 
equal distant from Cys336A and therefore more than one possible bridge can be formed between 
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the substrate and enzyme, replacing a disulfide loss upon mutation.  Multiple, subsequent 
mutations within the CteA substrate would be required to answer this question.  Further 
experiments are underway to elucidate the role Cys336 plays in complex formation and activity 
of CteB.  
The structure of CteB exhibits three discernable domains (Figure 2.3a and b): (1) a 
partial (β/α)6 triose phosphate isomerase (TIM) barrel (residues 95-319) containing one [4Fe-4S] 
cluster (canonical radical SAM domain) in green, which is flanked by (2) an N-terminal winged 
helix-turn-helix (wHTH) motif (residues 1-71) in purple and (3) a C-terminal extension (residues 
338-450), which chelates two additional [4Fe-4S] clusters in orange.  These are discussed 
individually below. 
The central portion of the CteB structure exhibits the characteristic )6-TIM barrel 
(residues 95-319), common to nearly all other members of the radical SAM superfamily.  This 
barrel is also known as the AdoMet or radical SAM (RS) domain for the fact is holds the [4Fe-
4S] cluster that binds and reductively cleaves SAM.  The [4Fe-4S] cluster motif (CX3CXφC) is 
found within the RS domain, in the loop between α1 helix and β1 loop (residues 100-125).  This 
cluster is ligated by three cysteines (residues 104, 108, and 111), leaving one site open to chelate 
the α-aminonitrogen and α-carboxyl oxygen of the SAM co-factor.3,46 The rest of the SAM 
binding pocket is similar to that of the SAM binding pocket of anSME and exhibits the four 
common SAM binding motifs: the GGE motif (residues 153-156), the ribose motif (residues 
Ser210 and Asp212), the GXIXGXXE motif (residues 254-262), and the β6 or adenine-binding 
motif (residues 281-284). In addition, Tyr110 forms a hydrogen bond to the N6 of the adenine 
present in SAM and Arg222 stabilizes the ribosyl and carboxyl moieties of the AdoMet; these 
interactions are also present in the anSME SAM binding pocket (see Appendix Figure A.9). 
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Interestingly there are two new SAM binding pocket interaction found in the CteB structure: 
Arg253 and Thr255 in the β5 strand form hydrogen bonds to N3 of the adenine base within 
SAM. These residues reside in a highly conserved RGT motif found in thermophilic 
sactisynthases. In summary, a total of eight residues make side chain or backbone polar contacts 
with SAM (see Appendix Figure A.9). Presumably these numerous interactions and motifs 
correctly position and orient SAM for radical-based hydrogen abstraction from its substrate in a 
very specific manner. 
Through a partially ordered loop, the RS domain is connected to the C-terminal SPASM 
domain which spans the residues 338-450. It holds the conserved seven-cysteine motif found in 
SPASM domains, CX9-15GX4CXnCX2CX5CX3CXnC and coordinates two additional [4Fe-4S] 
clusters known as auxiliary clusters.  The CteB SPASM domain exhibits structural homology 
(see Appendix Figure A.9, R.M.S.D. of 2.3 Å over 113 Cα) to the SPASM domain from anSME 
with several notable differences between the two. The SPASM domain in CteB extends from the 
C-terminus of the TIM barrel RS domain via a partially ordered loop to coordinate the first 
auxiliary [4Fe-4S] cluster (Aux I) at Cys344 and Cys362.  A short hairpin loop (β1’/β2’) 
separate these two coordinating residues.  In anSME, a short amino acid insertion harbors 
Cys261, which is the fourth ligand to Aux I. This amino acid insertion and thus the fourth 
cysteine, is absent in CteB. As in anSME, the CX2CX5CX3C motif in the central region of 
SPASM domain provides three ligands for the second auxiliary [4Fe-4S] cluster (Aux II) and one 
additional cysteine ligand for Aux I in CteB. Cys400, Cys403, and Cys409 from CteB all 
coordinate Aux II, while the fourth cysteine of the motif, Cys413, crosses back to provide a third 
ligand for Aux I. Cys432 provides the fourth and final ligand for Aux II (Figure 2.3b).  Aux II is 
also exposed to the surface by a small channel on the back side of the protein.  In contrast to 
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ansME, where both Aux I and Aux II are fully ligated, Aux I of CteB is left with an open 
coordination site. The fourth coordinating ligand, present in anSME but absent in CteB, to Aux I, 
besides leaving an open coordination site, results in the positioning of the [4Fe-4S] cluster AuxI 
closer to the RS cluster in CteB. The RS cluster resides 14.4 Å from the open coordination site of 
Aux I (Figure 2.3c), which is ~ 2.5 Å closer than seen in the structure of anSME (16.9 Å). The 
distance between Aux I and Aux II in CteB is 11.6 Å, which is slightly compressed compared to 
that seen in the SPASM domain of anSME (12.9 Å). These differences indicate that the overall 
arrangement and separation of all [4Fe-4S] clusters within these SPASM family proteins is likely 
to support the different chemistries that are catalyzed by these different proteins. 
In the CteB+SAM+CteA-M1-C21 structure, electron density is observed around the open 
coordination site of Aux I. We first attempted to model this electron density as a weakly bound 
DTT (present in the crystalizing conditions) molecule as observed in the crystal structure of 
lipoyl synthase
47
 but this model did not result in a satisfactory fit of the electron density.  We 
next hypothesized that the free thiol of Cys21, from the CteA-M1-C21 peptide, could reach into 
the active site and coordinate to the open ligation site in Aux I. The modeling of residues of 
Gly20 and Cys21 of the CteA-M1-C21 peptide into this density provided a plausible fit (Figure 
2.3d). The lack of electron density for the peptide sequence between Gly9 and Gly20 is most 
likely due to innate flexibility of the peptide and the lack of hydrogen bonding or hydrophobic 
contacts between CteA and CteB in this region. Because only a fragment of the precursor peptide 
(residues 1-21) was found to co-crystallize with CteB, it is possible that the Cys21-Fe ligation 
seen in the reported structure is not mechanistically relevant, but rather represents a 
thermodynamically stable state of the peptide in the absence of the full, native sequence.  
Therefore, we propose that this Cys21 coordination may be analogous and similar to the enzyme-
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substrate interactions that would occur during the catalytic cycle, involving one of the six 
cysteines from CteA and Aux I. 
 
Figure 2.3.  Structure of CteB. a) Overall structure of CteB. The β6/α6 core of the RS domain 
(green) contains one [4Fe-4S] cluster that coordinates one molecule of SAM. The C-terminal 
SPASM domain (orange) contains the [4Fe-4S] clusters Aux I and Aux II and comprises of 
residues 344 - 432. The N-terminal RRE domain (purple) of CteB provides the binding 
specificity for the peptide substrate leader sequence of CteA (yellow, stick representation). b) 
Topology figure of CteB with matching color scheme as a). c) Zoom of [4Fe-4S] clusters present 
in CteB along with their distances from one another. The distance from RS to Aux I is 14.4 Å 
while the distance from Aux I to Aux II is 11.6Å. RS, radical SAM cluster, Aux I, and, Aux II d) 
Omit map (2Fo-Fc) contoured to 1.5 σ of Gly20 and Cys21 from CteA-M1-C21 substrate bound to 
Aux I. The distance between the Fe and Sϒ of Cys21 is 2.7 Å. 
One structural feature that is absent in anSME, but has been predicted to occur in AlbA 
and other SPASM domain proteins, is the RiPPs precursor peptide recognition element (RRE). 
The winged helix-turn-helix (wHTH) motif present in CteB is structurally homologous to the 
RREs, which have recently been identified in the crystal structures of other RiPP modifying 
enzymes, such as LynD, PaaA, and NisB.
21,48-54
 The wHTH in CteB spans residues 4-71 and 
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represents just the fourth reported structure of a leader-bound RRE structure (Figure 2.4a and 
d).
48,49
 These reported structures all exhibit a common pattern in the conserved wHTH domain 
architecture and β-strand conformation when bound to peptide substrate (Figure 2.4a-c).  While 
the RREs vary greatly in sequence, they are predicted based upon secondary structure.  Despite 
sharing only 13% sequence identity to the RRE domains of LynD and NisB, the RRE domain of 
CteB exhibits a relatively small overall R.M.S.D at 2.16 Å and 3.05 Å, respectively over 71 Cα.  
The RRE domain provides one of the primary structural motifs for leader peptide recognition. 
The three-stranded β-sheet, or wing, of the RRE interacts with the backbone of the N-terminus of 
the CteA fragment in the co-crystal structure in a manner similar to LynD and NisB (Figure 
2.4a-c).  A very extensive hydrogen bond network is formed by backbone carbonyl and amide 
interaction of the RRE with CteA (Figure 2.4d and Table 2.3). Hydrogen bonds can be seen 
between side-chain and main-chain atoms of CteA. His3 from CteA forms a series of salt bridges 
with the CteB residues Asp27, Glu60 and Glu64. CteA also makes favorable van der Waals 
interactions with the RRE domain via Ile4 and Ile6, both of which fit into hydrophobic pockets 
found in the cleft between α3 and β3 strands. The RRE is connected to the N-terminus of β1 of 
the partial (β/α)6 TIM barrel by a long, flexible linker, which passes across the face of the 
SPASM domain to position the RRE next to the α6’ helix (Figure 2.3a and b). β1 and β2 of the 
RRE also make hydrophobic contacts with the α6’ helix coming from the C-terminus of the 
SPASM domain, which weakly stabilizes its position relative to the active site. In addition, the 
RRE domain makes limited crystallographic contacts with symmetry molecules and, as a result, 
shows higher than average β-factors than the core of CteB. This explains why the density for the 
leader peptide is weaker than the resolution would predict. 
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Table 2.3.  List of CteB(RRE) and CteA(M1-G9) hydrogen bond interactions 
CteA H-bond atom CteB H-bond atom Distance
 
1 – N-term NH 64 – Glu OE2 3.1 
2 – backbone NH 64 – Glu OE1 3.3 
3 – backbone NH 64 – Glu OE1 2.8 
3 – His NE2 60 – Glu OE1 3.3 
3 – His ND1 27 – Asp OD2 2.7 
3 – backbone CO 27 – backbone NH 3.2 
5 – backbone NH 25 – backbone CO 2.9 
5 – backbone CO 25– backbone NH 2.7 
7 – backbone NH 23 – backbone CO 2.6 
8 – Asn OD1 23– backbone NH 3.1 
 
 
Figure 2.4.  Leader peptide and binding to RRE of CteB. Comparison of RRE domains from 
CteB (a), LynD (b), NisB (c). d) Simulated annealing omit composite map (2Fo-Fc) contoured to 
1.0 σ of residues 1 – 9 of the leader peptide (yellow sticks) of CteA. Residues from CteA 
involved in binding of the leader peptide are shown in yellow. Hydrogen bond interactions are 
shown as dashed lines. For full list of interactions and distances see Table 2.3. 
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2.4 Homology and Comparison to other SPASM and Twitch Domains 
There are not many proteins to which CteB can be compared to as it is the first of its kind 
to be structurally characterized.  CteB is only the second example of a SPASM domain to be 
structurally characterized, the first being anSME.   In addition, BtrN
55
 and MoaA
56 
exhibit 
smaller, single [4Fe-4S] cluster domains dubbed “Twitch” domains.2 Taken together, the four 
structures of the SPASM and Twitch domains provide four different coordination architectures 
for Aux I (Figure 2.5). All four of these enzymes use the two conserved cysteines present on 
either side of the β1’/β2’ hairpin loop (Cys344 and Cys362 in the case of CteB) but differ in the 
positioning of the remaining coordinating cysteines. MoaA has an open coordination site on Aux 
I, similar to that of CteB.  However, the open iron sites in these two structures differ as they are 
on alternate sides of Aux I. While Cys413 from the CX2CX5CX3C SPASM motif loops back to 
provide the third coordination in CteB, this cysteine motif is not present in MoaA’s twitch 
domain, and MoaA’s corresponding Aux I is instead ligated by an additional cysteine, Cys264, 
upstream of the β1’/β2’ hairpin loop. Cys264 in MoaA is analogous to the cysteine, Cys261, 
present in anSME, but absent in CteB. The difference in coordination pattern results in the open 
coordination site of CteB’s Aux I being oriented towards the active site entrance, favorably 
positioned for coordination by an incoming peptide substrate. In contrast, the open coordination 
site of Aux I in MoaA is oriented towards the interior of the active site, potentially to aid in 
capturing its smaller substrate.  This open coordination site is analogous to how the RS cluster 
ligates to the amine-nitrogen and carboxyl oxygen from the methionine present in SAM.  The 
specific orientation of these [4Fe-4S] clusters also impacts their distance from the SAM 
activating cluster: this distance is 14.4 Å in CteB (Figure 2.3c), whereas it is ~17.0 Å in anSME, 
BtrN, and MoaA (16.8, 16.9, and 17.3 Å, respectively). The more compact architecture in CteB 
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could facilitate the pseudo-intermolecular bond formation reaction between Cys32 and Thr37 of 
the CteA peptide substrate.   
 
Figure 2.5. Comparison of Aux I and Aux II clusters. a) Topology diagrams of known 
crystallized enzymes that hold either one or both Aux I and Aux II clusters. Yellow-BtrN, gray-
MoaA, red anSME, and orange-CteB. b) Sequence alignments of those domains. 
Removing the RRE domain of CteB, the other domains of CteB and anSME (RS and 
SPASM) adopt similar structural organizations (R.M.S.D. of 2.52 Å over 300 Cα atoms) (see 
Appendix Figure A.9), despite sharing only 20% sequence identity between the two proteins. 
Interestingly, the conserved Asp277 and Tyr24 active site residues of anSME are absent in CteB. 
In particular, Asp277 was shown to be absolutely required for anSME activity and was proposed 
to act as a base in the anSME reaction mechanism.
9
 His363 and Tyr350 in CteB are within 8 Å 
of Aux I and we hypothesized that these residues could play analogous roles in the CteB reaction 
mechanism. However, when we prepared and tested the H363A and Y350A mutants, we 
observed formation of the thioether bridge on CteA (see Appendix Figure A.2). These 
observations suggest that these residues do not act as essential bases during the reaction, unlike 
Asp277 in anSME. Studies are currently under way to determine which active site residues are 
critical for the activity of CteB within both the RS and SPASM domains. 
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2.5 Contributions to Binding Affinity of CteA 
A series of CteA derivatives were prepared in order to assess the separate contributions of 
leader peptide, core, and cysteine residues to affinity of CteA for CteB. A fluorophore-labeled 
probe was prepared by SPPS; specifically CteA-M1-C21 was synthesized with a TAMRA label 
on the N-terminus for use in fluorescence polarization (FP) binding assays.  The leader peptide 
alone exhibits a 0.7 ± 0.2 μM binding affinity, in good agreement with affinities for similar 
leader peptide-RRE interactions.
21,57
 The unlabeled peptides CteA-M1-G20, CteA-M1-G20-H3A, 
wildtype CteA, and CteA-C32A were used with the fluorophore-labeled peptide in competition 
assays.  Both wild-type CteA and CteA-C32A exhibit a slightly weaker affinity, than the leader 
peptide alone (Kd 3.0 ±1.0 and 4.0 ±1.0, respectively). Notably, the C32A mutant did not 
substantially impact binding, but the H3A variant leader peptide was unable to compete off the 
labeled peptide (Kd >100). The fact that the H3A variant exhibits greatly reduced binding to 
CteB provides strong evidence that the histidine side chain interactions with the RRE domain of 
CteB are critical for CteA recognition by CteB. These observations also provide evidence that 
the peptide substrate sequence is modeled correctly within the reported structure. Taken together, 
these observations suggest that the leader peptide contributes significantly to binding in this 
system and that key interactions between the leader peptide and RRE (e.g. His3) can 
significantly impact binding.  The results are summarized in Figure 2.6 below. 
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Figure 2.6.  Fluorescence Polarization binding of CteA to CteB. a) Binding curve of 2 nM of 
TAMRA-CteA-M1-C21 to CteB. To produce the curve, two replicates done in triplicate and 
analyzed by GraphPad Prism 5 (One site- Specific Binding with Hill Slope). b) Competition 
Assay with full length competitors (CteA (WT or C32A) and leader peptide truncates (GGSSG-
CteA (M1-G20) or CteA (M1-G20)-H3A).  The fluorophore concentration was set at 5 nM while 
the protein concentration was set at 5 μM.  To produce individual curves, one set of data was 
done in triplicate and analyzed by GraphPad Prism 5 (log (inhibitor) vs. response-Variable slope 
(four parameters)).  Kd values were calculated using the following equation: 
Kd=IC50/(1+[L]/Kd,labled) where Kd is the dissociation constant of for the unlabeled peptide, [L] 
is the concentration of labeled peptide (5 nM), and Kd,labeled is the dissociation constant for the 
labeled peptide (0.7 μM from Figure 2.6a). 
2.6 Summary and Discussion 
Perhaps the most important feature that comes from the CteB structure is the clear 
presence of an open coordination site on Aux I in the substrate free-state, which appears to be 
filled by a cysteine from the peptide substrate in the peptide bound structure. The coordination 
state of this particular predicted [4Fe-4S] cluster within sactisynthases has been the subject of 
debate for years. Berteau
6
 and Drennan
2,9
 both note number of cysteines for complete ligation of 
the two predicted [4Fe-4S] clusters is insufficient in the sactisynthase AlbA. Berteau postulated 
that the ligation state may be fulfilled by a serine or arginine as in LipA
58
 and BioB
59
, 
34 
 
respectively, whereas Drennan and co-workers hypothesized that an open site on the [4Fe-4S] 
cluster might be involved in substrate binding as in MoaA.
2
 The structures of CteB are consistent 
with a mechanism in which the open coordination of Aux I in CteB is involved in substrate 
binding, namely through one of the six cysteines present in CteA. Substrate coordination at this 
open site also appears to be consistent with spectrophotometric data reported by Marahiel et al. 
for AlbA, where substrate titration into a solution of enzyme was accompanied by a shift in the 
UV-spectrum where the [4Fe-4S] clusters absorb (300-500 nm), which is absent in enzyme 
mutants that disrupt the predicted Aux I present in AlbA.
37
 Although the current structure shows 
a terminal cysteine, Cys21 from the peptide fragment, coordinating to Aux I, we hypothesize that 
in the full-length, native substrate, coordination of the reacting cysteine (Cys32) would serve to 
orient and activate the cysteine for thioether bridge formation. 
Two mechanisms have been proposed for enzymatic formation of sactionine bridges 
(Figure 2.7a).  The first mechanism, involves separate activation of the bridging partner α-
carbon and the cysteine sulfur by distinct [4Fe-4S] clusters, followed by attack of the carbon 
centered radical on the coordinated/activated sulfur atom (Figure 2.7a, Mechanism A).  An 
alternative mechanism, in which the intermediate α-carbon radical undergoes a one-electron 
oxidation to the ketoimine (Figure 2.7a, Mechanism B), has been proposed by Bandarian and 
co-workers in their work on Tte1186.
41
 In this mechanism, the thioether is formed by 
nucleophilic attack of the cysteine sulfur on the ketoimine.  Both mechanisms would be catalytic 
if the SAM cleavage cluster acts as an oxidant or electron acceptor via chain transfer to return to 
its active, reduced state.  Justification for mechanism B is based on the observance of sactionine 
linkages with both D- and L- stereochemistry in sactipeptides like Subtilosin A.  The polar 
mechanism would clearly allow for attack on either re- or si-face of the ketoimine; however, the 
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low barrier to inversion of a carbon centered radical, especially when it may proceed via the enol 
radical tautomer cannot realistically rule out Mechanism A.  The open coordination site on Aux I 
neither refutes nor supports either of the proposed mechanisms.  Both mechanisms can 
reasonably be drawn, as in Figure 2.7a, with a substrate Cys-ligated Aux I. 
 
Figure 2.7.  Proposed mechanisms of sactionine bridge formation. a) Mechanisms describing 
either separate activation of the bridging partner α-carbon and the cysteine sulfur by distinct 
[4Fe-4S] clusters followed by attack of the carbon centered radical on the coordinated sulfur 
atom (Mechanism A) or the intermediate α-carbon radical undergoes a one-electron oxidation to 
the ketoimine which is then subject to nucleophilic attack of the cysteine sulfur (Mechanism B). 
b) Proposed binding of substrates in their enzymes. c) Rosetta model of CteA-CteB complex 
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with Cys32 ligated to Aux I. This computational model shows possible interactions between 
CteA (yellow) and CteB. In the model Cys32 from CteA ligates the free coordination site on Aux 
I and Thr37 is placed in close proximity to where the 5’-dA radical is formed from SAM (gray)  
This newly discovered free ligation site on Aux I has other potential ramifications for the 
mechanism of thioether bond formation. Based on coordination of Cys21 in the peptide bound 
structure of CteB, a site that does not make a thioether bridge in CteA in vitro, it seems possible 
that the observed coordinating cysteine could be artificial. An alternative is that the bound Cys21 
in the current structure mimics the physiologically relevant cysteine in CteA, Cys32, which 
would be activated for crosslinking by coordinating to this [4Fe-4S] cluster. By analogy to 
anSME, CteA would bind the RRE with its N-terminus (residues 1-9) and likely project down 
into the bowl-like active site, where the reactive Cys32 sulfur may coordinate to Aux I (Figure 
2.7b).  Substrates then make an abrupt turn and climb out of the active site, aided by a number of 
conserved H-bonding residues on the β5 and β6 strands of the TIM barrel.  The peptide 
trajectory presumably places the bridging partner residue in front of the SAM binding pocket for 
activation, but there are no obvious pockets capable of dictating stereochemistry.  The open 
coordination site on Aux I present in CteB could also provide either an electron sink for the 
radical mechanism (Mechanism A) or an oxidant and intermediate Lewis acid for the 
polar/ketoimine intermediate mechanism (Mechanism B). The CteB structure demonstrates that 
Aux I and Aux II of CteB are in sufficient proximity to act as electron transfer partners.
60 
Patches 
of highly conserved surface residues border the RS and Aux II clusters of CteB (Figure 2.8), 
showing possible recognition surfaces for single electron donors and acceptors, such as 
ferrodoxins or the flavodoxin-flavodoxin reductase system.
1
 
With the help of the Kuhlman Lab at UNC, Rosetta3 macromolecular modeling suite was 
used to build the full length CteA substrate peptide into the active site of CteB based on the 
CteB+SAM+CteA-M1-C21 (Pep-Bound-CteB) structure to generate a computational model (see 
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Experimental 2.7.8, Figure 2.7c and Appendix A.17 and 18). Distance constraints were used 
to ensure Cys32 from CteA remains in ligation proximity to the [4Fe-4S] cluster AuxI and Thr37 
from CteA was immediately next to C5 of the SAM cofactor.  Another single, loose distance 
constraint between the C-terminal Arg46 of CteA and residue Thr342 of CteB at the periphery of 
the binding pocket was used to keep the substrate in the active site.   Two representative lowest 
energy structures from the model are shown in Figure 2.7c and Appendix A.18.  These models 
show that Cys32 of CteA can ligate to the open coordination site of the [4Fe-4S] cluster of AuxI 
and that Thr37 of CteA does not clash with the SAM cofactor bound in CteB.  Thus this model 
gives a representation of a possible interaction between CteA and CteB.   Thr37 of CteA is 
within ~5 Å of the C5 of the SAM cofactor making it plausible for the radical formed at this 
position to abstract the α-hydrogen from Thr37.  The model also puts Thr37 in close proximity to 
Cys32 (~5 Å), making it reasonable for a sactionine bridge to form, just as described and 
confirmed in the in vitro system.  Another interesting development from the model is the 
proximity of Cys336 from CteB to Cys21, 24, and 28 from CteA.  In the model, Cys21, 24, and 
28 reside on the same face of the α-helix formed by CteA, orienting them in such a way as to 
possible interact with Cys336 from CteB.  While the distances in the model are much too great to 
form a disulfide (average ~13 Å), it is interesting that the lowest possible energy states indicate 
an interaction in the region between cysteines may be favorable shedding light on how the actual 
enzyme interacts with its substrate.  There are several other polar interactions between the 
substrate and enzyme in the model that could be tested to ascertain the validity of the model 
presented.  Besides the numerous hydrogen bonding contacts between the amide backbone of 
CteA and residues in CteB as well as intramolecular hydrogen bonding between residues and the 
backbone within CteA, there were two key hydrogen bonding  interactions between amino acid 
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side chains of CteA and CteB.  First there is a polar interaction predicted between the carboxylic 
acid in Asp150 from CteB and the terminal amine in Lys33 from CteA.  Second there is another 
polar interaction predicted between the guanidinium group from Arg182 of CteB and the 
carbonyl in the terminal amide group of Gln41.  The model can be tested by canceling out and/or 
flipping these interactions by exchanging the interacting residues between CteA and CteB.  If 
activity or binding is altered, it is a strong possibility that the interactions predicted by the model 
are real and the model is a good representation of how the substrate sits in the active site of the 
enzyme.  Experiments are ongoing to determine if the aforementioned interactions are a true 
representation of substrate-enzyme interaction.  
Based on sequence analysis, the open site on Aux I is predicted to be conserved in several 
sactisynthases, suggesting that coordination may be a common feature of substrate recognition 
within the sactisynthases. For example, multiple sequence alignments (see Appendix Figures 
A.13 and 14) indicate that sactisynthases from thurincin H (ThnB, which forms 4 bridges) and 
subtilosin A (AlbA, which forms 3 bridges) biosynthesis should have very similar architectures 
to CteB, but unlike CteB capable of making multiple sactionine linkages. Two other SPASM-
containing enzymes, PqqE and StrB, also align well with the CteB SPASM architectures; 
however, the chemistry carried out by PqqE and StrB differ significantly from CteB, forming C-
C bonds instead of C-S, and it is unclear how a coordination state might contribute in these 
enzymes. However, not all known sactisynthases align well with CteB.  TrnC and TrnD, 
sactisynthases responsible for the biosynthesis of two component system thuricin CD, and SkfB 
responsible for the biosynthesis of sporulation killing factor, vary significantly in the SPASM 
architecture.  The connection of these structural changes to the chemistry these enzymes carry 
out remains to be defined.  It remains unclear how CteB-related sactisynthases catalyze the 
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formation of multiple nested thioether linkages. For example, AlbA catalyzes formation of three 
sactionine linkages in subtilosin A and ThnB makes four in thurincin H biosynthesis. Dynamics 
in the active site and a degree of substrate control could both play roles in the formation of 
additional thioethers linkages. Initial substrate coordination may act to “set the register” for 
thioether positioning in these multiply bridged systems. Along with this, the long RRE linker 
would presumably allow greater flexibility of the N-terminus, and enable a more diverse 
ensemble of approaches to the catalytic site. 
A sequence similarity network (SSN) of the radical SAM protein family (PF04055) was 
made using the EFI-Enzyme Similarity Tool online (Appendix A.12).  This SSN shows the 
similarity and relationship between different rSAM enzymes belonging to the same family.  Even 
though there is sequence similarity in the RS and SPASM domains (Appendix A.13 and 14), the 
SSN shows that the known, biochemically characterized sactionine synthases are widely 
different from one another, with the exception of CteB and Tte1186.  These differences could 
play a part in the number of sactionine bridges each enzyme imparts.  AlbA, ThnB and TrnD, 
enzymes that impart three or more sactionine bridges, are away from big clusters of proteins 
unlike CteB and Tte1186.  This could be an indication that AlbA, ThnB, and TrnD are outliers in 
sactionine synthases and thus so is there unique activity of more than one thioether bridge.  CteB 
is firmly in the center of a large cluster of proteins that represents the SCIFF maturases.  This 
could be an indication that CteB, along with its activity, is not so alone and that they belong to a 
large group of enzymes with the same activity, making the more promiscuous sactionine 
synthases the outliers.  This hypothesis can only be tested once more sactionine synthases are 
isolated and characterized. 
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The RRE is a fairly new motif to be structurally characterized in RiPPs enzymes; 
however its prevalence can be seen in predictions and bioinformatic analyses.  In Burkhart et 
al.
21
, using HHpred, RRE’s based on PqqD were predicted in myriad of RiPPs biosynthetic 
proteins including the cyclodehydratases (LynD), dehydratases (NisB), adenylases (PaaA), 
proteases, methyltransferases, epimerases, and of course thioether bond formation (AlbA), and 
carbon-carbon bond formation (PqqD/PqqE).  Some of these RRE’s have been structurally 
characterized, such as LynD, NisB, PaaA, and now CteB a sactionine synthase, but there are 
significant differences between the recognition of peptidyl substrates of these enzymes.
21,48-54
 In 
LynD and NisB, the RRE binds to the N-terminal LP portion of their substrates through mostly 
hydrophobic interactions but in the middle of the leader peptide sequence, leaving the very N-
terminus of the peptide free.  CteB’s RRE binds the very N-terminus of leader peptide of CteA 
through amide backbone hydrogen bonding, but there is a very significant polar interaction 
between His3 and the wing in the RRE that is not present in the other structurally characterized 
RRE motifs.  These changes make the RRE of CteB unique among other RREs that have been 
structurally characterized.  The RRE is important for peptide recognition, but it is only a 
recognition element and has no catalytic activity, this is done by the active site, the partial TIM 
barrel and SPASM domain in the case of CteB.  It has been shown that the core peptide can be 
mutated very rigorously and the enzyme itself is very tolerant to those changes as long as the 
leader peptide is intact and can bind to the RRE.
16-20,43 
This makes RiPPs enzymes very 
promiscuous and valuable in biosynthesis of new and natural products.  CteB may also have this 
inherent promiscuity but further experiments and analysis are needed to fully probe this.  
41 
 
 
Figure 2.8. Conservation of CteB homologs. Surface map (ConSURF server) of sequence 
conservation based on 150 sequences with homology ranging from 35% to 90% identity. 
Conservation scores are based on Bayesian method. a) The highest sequence conservation can be 
found around the active site and peptide binding surface of the RRE domain. b) 180 ° rotation 
showing the bottom of CteB. A patch of highly conserved residues are found around the RS and 
Aux II clusters. These sites may have a role in the recognition of redox partners. 
In conclusion, we have biochemically characterized a new sactionine synthase, CteB 
from C. thermocellum ATCC 27405, which installs a single sactionine bridge on the 
thermocellin precursor peptide. We also determined the X-ray crystal structures of CteB both in 
the presence and in absence of a fragment of the peptide substrate CteA, which represent the first 
structures of a sactionine synthase and PqqE-like enzyme. The structures reveal a conserved 
SAM activating domain, as well as a new SPASM domain motif displaying a single open 
coordination site on the internal auxiliary iron-sulfur cluster (Aux I). These structures provide 
valuable insight into the enzymatic mechanism of sacti-bridge formation and, by analogy, into 
the mechanisms of related, PqqE-like enzymes. In particular, these structures provide evidence 
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for the role of SPASM auxiliary clusters in direct substrate ligation and potential residue 
activation required to facilitate product formation. We anticipate that this structure will have 
utility for the continued mechanistic understanding and engineering of sactionine synthases and 
other PqqE-like RiPP enzymes. 
2.7 Experimental 
2.7.1 General Cloning and Molecular Biology Techniques 
Cloning of cteA and cteB into pMCSG7 
The genes cteA (encoding the 51 amino acid precursor peptide) and cteB (encoding the 
RS sactisynthase) were codon-optimized for expression in E. coli and synthesized by Integrated 
DNA Technologies as gene-blocks (Table 2.4). The codon-optimized cteA and cteB were 
amplified from their respective gene-block templates by PCR using primers from Table 2.5 and 
Q5® High-Fidelity DNA Polymerase with Q5 Reaction Buffer following the manufacturer’s 
manual (NEB).  The purified PCR product was phosphorylated with T4-PNK and then treated 
with T4-DNA Polymerase to create ligation independent cloning (LIC)-overhangs.  In parallel, 
pMCSG7 (ampicillin resistant) was linearized with SspI and dephosphorylated with Antarctic 
Phosphatase and then treated with T4-DNA Polymerase to create complimentary LIC overhangs.  
The digested PCR products and vector were combined and allowed to anneal for 10 min at 22 
o
C, 
then were transformed into One-Shot ® Top 10 cells.  A single colony we used to inoculate 5 
mL of LB culture. The recombinant plasmids were purified with the GeneJET Plasmid Miniprep 
kit following the manual.  The final constructs were verified by DNA sequencing. The cloning 
cteA and cteB into pMCSG7 added a hexa-histidine (His) tag to the N-terminus of both genes 
with a TEV protease site that allows removal of the His tag after purification of the proteins.   
 
43 
 
Generation of CteA and CteB variants 
The cteA or cteB gene-blocks were used as templates to produce mutations with primers 
from Table 2.5.  PCR was performed with Q5® High-Fidelity DNA Polymerase following the 
manufacturer’s manual.  Primer 1 and corresponding reverse mutant primer (Table 2.5) were 
used to create Piece I for CteA.  Primer 2 and corresponding forward mutant primer (Table 2.5) 
were used to create Piece II for CteA.  Primer 3 and corresponding reverse mutant primer (Table 
2.5) were used to create Piece I for CteB.  Primer 4 and corresponding forward mutant primer 
(Table 2.5) were used to create Piece II for CteB. The two PCR pieces were purified and kept in 
water. In parallel, pMCSG7 was prepared as above.  Piece I and II were mixed with linearized 
pMCSG7, then ligated using Gibson Assembly® Master Mix according to the manufacturer’s 
protocol (NEB). Then, 3 μL of reaction mixture was then transformed into 50 μL of One-Shot ® 
Top 10 cells.  A single colony we used to inoculate 5 mL of LB culture.  The plasmid was 
purified as above.   
Cloning cteA and cteB into Duet plasmid 
His-cteA was cloned into MCS1 (NcoI and HindIII) from the pMCSG7-Cthe0907 using 
primers 5 and 6 (Table 2.5) while cteB (no His-tag) was cloned into MCS2 (NdeI and XhoI) 
from the codon-optimized gene-block using primers 7 and 8 (Table 2.5).  PCR was conducted 
with Q5® High-Fidelity DNA Polymerase following the manufacturer’s manual. The purified 
PCR products and pETDuet plasmid were digested using the corresponding restriction enzymes 
for each site (Table 2.5).  The purified digested plasmid was treated with Antarctic Phosphatase 
and then combined with the purified digested PCR product in the presence of T4 ligase.  The 
ligation was allowed to go overnight at 16 
o
C.  After ligation, T4 ligase was heat inactivated at 
65 
o
C for 10 min before the ligation reaction was transformed into One-Shot ® Top 10 cells.  
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The resulting plasmids were purified as above.  cteB was cloned into MCS2 first and once the 
resulting plasmid was sequencing confirmed, His-cteA was cloned into MCS1.  
Expression of His-CteA peptides 
His-CteA and its variant plasmids were transformed into BL-21 (DE3) or BL-21 (DE) 
cells harboring the pPH151 corrector plasmid by electroporation. The cells stocks were made 
electrocompetent according to standard molecular biology protocols found in Green et al.
61
 The 
electroporation was carried out in a 0.1cm cuvette, at 1.8 kV, 200 Ω, and 20 μFD.  His-CteA 
precursor peptide (in pETDuet-His-CteA-1, CteB-2) was heterologously expressed in E. coli 
(pPH-151/BL21 DE3) while His-CteA (in pMCSG7) variants were heterologously expressed in 
E. coli (BL21 DE3) cells.  LB media was supplemented with ampicillin (100 μg/mL) with or 
without chloramphenicol (34 μg/mL). A 5 mL LB overnight culture was used to inoculate a 1 L 
LB culture.  Cultures are grown at 37 
o
C and 200 rpm to an OD600~0.6-0.7, at which point IPTG 
was added to a final concentration of 0.5 mM and the culture was grown at 18 
o
C, 200 rpm for 
22-24 hours.  
Expression of His-CteB proteins 
His-CteB and its mutant plasmids were transformed into BL-21 (DE) cells harboring the 
pPH151 corrector plasmid by electroporation. His-CteB enzyme (in pMCSG7-CteB) was 
heterologously expressed in E. coli (pPH-151/BL21 DE3) cells using 1 L of auto-induction 
media, adapted from Studier.
62
 Auto-induction media was supplemented with ampicillin (100 
μg/mL) and chloramphenicol (34 μg/mL). A 5 mL overnight culture of ZYP-0.8G was used to 
inoculate 1 L of ZYP-5052.  Cultures were grown at 37 
o
C and 200 rpm to an OD600 ~ 0.6-0.8, at 
which point the culture was cooled to 30 
o
C for 30 minutes. After cooling, cysteine was added to 
a final concentration of 300 μM.  The culture was allowed to grow at 30 oC, 200 rpm for 18-24 
45 
 
hours before harvest.   
Table 2.4.  Gene-blocks ordered from Integrated DNA Technologies (IDT), codon optimized 
used in CteB study 
CteA 5’-ATG AAG CAC ATT AAA ATT TTG AAC GGG TCA ACA CTG AAA GAC AGC CTG AAA AAA GGT GGG TGT 
GGG GAA TGT CAA ACC TCT TGC CAG TCA GCT TGC AAG ACC TCA TGT ACC GTT GCT AAT CAG TCA 
TGC GAA AAG CGT TAA  -3’ 
CteB 5’-ATG GCG ATG ATC CAC AAA TTC TCG ATG ATG GGC ACA AAC ATT GTG GTG GAC GTA AAT TCA GGT 
GCT GTA CAC GTG GTT GAT GAT ATC AGT TTT GAT ATC CTT GAT TAT TAC AAG AAT TTT ACC GCG GGT 
GAG ATC AAG AAC AAG TTG GCG CAT AAG TAC AAT GCC GAC GAA ATC GAC GAA GCG TTA CGC GAA 
ATC GAG TCA TTA GAA GCT GAG GGC CTG TTA TTT TCA GAG GAC CCG TAT AAA GAA TAC GTA TCA 
TCT ATG GAC CGC AAG TCC GTC GTA AAA GCG TTG TGT CTT CAT ATC TCA CAC GAC TGT AAT CTG CGC 
TGC AAA TAT TGT TTT GCT TCG ACA GGA AAT TTC GGG GGC CAG CGT AAT ATG ATG TCC CTG GAG 
GTT GGA AAG AAG GCT ATT GAC TTC CTT ATT TCG GAA TCA GGT AAC CGC AAG AAT CTT GAG ATC 
GAT TTC TTT GGG GGC GAG CCC ATG ATG AAC TTC GAC GTC GTA AAG GGT ATT ATT GAG TAT GCC 
CGT CAG AAA GAG AAG GAG CAT AAT AAA AAC TTT CGC TTT ACA TTG ACT ACT AAT GGT CTG CTT 
CTG AAT GAT GAA AAT ATT AAG TAC ATT AAC GAA AAC ATG CAG AAT ATC GTT TTA TCG ATC GAC 
GGT CGC AAG GAA GTC AAT GAC CGT ATG CGC ATT CGC ATT GAC GGA TCC GGT TGT TAT GAT GAC 
ATT CTG CCC AAA TTC AAA TAT GTA GCC GAA AGC CGC AAT CAA GAC AAT TAC TAT GTT CGT GGC 
ACG TTC ACA CGC GAG AAT ATG GAC TTT TCA AAT GAC GTG TTA CAC TTG GCC GAC GAA GGG TTC 
CGT CAA ATT AGC GTT GAA CCG GTG GTT GCT GCT AAA GAC TCT GGT TAC GAC CTT CGT GAA GAA 
GAT CTG CCT CGT CTT TTT GAG GAA TAT GAA AAG CTG GCG TAC GAG TAC GTG AAA CGT CGT AAG 
GAG GGA AAT TGG TTT AAT TTC TTC CAC TTC ATG ATT GAC TTA ACA CAA GGT CCA TGT ATT GTA AAG 
CGC CTT ACC GGA TGT GGT AGC GGA CAC GAA TAT TTG GCC GTC ACG CCT GAA GGG GAT ATT TAC 
CCA TGC CAC CAA TTC GTA GGG AAT GAG AAG TTC AAG ATG GGC AAT GTA AAG GAG GGC GTC CTT 
AAC CGC GAT ATC CAA AAC TAC TTC AAA AAC AGC AAT GTA TAC ACT AAG AAG GAA TGT GAT TCC 
TGT TGG GCT AAA TTC TAT TGC AGT GGA GGC TGT GCA GCG AAC TCC TAC AAT TTC CAC AAA GAC 
ATT AAT ACG GTG TAC AAA GTT GGT TGT GAA TTG GAA AAG AAA CGT GTG GAG TGC GCT TTA TGG 
ATC AAG GCG CAA GAG ATG TAA  -3’ 
 
Table 2.5.  Plasmids, sites, and primers (ordered from Eton Bioscience, Inc.) used in CteB study 
LIC-plasmid pMCSG7 SspI 
MCS1-Duet pETDuet NcoI, HindIII 
MCS2-Duet pETDuet NdeI, XhoI 
Primer 1 pMCSG7-CteA-F 5’-TAC TTC CAA TCC AAT GCG ATG AAG CAC ATT AAA ATT TTG 
AAC GG- 3’ 
Primer 2 pMCSG7-CteA-R 5’-TTA TCC ACT TCC AAT GCG CTA TTA ACG CTT TTC GCA TGA 
CTG ATT AG -3’ 
Primer 3 pMCSG7-CteB-F 5’- TAC TTC CAA TCC AAT GCG ATG GCG ATG ATC CAC AAA -3’ 
Primer 4 pMCSG7-CteB-R 5’- TTA TCC ACT TCC AAT GCG CTA TTA CAT CTC TTG CGC CTT 
GAT CCA T -3’ 
Primer 5 His-CteA-into Duet-
MCS1-F 
5’-GAT CGA TCC CAT GGG CAT GCA CCA TCA TCA TCA TCA TTC 
TT -3’ 
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Primer 6 His-CteA-into Duet-
MCS1-R 
5’-GAT CGA TCA AGC TTT TAA CGC TTT TCG CAT GAC -3’ 
Primer 7 CteB-into Duet-
MCS2-F 
5’-GAT CGA TCC ATA TGG CGA TGA TCC ACA AA -3’ 
Primer 8 CteB-into Duet-
MCS2-R 
5’-GAC TGA TCC TCG AGT TAC ATC TCT TGC GC -3’ 
Primer 9 CteB-Y350A-F 5’-GTG GTA GCG GAC ACG AAG CGT TGG CCG TCA CGC CTG-3’ 
Primer 10 CteA-Y350A-R 5’-CAG GCG TGA CGG CCA ACG CTT CGT GTC CGC TAC CAC -3’ 
Primer 11 CteB-H363A-F 5’-GGA TAT TTA CCC ATG CGC GCA ATT CGT AGG GAA TG-3’ 
Primer 12 CteB-H363A-R 5’-CAT TCC CTA CGA ATT GCG CGC ATG GGT AAA TAT CC -3’ 
Primer 13 CteA-C32A-F 5’-CCT CTT GCC AGT CAG CTG CTA AGA CCT CAT GTA CCG -3’ 
Primer 14 CteA-C32A-R 5’-CGG TAC ATG AGG TCT TAG CAG CTG ACT GGC AAG AGG -3’ 
 
2.7.2 Purification of Substrates and Enzymes 
Purification of His-CteA (WT and variants) peptide and cleavage to SNA-CteA (WT and 
variants) 
Purification procedures were modified from Li et al.
63 
A 5 mL cell pellet was suspended 
in 30 mL of Start Buffer (20 mM Na2(PO4) pH 7.5, 500 mM NaCl, 0.5 mM imidazole, 20% 
glycerol) supplemented with 0.5 mL of 25 mg/mL T4 lysozyme and 0.5 mL of 150 mM PMSF 
and then incubated on ice for 10 minutes.  The cell pellet was then sonicated.  The cell debris 
was pelleted by centrifuging the lysate at 15,000 rpm at 4 
o
C for 10 minutes.  The supernatant 
was then discarded and the pellet was washed and resuspended in 30 mL of IB Buffer (20 mM 
Na2(PO4) pH 7.5, 6 M Guanidinium-HCl, 500 mM NaCl, 50 mM imidazole) by using a spatula 
to break up the pellet coupled with extensive vortexing.  The debris was again pelleted and the 
supernatant collected and filtered through a 0.45 μm syringe filter.  The flow through from the 
filter was then passed over a Ni
2+
 IMAC column (HISTrap
TM
 HP 5mL GE Healthcare) coupled 
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to an FPLC (NGC-Quest-10 Bio-Rad).  The Ni
2+
 IMAC column was washed with 6 column 
volumes (CV) of IB Buffer.  The peptide was eluted with a gradient of 0-100% of elution buffer 
(25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 500 mM imidazole) over 10 CV.  The peptide eluted 
between 15-25% elution buffer. Fractions containing the peptide were combined and dialyzed 
against 25 mM Tris-HCl, pH 7.0 and 150 mM NaCl in a 2000 MWCO cassette from Thermo 
Fischer.  The buffer exchange was repeated three times, while being maintained at 4 
o
C.  The 
peptide solution was then collected and tobacco etch virus (TEV) protease was added at 
approximately a 1:15 ratio of TEV to peptide.  The protease reaction was incubated overnight at 
4 
o
C.  The cleaved CteA peptide was further purified by preparative HPLC.  Preparative HPLC 
was performed on a Shimadzu UFLC CBM-20A with a dual channel wavelength detector at 220 
nm and 280 nm with a Luna® 10 µm, 100 Å, 250 x 30 mm) AXIA™ (Phenomenex®) 
semipreparatory column. Purification was carried out with a two solvent system (solvent A = 
0.1% trifluoroacetic acid (TFA) in water; solvent B = 0.1% TFA in acetonitrile) using gradient of 
30-60% B over 20 min at a flow rate of 15 mL/min. The peptide eluted from the column between 
40-45% solvent B.    The peptide product after these steps is CteA with three additional amino 
acids (SNA) at the N-terminus, and is hereby denoted as CteA. The fractions containing the 
CteA (or its variants) were pooled and partially concentrated with a rotary evaporator, followed 
by flash freezing and lyophilization to obtain the purified solid product.  The yield of peptide 
was ~ 1mg of CteA per 1 L of culture.  The peptide was then dissolved in dimethyl sulfoxide 
(DMSO) to a final concentration of 1.25 mM (based on mass).   
Purification of His-CteB protein 
A 10 mL cell pellet was suspended in 30 mL of Buffer A (50 mM HEPES, pH 7.5, 150 
mM NaCl, 50 mM imidazole) supplemented with 0.5 mL of 25 mg/mL T4 lysozyme, 0.5 mL of 
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150 mM PMSF, 80 μl of DNaseI (1u/μl), one tablet of PierceTM Protease Inhibitor Tablets 
(EDTA Free from Thermo Scientific), and then incubated on ice for 10 minutes.  The cell pellet 
was then sonicated.  The lysate was clarified by centrifugation at 15,000 rpm at 4 
o
C for 15 
minutes.  The supernatant was collected and filtered through a 0.45 μm syringe filter.  The flow 
through from the filter was then passed over a Ni
2+
 IMAC column (HISTrapTM HP 5mL GE 
Healthcare) coupled to an FPLC (NGC-Quest-10 Bio-Rad).  The Ni
2+
 IMAC column was 
washed with 5 column volumes (CV) of Buffer A.  CteB was eluted from the Ni
2+
 IMAC column 
with a gradient of 0-100% of elution buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 500 mM 
imidazole) over 10 CV.  The protein eluted between 20-35% elution buffer. Fractions containing 
CteB were pooled and concentrated in a 30,000 MWCO filter in an Amicon stirred cell.  The 
concentrated protein was then exchanged into reconstitution (RC) buffer (50 mM HEPES, pH 
7.5, 150 mM NaCl, 10 mM dithiothreitol (DTT)) by passage over a Sephadex
TM
 PD-10 column 
(GE Healthcare) equilibrated in RC bufer.  The protein concentration was estimated by A280 
using an extinction coefficient of 0.98 mg•mL-1•AU-1. 
2.7.3 In vitro Reconsitution. Assays and Characterization of Products 
All the following were done in strictly anaerobic conditions in a Coy anaerobic chamber from a 
procedure Modified from Flühe et al.37 
In vitro reconstitution of CteB or variants 
All solutions (1 M DTT, 100 mM ammonium ferric citrate, and 100 mM lithium sulfide) 
were made fresh in the anaerobic chamber with degassed RC buffer (described above). The 
protein solution was placed in the anaerobic chamber and passively degassed at RT for 
approximately one hour. Then, 100 equiv. of DTT were added to the protein solution and 
incubated on ice for an additional hour.  After, 10 equiv. of ammonium ferric citrate were added 
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dropwise to the protein solution with gentile mixing.  The solution was then allowed to incubate 
on ice for five minutes.  During this time the solution turned reddish to dark red in color.  Then 
10 equiv. of lithium sulfide were added dropwise to the protein solution and the reaction was 
further incubated overnight (16-18 hours) on ice.  The final color of the reaction mixture was a 
dark brown solution.  The excess iron and sulfide was removed by buffer exchange with a PD-10 
gel filtration column equilibrated in RC buffer.  This protein is denoted as RC CteB.  
SAM cleavage assays with CteB or its variants 
All assays were carried with freshly RC CteB and its variants under anaerobic conditions.  
Solutions of S-adenosylmethionine (SAM) and dithionite (DT) were made fresh in the anaerobic 
chamber with RC Buffer.  RC CteB was added to a final concentration of 20 μM in H2O and was 
incubated with 300 μM DT for five minutes at RT, followed by the addition of 300 μM SAM in 
a total reaction volume of 47.5 μL.  The reaction was allowed to proceed at RT for five hours.  
The reaction was then removed from the anaerobic chamber and quenched by adding 2.5 μL of 
neat formic acid (final concentration 5% v/v).  The samples were then centrifuged at 15,000 rpm 
at 4 
o
C for 15 minutes to remove precipitated protein.  The supernatant was collected and 
analyzed by LC-MS Method 1.  
Peptide modification assays 
All assays were carried with freshly prepared reagents and RC CteB as above. CteA (in 
DMSO) was allowed to passively degas in anaerobic chamber overnight at RT.  CteB (20 μM) 
was added to a reaction mixture consisting of 20 μM CteA (or variants), and 1mM DT in a total 
volume of 49 μL.  The reaction was incubated for five minutes at RT, followed by the addition of 
1 mM SAM.  The reaction (16 % DMSO, final volume 50 μL) was allowed to proceed for five 
hours, after which the reaction was removed from the anaerobic chamber.  The reaction products 
50 
 
then worked up with method 1 or method 2.  
Workup method 1: If the free cysteines of CteA were not to be modified, tris(2-
carboxyethyl)phosphine (TCEP) was added to the reaction at a concentration of 10 mM and 
subsequently incubated at 37 
0
C for 10 minutes.  Methanol was added in a 1:1 ratio (volume) to 
precipitate the protein.  The mixture was centrifuged at 15,000 rpm at 4 
o
C for 15 minutes to 
pellet the enzyme.  The supernatant was collected and analyzed by the LC-MS Method 2.   
Workup method 2: If the free cysteines of CteA were to be modified with n-
ethylmaleimide (NEM), as above, TCEP was added to a final concentration of 10 mM and the 
reaction was incubated at 37 °C for 10 minutes.  Then 20 mM NEM (dissolved in ethanol) was 
added and the reaction was further incubated at 37 
o
C for 30 minutes.   Methanol was added in a 
1:1 ratio (volume) to precipitate the protein.  The mixture was centrifuged at 15,000 rpm at 4 
0
C 
for 15 minutes to pellet the enzyme.  The supernatant was collected and analyzed by the LC-MS 
Method 2.  This procedure was modified from Thibodeaux et al.
64
 
LC-MS Method 1 
LC-MS analysis was performed on an Agilent 1200 HPLC system coupled to an Agilent 
6520 Accurate-Mass Q-TOF spectrometer with an electrospray ionization (ESI) source operated 
in positive ion mode.  The products were separated with a Phenomenex® Kinetex C18 column 
(2.1 mm x 50 mm, 100 Å, 2.6 μm) with the gradient program described below.  Solvent A 
consisted of H2O with 0.1 % formic acid (FA) and solvent B consisted of acetonitrile with 0.1% 
FA.  Analytes from the column were sent to the MS and spectra were acquired in centroid mode 
using a gas temperature of 350 
o
C and a fragmentor voltage of 70 V. 
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Flow Rate 0.5 ml/min 
Post time 2 min 
Time (min) %B 
0.00 1 
10.00 1 
20.00 100 
22.00 100 
22.01 1 
 
LC-MS Method 2 
LC-MS analysis was performed as above except spectra were acquired in profile mode 
using a gas temperature of 350 
o
C and a fragmentor voltage of 250 V.  The gradient program is 
described below. 
Flow Rate 0.5 ml/min 
Post time 4 min 
Time (min) %B 
0.00 2 
2.00 2 
15.00 100 
16.00 100 
18.01 2 
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When running tandem MS/MS, the +7 charge state (Z) of modified CteA product was used as the 
target ion.  A specific retention time of 7 minutes +/- 0.5 minutes and used for the MS/MS and 
an isolation width of 1.3 m/Z.  Collision energies of 25-35 eV were used to obtain MS/MS 
spectra. 
2.7.4 Fluoresence Polarization Assays 
Synthesis of TAMRA-CteA-M1-C21, GGSSG-CteA-M1-G20, CteA-M1-G20 H3A 
 All syntheses were carried out by microwave assisted solid-phase peptide synthesis 
(SPPS).  ChemMatrix solid support (0.47 mmol/g) on a 0.047 mmol scale was used.  The solid 
support was initially swollen in DMF (1.5 mL) for 20 min at 70 °C. Fmoc-Amino Acids-OH (0.5 
M in DMF) or 5,6 TAMRA-OH (0.5 M in DMF, VWR) at 7.0 - 10.0 equiv were coupled with 
HATU (0.2 M in DMF) at 6.86 equiv., and DIEA (0.2 M in DMF) at 14.0 equiv.  The reagents 
were added to the swollen resin in the above. The resulting suspension was heated under 
microwave irradiation for 5 min at 75 °C.  The reaction vessel is then drained and resin is 
thoroughly washed with DMF four times.  Removal of the Fmoc protecting group was 
accomplished after amino acid coupling using excess 20% piperidine.  20% piperidine was added 
to the reaction vessel and allowed to incubate at RT for 3 min with constant stirring. The reaction 
vessel was then drained, washed with DMF and excess 20% piperidine was again added and the 
reaction was incubated for another 10 min at RT. The reaction vessel was then drained and the 
resin thoroughly washed with DMF four times.  After washing the resin with DCM, the resin was 
dried and cleaved using the standard cleavage cocktail (TFA/TIPS/H2O, 95:2.5:2.5) to yield the 
fully deprotected peptides.  The peptides were concentrated by precipitation with cold diethyl 
ether.  Preparative HPLC was performed as described above for purification of the CteA peptide.  
The TAMRA-CteA-M1-C21 eluted from the column between 40-45% B, while GGSSG-CteA-
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M1-G20 and CteA-M1-G20 H3A eluted between 30-35%B.  Relevant fractions were collected and 
partially concentrated in a rotary evaporator, followed by flash freezing and lyophilization to 
obtain the purified solid product.  The identities were confirmed by LC-MS by the method 
described above. 
FP assay set-up and measurement 
 Polarization measurements were performed on a LJL Biosystems Acquest Plate Reader 
using Greiner low volume black-384 well plates.  Excitation was set with the Rho/TAMRA at 
530/25 nm and emission was set with the Rho/TAMRA at 580/10 nm.  For every measurement, 
there is one read per well, with an integration time of 100 ms with the lamp source continuous 
and the Z-height set for the bottom of the well.  All mixtures were prepared in triplicate in the 
Coy anaerobic chamber to ensure that His-CteB was kept in its active state.  All data analyses 
were done in GraphPad Prism 5.  The affinity of TAMRA-CteA-M1-C21 peptide binding to CteB 
was conducted by adding 2 nM of the peptide, while varying the concentration of the CteB from 
50 μM to 0.0954 nM by halving the concentration twenty times for twenty separate readings.  
The peptide and protein were mixed together in RC Buffer containing 0.005% Tween 20 and 1% 
DMSO.  All reagents were passively degassed for at least one hour in the Coy anaerobic 
chamber.  To carry out the assay, first the TAMRA-CteA-M1-C21 peptide was added to the wells, 
then the varying concentration His-CteB protein solutions.  The plate was then sealed with an 
adhesive cover and allowed to incubate at room temperature for 30 minutes.  After incubation, 
the sealed plate was removed from the anaerobic chamber.  The plate was briefly spun in the 
centrifuge to remove any bubbles.  The cover was then removed and readings were taken within 
five minutes to limit the amount of oxygen that entered the sample.  To measure the ability of 
CteA (or variants), GGSSG-CteA-M1-G20, or CteA-M1-G20 H3A to compete with the binding of 
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the TAMRA-CteA-M1-C21 peptide to CteB, 5 nM of the TAMRA-CteA-M1-C21 peptide was first 
mixed with 5 μM of the His-CteB in RC buffer and incubated for 30 min at RT.  The different 
concentrations of each peptide was added to the plate (peptide solutions varied from 200 μM to 
24.4 nM), followed addition of His-CteB/ TAMRA-CteA-M1-C21 protein solution. The plate was 
then sealed with an adhesive cover and allowed to incubate at room temperature for 45 minutes.  
After incubation, the plate was removed from the anaerobic chamber.  The plate was briefly spun 
in the centrifuge to remove any bubbles.  The cover was then removed and readings were taken 
within five minutes to limit the amount of oxygen that entered the sample. 
2.7.5 Oxidation of CteB with Glutathione 
 CteB ( 200 μM) in 200 μL was passed over a Superdex 200 Increase 10/300 GL column 
with an ÄKTA express FPLC system (GE Life Sciences) housed in a MBraun anaerobic 
chamber.  The column was equilibrated in running buffer consisting of 25 mM HEPES, pH 7.5, 
300 mM KCl, 10% glycerol.  CteB was then collected and concentrated with vivaspin 20 
concentrator (Sartorius Stedium Biotech).  CteB (35 μM) was mixed 50 mM Tris, pH 80, 200 
KCl, and a 10 mM series of GSH:GSSG ratios ranging from 95:5 to 2:98.  This yields a solution 
redox potential of – 377 mV to – 223 mV.  The mixture was incubated at RT for 30 min, then 
100 mM iodoactemide was added and the reaction was incubated for another 10 min.  The 
reactions were quenched by adding 2 X non-reducing SDS-PAGE loading buffer (SDS-PAGE 
loading buffer without BME or DTT).  The samples were separated on a Bio-Rad AnykD™ 
Criterion™ TGX™ Precast Midi Protein Gel. 
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2.7.6 Size Exclusion Chromatography 
Determination of oligomeric state of CteB 
 All size exclusion experiments were conducted with an ÄKTA express FPLC system (GE 
Life Sciences) coupled to a Superdex 200 Increase 10/300 GL column housed in a MBraun 
anaerobic chamber.  The column was equilibrated in running buffer consisting of 25 mM 
HEPES, pH 7.5, 300 mM KCl, 10% glycerol, and 5 mM DTT.  A 100 μl injection of Bio Rad 
Molecular Weight Standards mix (cat no. 151-1901) were used to create a standard curve.  TEV 
cleaved CteB (100 μM) was incubated with 500 μM SAM and in the presence or absence of 
CteA-M1-C21 (150 μM) at a final volume of 110 μL.  The complete mixture was injected and 
separated with a flow rate of 0.5 mL • min-1.  
Determination of intermolecular disulfide state of CteB+SAM+CteA-M1-C21 crystals 
 To determine the disulfide state of crystals of CteB+SAM+CteA-M1-C21, the same 
protocol as above was followed, except running buffer did not include 5 mM DTT.  
Approximately 50 crystals of CteB+SAM+-M1-C21 were looped from 1 μL crystallization drops 
and dissolved in 100 μL of 10 mM HEPES, pH 7.5.  This solution was analyzed as above.   
2.7.7 Crystallography Methods 
Preparation of CteB for crystallography 
 The pMCSG-7 plasmid containing His-CteB Wt was transformed into BL-21(DE3) cells 
that already harbored the pPH151 plasmid.  The transformants were selected on an LB/agar plate 
containing 100 μg•mL-1 carbenicillin (a substitute for ampicillin) and 34 μg•mL-1 
chloramphenicol.  A single colony was used to inoculate 20 mL of LB overnight culture 
containing the above antibiotics.  The overnight culture was used to inoculate 2 L of Studier’s 
auto induction media (ZYP-5052 supplemented with 200 μM FeCl3) housed in a 2 L PYREX® 
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media bottle.  The culture was grown at 37 °C in a water bath with constant aeration using a 
sparging stone attached to a pressurized, 0.22 μm filtered air source.  After 5 hr, aeration was 
stopped and the culture was placed in an ice bath for 1 hr.  The culture was returned to a 22 °C 
water bath and light aeration was resumed.  After 5 min, cysteine was added to a final 
concentration of 600 μM.  The culture was grown at 22 °C for ~ 20 hr before being harvest by 
centrifugation at 10,000 x g.  Cell pellets were flash frozen and stored in LN2 until purification.  
All subsequent steps were carried out in an MBraun anaerobic chamber maintained at < 0.1 ppm 
oxygen (MBraun, Stratham, NH).  Plastics were brought into the chamber and allowed to sit for 
two weeks before use.  All solvents and buffer stocks were degassed by sparging with argon gas 
for 4 hr before being taken into the chamber. To purify His-CteB, ~ 30 grams of cell paste were 
resuspended in 30 mL of lysis buffer containing 50 mM HEPES, pH 7.5, 300 mM KCl, 4 mM 
imidazole, 10 mM 2-mercaptoethanol (BME), 10% glycerol, and 1 % Triton-X305. The 
resuspension was subjected to 50 rounds of sonic disruption (80% output, 3 s pulse on, 12 s pulse 
of) at 4 °C. The lysate was cleared by centrifugation at 4 °C for 1 hour at 15,000  × g. The 
supernatant was loaded onto a 5 mL fast-flow HisTrap
TM
 column (GE Healthcare Life Sciences) 
equilibrated in lysis buffer lacking Triton-X305 with an ÄKTA express FPLC system. The 
column was washed with 10 CV of lysis buffer before elution with 5 mL of buffer containing 50 
mM HEPES, pH 7.5, 300 mM KCl, 300 mM imidazole, 10 mM BME, and 10% glycerol.  The 
protein fractions were immediately passed over a HiPrep 16/60 Sephacryl S-200 HR column 
equilibrated in 20 mM HEPES, pH 7.5, 300 mM KCl, 5 mM DTT, and 10% glycerol.  The 
brown fractions were pooled and RC as previously described.  The RC His-CteB was 
concentrated to 1 mL with a vivaspin 20 concentrator (Sartorius Stedium Biotech).  The protein 
was again passed over a HiPrep 16/60 Sephacryl S-200 HR column as above and the fraction 
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corresponding to RC CteB were pooled and concentrated to 100 mg•L-1.  The protein 
concentration was estimated by A280 using an extinction coefficient of 0.98 mg•mL
-1•AU-1. 
Structure determination of CteB+SAM+CteA-M1-C21 peptide 
 RC His-CteB (100 mg) was first treated with 0.1 mg (1:1000 ratio) of MHT238Δ TEV65 
at 12 °C for ~15 hr. The protein was then passed over a 5 mL HisTrap
TM
 HP IMAC column 
equilibrated in 20 mM HEPES, pH 7.5, 300 mM KCl, 5 mM DTT, and 10% glycerol to remove 
the cleaved His-tag and the TEV protease.  The flow-through was collected and concentrated to 
~ 100 mg•mL-1 with vivaspin 20 concentrator.  Diffraction quality crystals of CteB+SAM+CteA-
M1-C21 peptide were obtained by sitting-drop vapor diffusion at 20 °C in an anaerobic chamber 
maintained at < 0.1 ppm oxygen (MBraun, Stratham, NH) by mixing 0.5 µL protein solution (10 
mg•mL-1 of CteB in 10mM HEPES, pH 7.5, 1 mM SAM, 0.5 mM CteA-M1-C21 peptide, 
(MKHIKILNGSTCKDSLKKGGC) with 0.5 µL precipitant (0.1 M Tris-HCl, pH 7.0, 0.2 M 
calcium acetate, 20% polyethylene glycol 3,000) equilibrated against a well solution of 0.5 M 
LiCl. Bar-shaped crystals would appear after two to five days and grow to dimensions of ~ 50 x 
50 x 200-400 μm.  Crystals were removed from the original drop and soaked for 1 min in mother 
liquor that contained 1 mM SAM and 1 mM CteA-M1-C21 peptide, mounted on nylon loops and 
flash-cooled in liquid nitrogen, inside the anaerobic chamber, and stored in liquid nitrogen prior 
to data collection. All diffraction data were integrated and scaled using the HKL3000 suite.
66
 A 
dataset was collected at 1.3776 Å to exploit the intrinsic iron-sulfur clusters of CteB. Phases 
were determined by SAD with autoSHARP
67
, and an initial poly-alanine model was built with 
ARP/wARP.
68
 This model was subjected to subsequent rounds of automated model building 
performed by AutoBuild
69
, interspersed with manual model building and refinement against a 
native dataset collected at 1.0333 Å X-ray wavelength using Coot
70
, phenix.refine
69
, and 
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Refmac5.
71
 All figures were produced using PyMOL (Shrodinger, LLC). The final model 
consists of residues 1 to 449 (450) of CteB, 12 iron ions, 12 sulfide ions, 2 calcium ions, 1 SAM, 
and 52 water molecules. Residues 115-121 are missing in a disordered loop immediately 
following the radical SAM cluster binding motif, while residues 334-336 are missing from a 
flexible loop region.  Simulated annealing composite omit maps were used to verify the final 
model.  Data collection and refinement statistics are shown in Appendix A Table A.1. 
Structure determination of CteB+SAM 
 To obtain crystals of the CteB in the absence of CteA-M1-C21 peptide, a solution 
containing 10 mg/mL of the above TEV-cleaved, reconstituted CteB was mixed with 10 mM 
HEPES pH 7.5, 1 mM AdoMet and was subsequently incubated overnight at room temperature 
in the anaerobic chamber. Diffraction quality crystals of CteB+SAM were obtained by sitting-
drop vapor diffusion, as above, by mixing 0.5 µL protein solution (10 mg•mL-1 of CteB in 
10mM HEPES, pH 7.5, 1 mM SAM) with 0.5 µL precipitant (0.1 M Tris-HCl, pH 8.5, 0.2 M 
calcium chloride, 25% polyethylene glycol 4,000) equilibrated against a solution of 0.5 M LiCl. 
Bar-shaped crystals would appear after thirty days and grow to dimensions of ~ 10 x 10 x 75 μm.  
Crystals were removed from the original drop and soaked for 1 min in mother liquor that 
contained 1 mM SAM, mounted on nylon loops and flash-cooled in liquid nitrogen, inside the 
anaerobic chamber, and stored in liquid nitrogen prior to data collection. The CteB+SAM+CteA-
M1-C21 peptide without ligands was used as a model to phase a dataset collected at 1.0333 Å 
using isomorphous replacement with subsequent rounds of automated model building performed 
by AutoBuild
69
, interspersed with manual model building and refinement using Coot
70
, 
phenix.refine
69
, and Refmac5.
71
 The final model consists of two monomers in the asymmetric 
unit.  Chain A contains residues 1-77, 91-115, 121-330, and 341-448 (of 450), while Chain B 
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contains residues 1-79, 90-114, 122-329, and 342-448 (of 450).  The model also contains 24 iron 
ions, 24 sulfide ions, 2 calcium ions, 2 SAM molecules, and 10 water molecules. Data collection 
and refinement statistics are shown in Appendix A Table A.1. 
2.7.8 Structual Modeling of the CteB Catalytic Site 
Several modules were used in the Rosetta3 macromolecular modeling suite to build the 
CteA substrate peptide into the active site of CteB.
72-74
 The input structure for the modeling was 
CteB+SAM+CteA-M1-C21, which lacked electron density for most of the CteA except for 
residues 1-9 and two amino acids including a Gly-Cys dipeptide in proximity to the FeS cluster 
AuxI. Firstly, the input structure was refined and ligated the Cys amino acid present in the 
structure to AuxI Fe2 imposing AtomPair distance constraints to be under 2 Å between the Fe2 
and SG atoms. From this point onwards the ligated Cys is modeled as Cys32. At the next stage 
RosettaRemodel was used to build the missing section of the peptide covering residues 10-31. 
Kinematic closure (KIC) using fragments was run for 100 build cycles followed by 5 outer 
containing 200 inner cycles each of cyclic coordinate descent (CCD) refinement. The lowest 
energy model was taken for the next step of modeling to build the remaining missing amino 
acids from 33-46. The missing amino acids were initially constructed using pymol and then 
modeled using the FloppyTail protocol allowing flexibility from residue 29 to the C-terminus. 
AtomPair distance constraints were used to ensure Cys32 remains in ligation proximity to FeS 
(AuxI), to position Thr37 immediately next to C5 of the SAM cofactor and finally a single very 
loose distance constraint between the C-terminal Arg46 and residue Thr342 at the periphery of 
the binding pocket. Finally, three representative lowest energy structures were refined assuring 
that Cys32 can ligate to Fe2 of AuxI and that Thr37 does not clash with the SAM cofactor. 
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Code and Steps in creating CteA-CteB Model 
1. First step modeling (preparing the input structure and ligating Cys32 to Fe2 (AuxI): 
The following command was used to generate 100 models: 
~/rosetta/main/source/bin/rosetta_scripts.linuxgccrelease \ 
 -database ~/rosetta/main/database \ 
 -s ../CthE_loopClosure.pdb \ 
 -nstruct 1 \ 
 -parser:protocol ../relax.xml \ 
 -nblist_autoupdate \ 
 -ignore_unrecognized_res \ 
 -load_PDB_components 1 \ 
 -PDB_components_file chemical/components.cif \ 
relax.xml file: 
<ROSETTASCRIPTS> 
        <SCOREFXNS> 
          <talaris_w_csts weights="talaris2014_cst.wts" /> 
          <talaris weights="talaris2014.wts" /> 
 </SCOREFXNS> 
 <RESIDUE_SELECTORS> 
          <Chain name="chA" chains="A" /> 
   <Index name="chB" resnums="1B-9B" /> 
 </RESIDUE_SELECTORS> 
        <TASKOPERATIONS> 
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   <OperateOnResidueSubset name="fixA" selector="chA" > 
            <PreventRepackingRLT/> 
          </OperateOnResidueSubset> 
   <OperateOnResidueSubset name="fixB" selector="chB" > 
            <PreventRepackingRLT/> 
          </OperateOnResidueSubset> 
 </TASKOPERATIONS> 
 <FILTERS> 
        </FILTERS>  
        <MOVERS> 
             <ConstraintSetMover name="cst" add_constraints="1" cst_file="constraints"/> 
   <AddConstraintsToCurrentConformationMover name="coord_constr1" CA_only="0" 
bb_only="1" coord_dev="0.5" cst_weight="1" task_operations="fixA"/> 
   <AddConstraintsToCurrentConformationMover name="coord_constr2" CA_only="0" 
bb_only="1" coord_dev="0.5" cst_weight="1" task_operations="fixB"/> 
   <AddChainBreak name="chainbreak" change_foldtree="1" find_automatically="1" 
distance_cutoff="2.5" /> 
   <FastRelax name="relax" repeats="1" scorefxn="talaris_w_csts"> 
      <MoveMap name="removejumps">  
         <Jump number="1" setting="0"/> 
         <Jump number="2" setting="0"/> 
         <Jump number="3" setting="0"/> 
         <Jump number="4" setting="0"/> 
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         <Jump number="5" setting="0"/> 
      </MoveMap> 
   </FastRelax>  
        </MOVERS>  
 <APPLY_TO_POSE> 
        </APPLY_TO_POSE>  
 <PROTOCOLS> 
<Add mover_name="chainbreak" /> 
             <Add mover_name="coord_constr1" /> 
             <Add mover_name="coord_constr2" /> 
             <Add mover_name="cst" /> 
             <Add mover_name="relax" /> 
        </PROTOCOLS> 
 <OUTPUT scorefxn="talaris" /> 
</ROSETTASCRIPTS> 
constraints file: 
AtomPair FE2 445 SG 459 BOUNDED  0 2  0.50 0.50 NOE 
2. Second step modeling (building the peptide covering residues 10-31): 
1000 models were generated using the following command: 
~/rosetta/main/source/bin/remodel.linuxgccrelease \ 
 -database ~/rosetta/main/database/ \ 
 -s ../CthE_loopClosure_0026.pdb \ 
 -remodel:blueprint ../blueprint \ 
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 -run:chain B \ 
 -remodel:num_trajectory 100 \ 
 -nstruct 1 
blueprint file: 
1 M . 
2 A . 
3 M . 
4 I . 
5 H . 
6 K . 
7 F . 
8 S . 
9 M . 
10 M . 
11 G . 
12 T . 
13 N . 
14 I . 
15 V . 
16 V . 
17 D . 
18 V . 
19 N . 
20 S . 
21 G . 
22 A . 
23 V . 
24 H . 
25 V . 
26 V . 
27 D . 
28 D . 
29 I . 
30 S . 
31 F . 
32 D . 
33 I . 
34 L . 
35 D . 
36 Y . 
37 Y . 
38 K . 
39 N . 
40 F . 
41 T . 
42 A . 
43 G . 
44 E . 
45 I . 
46 K . 
47 N . 
48 K . 
49 L . 
50 A . 
51 H . 
52 K . 
53 Y . 
54 N . 
55 A . 
56 D . 
57 E . 
58 I . 
59 D . 
60 E . 
61 A . 
62 L . 
63 R . 
64 E . 
65 I . 
66 E . 
67 S . 
68 L . 
69 E . 
70 A . 
71 E . 
72 G . 
73 L . 
74 L . 
75 F . 
76 S . 
77 E . 
78 D . 
79 P . 
80 Y . 
81 K . 
82 E . 
83 Y . 
84 V . 
85 S . 
86 S . 
87 M . 
88 D . 
89 R . 
90 K . 
91 S . 
92 V . 
93 V . 
94 K . 
95 A . 
96 L . 
97 C . 
98 L . 
99 H . 
100 I . 
101 S . 
102 H . 
103 D . 
104 C . 
105 N . 
106 L . 
107 R . 
108 C . 
109 K . 
110 Y . 
111 C . 
112 F . 
113 A . 
114 S . 
115 Q . 
116 R . 
117 N . 
118 M . 
119 M . 
120 S . 
121 L . 
122 E . 
123 V . 
124 G . 
125 K . 
126 K . 
127 A . 
128 I . 
129 D . 
130 F . 
131 L . 
132 I . 
133 S . 
134 E . 
135 S . 
136 G . 
137 N . 
138 R . 
139 K . 
140 N . 
141 L . 
142 E . 
143 I . 
144 D . 
145 F . 
146 F . 
147 G . 
148 G . 
149 E . 
150 P . 
151 M . 
152 M . 
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153 N . 
154 F . 
155 D . 
156 V . 
157 V . 
158 K . 
159 G . 
160 I . 
161 I . 
162 E . 
163 Y . 
164 A . 
165 R . 
166 Q . 
167 K . 
168 E . 
169 K . 
170 E . 
171 H . 
172 N . 
173 K . 
174 N . 
175 F . 
176 R . 
177 F . 
178 T . 
179 L . 
180 T . 
181 T . 
182 N . 
183 G . 
184 L . 
185 L . 
186 L . 
187 N . 
188 D . 
189 E . 
190 N . 
191 I . 
192 K . 
193 Y . 
194 I . 
195 N . 
196 E . 
197 N . 
198 M . 
199 Q . 
200 N . 
201 I . 
202 V . 
203 L . 
204 S . 
205 I . 
206 D . 
207 G . 
208 R . 
209 K . 
210 E . 
211 V . 
212 N . 
213 D . 
214 R . 
215 M . 
216 R . 
217 I . 
218 R . 
219 I . 
220 D . 
221 G . 
222 S . 
223 G . 
224 C . 
225 Y . 
226 D . 
227 D . 
228 I . 
229 L . 
230 P . 
231 K . 
232 F . 
233 K . 
234 Y . 
235 V . 
236 A . 
237 E . 
238 S . 
239 R . 
240 N . 
241 Q . 
242 D . 
243 N . 
244 Y . 
245 Y . 
246 V . 
247 R . 
248 G . 
249 T . 
250 F . 
251 T . 
252 R . 
253 E . 
254 N . 
255 M . 
256 D . 
257 F . 
258 S . 
259 N . 
260 D . 
261 V . 
262 L . 
263 H . 
264 L . 
265 A . 
266 D . 
267 E . 
268 G . 
269 F . 
270 R . 
271 Q . 
272 I . 
273 S . 
274 V . 
275 E . 
276 P . 
277 V . 
278 V . 
279 A . 
280 A . 
281 K . 
282 D . 
283 S . 
284 G . 
285 Y . 
286 D . 
287 L . 
288 R . 
289 E . 
290 E . 
291 D . 
292 L . 
293 P . 
294 R . 
295 L . 
296 F . 
297 E . 
298 E . 
299 Y . 
300 E . 
301 K . 
302 L . 
303 A . 
304 Y . 
305 E . 
306 Y . 
307 V . 
308 K . 
309 R . 
310 R . 
311 K . 
312 E . 
313 G . 
314 N . 
315 W . 
316 F . 
317 N . 
318 F . 
319 F . 
320 H . 
321 F . 
322 M . 
323 I . 
324 D . 
325 L . 
326 T . 
327 Q . 
328 G . 
329 P . 
330 C . 
331 I . 
332 V . 
333 K . 
334 R . 
335 L . 
336 T . 
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337 G . 
338 C . 
339 G . 
340 S . 
341 G . 
342 H . 
343 E . 
344 Y . 
345 L . 
346 A . 
347 V . 
348 T . 
349 P . 
350 E . 
351 G . 
352 D . 
353 I . 
354 Y . 
355 P . 
356 C . 
357 H . 
358 Q . 
359 F . 
360 V . 
361 G . 
362 N . 
363 E . 
364 K . 
365 F . 
366 K . 
367 M . 
368 G . 
369 N . 
370 V . 
371 K . 
372 E . 
373 G . 
374 V . 
375 L . 
376 N . 
377 R . 
378 D . 
379 I . 
380 Q . 
381 N . 
382 Y . 
383 F . 
384 K . 
385 N . 
386 S . 
387 N . 
388 V . 
389 Y . 
390 T . 
391 K . 
392 K . 
393 E . 
394 C . 
395 D . 
396 S . 
397 C . 
398 W . 
399 A . 
400 K . 
401 F . 
402 Y . 
403 C . 
404 S . 
405 G . 
406 G . 
407 C . 
408 A . 
409 A . 
410 N . 
411 S . 
412 Y . 
413 N . 
414 F . 
415 H . 
416 K . 
417 D . 
418 I . 
419 N . 
420 T . 
421 V . 
422 Y . 
423 K . 
424 V . 
425 G . 
426 C . 
427 E . 
428 L . 
429 E . 
430 K . 
431 K . 
432 R . 
433 V . 
434 E . 
435 C . 
436 A . 
437 L . 
438 W . 
439 I . 
440 K . 
441 A . 
442 Q . 
443 E . 
444 M . 
445 M . 
446 K . 
447 H . 
448 I . 
449 K . 
450 I E PIKAA I 
0 x L PIKAA L 
0 x L PIKAA N 
0 x L PIKAA G 
0 x L PIKAA S 
0 x L PIKAA T 
0 x L PIKAA L 
0 x L PIKAA K 
0 x L PIKAA D 
0 x L PIKAA S 
0 x L PIKAA L 
0 x L PIKAA K 
0 x L PIKAA K 
0 x L PIKAA G 
0 x L PIKAA G 
0 x L PIKAA C 
0 x L PIKAA G 
0 x L PIKAA E 
0 x L PIKAA C 
0 x L PIKAA Q 
0 x L PIKAA T 
0 x L PIKAA S 
0 x L PIKAA C 
0 x L PIKAA Q 
0 x L PIKAA S 
451 A E PIKAA 
A 
452 C
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3. Third step modeling (building the peptide covering residues 32-46): 
The following command was run to generate 400 models: 
~/rosetta/main/source/bin/FloppyTail.linuxgccrelease \ 
-database ~/rosetta/main/database/ @../options3 
options3 file: 
#input PDB 
-s ../CthE_cterExt_0026_0799.pdb 
#ex flags give extra rotamers for packing; use_input_sc allows the pre-existing rotamer when 
packing (useful when paired with sidechain minimization) 
-ex1 
-ex2 
-packing:repack_only 
#start of tail 
-FloppyTail:flexible_start_resnum 473 
-FloppyTail:flexible_chain B 
#used for preventing loss of compactness at centroid/fa switch; see documentation 
-FloppyTail:short_tail:short_tail_off 0 
-FloppyTail:short_tail:short_tail_fraction 1.0 
#shear does nothing for extended tails; see documentation 
-FloppyTail:shear_on .33333333333333333333 
#constraints 
-constraints::cst_file ../constraints 
-constraints::cst_weight 10 
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-constraints::cst_fa_file ../constraints 
-constraints::cst_fa_weight 10 
-FloppyTail:refine_repack_cycles 10 
-FloppyTail:perturb_cycles 500 
-FloppyTail:refine_cycles 300 
-nstruct 1 
-ignore_unrecognized_res 
constraints file: 
AtomPair CA 278 SG 476 BOUNDED  8 10 0.50 0.50 NOE 
AtomPair CA 338 SG 476 BOUNDED  6 8 0.50 0.50 NOE 
AtomPair CA 357 SG 476 BOUNDED  7 9 0.50 0.50 NOE 
AtomPair CA 111 CA 481 BOUNDED  8 10 0.50 0.50 NOE 
AtomPair CA 145 CA 481 BOUNDED  8 10 0.50 0.50 NOE 
AtomPair CA 201 CA 481 BOUNDED  8 10 0.50 0.50 NOE 
AtomPair CA 336 CA 490 BOUNDED  8 10 0.50 0.50 NOE 
4. Fourth step modeling (reintroducing the ligands with pymol and refining using Rosetta): 
The following command was run over the three of the lowest energy structures from the previous 
step to generate 100 models: 
~/rosetta/main/source/bin/rosetta_scripts.linuxgccrelease \ 
 -database ~/rosetta/main/database \ 
 -s ../CthE_cterExt_0026_0799_0177_withCofactors.pdb \ 
 -nstruct 1 \ 
 -parser:protocol ../relax.xml \ 
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 -nblist_autoupdate \ 
 -ignore_unrecognized_res \ 
 -load_PDB_components 1 \ 
 -PDB_components_file chemical/components.cif \ 
 -auto_setup_metals 
relax.xml file: 
<ROSETTASCRIPTS> 
 <SCOREFXNS> 
          <ScoreFunction name="talaris_w_csts" weights="talaris2014_cst.wts" /> 
          <ScoreFunction name="talaris" weights="talaris2014.wts" /> 
 </SCOREFXNS> 
 <RESIDUE_SELECTORS> 
   <Index name="res" 
resnums="112A,278A,338A,339A,340A,344A,355A,356A,357A,358A,359A,383A,406A,407A,
408A,409A,410A,451B,452B,452B,453B,454B,456B,457B,458B,459B,460B,461B,462B,463B,
464B,465B,466B,467B,468B,469B,470B,471B,472B,473B,474B,475B,476B,477B,478B,479B,
480B,481B,482B,483B,484B,485B,486B,487B,488B,489B,490B" /> 
   <Neighborhood name="nghb" selector="res" distance="4.5" /> 
   <Not name="fix" selector="nghb" /> 
 </RESIDUE_SELECTORS> 
 <TASKOPERATIONS> 
   <OperateOnResidueSubset name="fix_outside" selector="fix" > 
            <PreventRepackingRLT/> 
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          </OperateOnResidueSubset> 
 </TASKOPERATIONS> 
 <FILTERS> 
        </FILTERS> 
        <MOVERS> 
   <ConstraintSetMover name="cst" add_constraints="1" cst_file="../constraints"/> 
   <AddConstraintsToCurrentConformationMover name="coord_constr" CA_only="0" 
bb_only="1" coord_dev="0.5" cst_weight="1" task_operations="fix_outside"/> 
   <AddChainBreak name="chainbreak" change_foldtree="1" find_automatically="1" 
distance_cutoff="2.5" /> 
   <FastRelax name="relax" repeats="1" scorefxn="talaris_w_csts"> 
      <MoveMap name="removejumps">  
         <Jump number="2" setting="0"/> 
         <Jump number="3" setting="0"/> 
         <Jump number="4" setting="0"/> 
         <Jump number="5" setting="0"/> 
      </MoveMap> 
   </FastRelax>  
        </MOVERS>  
 <APPLY_TO_POSE> 
        </APPLY_TO_POSE>  
 <PROTOCOLS> 
   <Add mover_name="chainbreak" /> 
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               <Add mover_name="coord_constr" /> 
   <Add mover_name="cst" /> 
   <Add mover_name="relax" /> 
        </PROTOCOLS> 
 <OUTPUT scorefxn="talaris" /> 
</ROSETTASCRIPTS> 
constraints file: 
AtomPair FE1 445 SG 338 BOUNDED  0 2  0.50 0.50 NOE 
AtomPair FE4 445 SG 407 BOUNDED  0 2  0.50 0.50 NOE 
AtomPair FE2 445 SG 476 BOUNDED  0 2  0.50 0.50 NOE 
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CHAPTER 3 
PRODUCTION OF SACTIPEPTIDES IN ESCHERICHIA COLI: PROBING THE 
SUBSTRATE PROMISCUITY OF SUBTILOSIN A BIOSYNTHESIS 
 
3.1 Introduction 
Sactipeptides are a growing class of modified peptide natural products. The 
characteristics of these compounds are the signature intramolecular thioether bridges between 
cysteine residue sulfurs and the unreactive α-carbons of the bridging partner amino acids, known 
as sactionine bridges or linkages (Figure 3.1a). As of the time of this writing, only five 
sactipeptides have been isolated and structurally characterized from their native producers.  This 
list includes subtilosin A and sporulation killing factor (Skf), both from Bacillus subtilis 168, 
thurincin H from Bacillus thuringiensis SF361, and the two component sactipeptide thuricin CD 
from Bacillus thuringiensis DPC 6431 (Figure 3.1b).
1−8
 These sactionine bridges, unlike the β-
thioether bridges found in lantipeptides, are quaternary due to the bridging partner side chain. 
Also, sactipeptide rings tend to be co-axial in regards to the peptide backbone constrained in a U-
like formation. Sactipeptide tend to have highly defined regions of secondary structure due to the 
distribution and number of sactipeptide bridges as well as the stereochemistry of the α,α-
disubstituted bridging partner residues.  Specifically, the N-terminus of subtilosin A adopts a 310 
helix while thuricin CD has two α-helical faces (Figure 3.1c). The amphipathic helicity of 
regions within these peptides is thought to grant subtilosin A and other sactipeptides narrow 
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spectrum activity through the ability to interact and disrupt bacterial cell walls resulting in often 
cell death through membrane disrubtion.
4,9,10
 Still, the precise mechanisms of action of many 
sactipeptides are not yet fully understood. 
 
Figure 3.1.  Sactipeptide biosynthesis. a) Sactionine linkage formation from cysteines and cross-
ring amino acid coupling partners. b) Comparison of amino acid sequences of known 
sactipeptides with sactionine cysteines in red and bridging partners in blue. c) NMR structure of 
subtilosin A, indicating sactionine linkages and head to tail cyclization. d) The subtilosin A 
biosynthetic cluster from Bacillus subtilis sp. 168 including the structural gene sboA and radical 
SAM sactionine synthase-encoding gene albA. 
In terms of biosynthesis, sactipeptides are ribosomally synthesized and post-
translationally modified peptide (RIPPs) natural products.
11
 RiPPs are produced from gene-
encoded precursor peptides, which are then subsequently modified, post-translationally, by 
enzymes to install the characteristic sactionine linkages. Recently, Marahiel and co-workers 
characterized the enzymes responsible for installing the sactionine linkages in subtilosin A, Skf, 
and thurincin H, specifically, the radical SAM enzymes, AlbA, SkfB, and ThnB, 
respectively.
12−14
 These enzymes called sactionine synthases are members of the newly defined 
SPASM domain, named for named for the biochemically characterized enzymes involved in 
subtilosin A, pyrroloquinoline quinone, anaerobic sulfatase and mycofactocin maturation.   The 
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SPASM domain in this family of enzymes are predicted to have two [4Fe-4S] clusters, one each 
for activating the sulfhydryl and for coupling partner carbon center which results in a 
radical−radical hetero-coupling during cyclization (Figure 3.1a).15 However, there are numerous 
large gaps that still exist in our understanding, specifically regarding the mechanism and 
promiscuity of these sactionine synthases and what the effect changes in precursor peptide 
sequence and structure may have on their innate bactericidal activity.  Some particular questions 
that remain unanswered are how the sactionine synthases, such as AlbA or ThnB, select multiple 
different bridging partner residues specifically at each bridge site and to what extent this can be 
manipulated or modified. 
A homologous expression system has already been reported for thurincin H, using a 
plasmid encoded copy of the precursor peptide in the background of a precursor-knockout of the 
native producer, B. thuringiensis SF361.
16
 Mutants of subtilosin A have also been genetically 
encoded on the pDG-148 plasmid and co-expressed with the native substrate.  The mutants were 
isolated in the native producer B. subtilis 168.
13
 Homologous expression does allow limited 
mutational sampling, but the study of the promiscuity of radical SAM (rSAM) could be obscured 
by multiple factors found in homologous expression systems.  These factors include (1) poor 
downstream processing by other pathway enzymes potentially also contributing to (2) inefficient 
export by the dedicated natural product transporters in the clusters, (3) decreased transcriptional 
amplification by the known feedback regulation mechanisms or (4) rapid proteolytic degradation 
of partially modified peptides by the potent intracellular protease activity inherent to many 
strains of Bacilli. 
Because of these problems, we thought that the development of a heterologous system for 
in vivo overexpression of partially to fully-modified sactipeptides would propel future 
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investigations of their biosynthesis forward, as well as, allow for quick and large-scale 
production of modified variants.
17−23
 We therefore sought a system that would allow (1) robust 
overexpression of precursor peptides, (2) allow modification by modifying enzymes, and (3) 
allow isolation of sufficient materials for downstream characterization and/or potential 
application. We decided to set out and develop a system to allow heterologous expression of 
processed (modified) sactipeptides in E. coli under the control of the strong T7 promoter and also 
allow purification from cell pellets. By implementing E. coli expression, we could adapt the 
mature amber stop-codon suppression technology which has been employed to varying successes 
with other RiPPs natural products.
20,24−28
  We chose to focus these first efforts on the sactipeptide 
subtilosin A made from its precursor peptide SboA, and sactionine synthase AlbA (Figure 3.1d). 
Fully matured subtilosin A contains three sactionine thioether bridges and, as such, provides a 
number of opportunities to examine the interdependency of the different bridge formation sites.  
3.2 Heterologous Production of Pre-subtilosin A 
To ensure Ni
2+
 IMAC purification would be easily achieved with our heterologously 
expressed sactipeptides, we first tested AlbA’s compatibility with both N-terminal and C-
terminal hexahistidine (6xHis) tags.  The subtilosin A precursor gene sboA was separately cloned 
into the pMCSG7 plasmid, which houses an N-terminal-6xHis tag and pET28c (C-terminal-
6xHis-tag) followed by expression and purification from E. coli BL21 (DE3) cells. Full length 
peptides were purified from inclusion bodies using HISTrap, Ni-NTA, columns according to the 
procedure of Li et al.
29
 In parallel, N-terminal-6xHis-tagged sactionine synthase AlbA was 
expressed, purified, and reconstituted as described by Flühe et al.13 Upon incubation of peptides, 
enzyme, and essential co-factors (dithionite and S-adenosylmethionine), we could confirm 
complete formation of all three sactionine bridges by LC/MS with either 6xHis-tag.  This result 
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suggested that tandem, heterologous expression of the AlbA sactionine synthase and the 6xHis-
tagged SboA substrate could in theory yield mature sactipeptides. We chose to move forward 
with the N-terminal 6xHis-tag as we postulated that the placement of several lysine residues in 
SboA would be advantageous and allow easy removal of the 6xHis-tag together with the leader 
peptide of SboA via trypsin digestion. 
 
Figure 3.2. Expression of sactipeptides in Escherichia coli. a) Vector map of pETDuet-SboA-
AlbA used in this study showing organization of genes in the two multiple cloning sites. b) LC-
MS comparison of in vivo production of unmodified precursor peptide (gray) and modified (red) 
from constructs under varied, listed, conditions. pPH151 containing the E. coli suf ABCDSE 
genes aids in expression and repair of [4Fe-4S] clusters of sactionine synthase (AlbA) required 
for activity. (c) QTOF-MS data of unmodified (top) and modified (bottom) SboA peptide from 
the E. coli heterologous expression system.  
N-terminal, 6xHis-tagged precursor peptide, SboA and the enzyme, AlbA were cloned 
into multiple cloning sites 1 (MCS1) and 2 (MCS2), respectively, of the pETDuet-1 plasmid to 
generate the bicistronic plasmid (Figure 3.2a). Unlike the native producer Bacillus subtilis 168, 
this particular expression system would not be capable of producing the fully modified head-to-
tail cyclized product as designed.  We did not include any candidate protease capable of forming 
this last linkage and therefore no head-to-tail cyclized product could be formed. However, it has 
already been shown that the lack of head-to-tail cyclization does not affect the ability of the 
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sactionine synthase, AlbA, to modify the precursor peptide.  Head-to-tail cyclization is often not 
present in a number of other sactipeptides, such as thurincin H and thuricin CD.
13
 A wide range 
and variety of conditions were tested to facilitate and improve sactionine formation in vivo 
(Figure 3.2b). We ultimately found that co-expression in the presence of pPH151, termed 
corrector plasmid, which contains the E. coli suf ABCDSE genes along with dropping the shake 
rate significantly improved expression of the modified sactipeptide.
30,31
 These two measures 
together ensure proper AlbA expression and activity by (1) proper assembly and repair of the 
[4Fe-4S] clusters, assisted by suf ABCDSE, and (2) limiting aeration and possible deactivation 
of the enzyme by oxidation through oxygen. SDS-PAGE gels of crude lysates showed 
remarkable improved expression of AlbA under these optimized conditions (see Appendix 
Figure B.28). The high copy duet vector pRSFDuet-1 was also tested but showed negligible 
improvement over our pETDuet-1 construct. We therefore employed this, pETDuet-SboA-AlbA, 
construct in our further examination of AlbA sactionine substrate promiscuity. 
3.3 Design and Evaluation of SboA Mutants 
Upon confirming production of modified sactipeptides by our system, the next step was 
to examine the ability of AlbA to accept alternate SboA substrates in vivo using our heterologous 
expression system.  Sactipeptide mutants have largely been limited to simple alanine scans or 
conservative mutations at bridging partner residues in the sactionine linkage. Preliminary efforts 
by Marahiel and co-workers suggested that the sactionine synthase AlbA is relatively non-
tolerant to substrate changes which stand in direct contrast to the vast majority of reported RiPP 
enzymes characterized to date. Because of these previously reported results, we designed our 
initial mutants with three primary goals in mind: (1) to test the promiscuity at bridging partner 
residues, (2) to examine requirements for substrate flexibility or “preorganization”, and (3) 
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cysteine spacing relative to the brief leader peptide (8 residues) sequence. Saturation 
mutagenesis would require a library size too large to allow specific probing of each of these 
areas; we therefore pursued a more conservative rational design approach compared to saturation 
mutagenesis. In the case of the three bridging positions present in subtilosin A, Cys4
S
-Phe31
Cα
, 
Cys7
S
-Thr28
Cα
, and Cys13
S
-Phe22
Cα
 (Figure 3.1c), we incorporated a small subset of sterically 
and electronically distinct amino acids that are observed at bridging partner positions in other 
known sactipeptides, specifically the amino acids Ala, Gln, Met, Phe, Ser, and Thr (Table 3.1a, 
entries 1−14). The second set of mutants targeted the flexible glycine residues that are adjacent 
to sactionine bridging residues by alanine mutation (Gly’s 26, 29, and 32), as well as two 
potential turn-inducing prolines at residues 18 and 20 respectively. The two prolines were also 
targeted for direct deletion in order to fully probe the effects of the residues 14−21 loop on 
priming sactionine bridge formation. (Table 3.1a, entries 15-27) The last set of mutations 
focused on the movement of the cysteine residues themselves, involved in sactionine bridge 
formation, around the “N-terminal side” or first half of SboA. In order to minimize the number 
of potential changes within this set, we chose to move cysteines by “swapping” or exchanging 
them with residues at their respective positions. (Table 3.1a, entries 28-40) The analogous Ala-
swap could also be considered for further investigation. 
For this initial study, we designed and fully characterized a total 40 sactipeptide mutants. 
Several of these mutants were accessed by QuikChange mutagenesis; however, the majority 
could be readily obtained by gene synthesis at equivalent or lesser cost and time (see 
Experimental Section 3.9.1). In each case, the mutant gene was incorporated with 6xHis-tag on 
the N-terminus into MCS1 of the pETDuet vector containing AlbA in MCS2 and expressed in 
the pPH151 background under the same optimized conditions as the wild-type SboA using small 
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(100 mL culture size) grow-ups. The peptides were induced with IPTG, as with the wild type, 
and isolated in a medium-throughput manner by using small spin Ni-NTA columns. To facilitate 
characterization by LC-MS, the peptides were digested with the use of trypsin to remove the 6x-
His-tag plus a portion of the leader peptide.  Trypsin seemed to leave the major product as the 
peptide cleaved at Lys,-6 of the leader peptide (Figure 3.1b). 
Table 3.1a. SboA mutants analyzed and sites of linkages identified by MS-MS 
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A very distinctive tandem mass spec. fragmentation pattern of sactionine linkages 
(Figure 3.3a) was used to identify bridge partnering residues of cysteines in the sactionine 
linkages.
4,32
 The thioamidals in sactionine bridges have been shown to undergo facile retro-
elimination and tautomerization to the corresponding dehydro-amino acid at low collision 
energies as presented in Figure 3.3a−d; the new amide bond formed from this dehydro-amino 
acid is much more labile than a typical peptide bond due to the resonance-stabilized enamine 
leaving group. Thus, at low collision voltages (~20-35 eV), only cleavage of these bonds is 
observed by the instrument while the other amide bonds stay intact, allowing the identification of 
the bridge partnering residues. This MS-generated formal dehydrogenation at bridging partners 
has previously been reported by Vederas et al., who exploited it to correctly assign the 
connectivity in the structure of the two-component sactipeptide system thuricin CD. The 
alternative method, employing nickel-borodeuteride desulfurization, did work in our hands but 
often gave variable and incomplete results, even with WT-subtilosin A itself.
7,8
 We hypothesize 
that this was potentially due to metal contaminants carried over from Ni- NTA purification of the 
sactipeptides or other catalyst poisons from the E. coli heterologous system. In the tandem mass 
spec. method, sactionine linkages were easily the most labile at lower collision energies, and thus 
provided strong qualitative confirmation of bridging partner residues with low parts-per-million 
(ppm) error. In all cases with mutant sactipeptide, the presence of less than three bridges could 
be readily confirmed by reductive treatment with N-ethylmaleimide (NEM) and LC-MS to show 
masses of the relevant NEM adducts. Although sactionine linkages can be formed with differing 
stereochemistry at the bridge partner α-carbon (D or L as is the case with subtilosin A), we did 
not examine the effects of mutants on stereochemistry within this system. Outside of nuclear 
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magnetic resonance (NMR), there are no good methods to measure sactionine stereochemistry, in 
regard to our system, reported in the literature to date. 
We did compared production of our modified peptides to native production of subtilosin 
A in B subtilis 168. B. subtilis is reported to produce subtilosin A at roughly 5.5 mg/L.
6
 We 
obtained between 1 and 2 mg/L dry weight or ∼20−40% of native production from the pETDuet 
system (see Appendix B). Production levels of mutants were highly variable, and many of them 
could only be detected very faintly by UV-vis absorption. Based on extracted ion chromatograms 
(EICs) of the products, yields of mutants varied from 10% to greater than 300% when compared 
to EIC of the modified wild type peptide on the same scale (see Appendix Figure B.30-B.59). In 
general, many of the cysteine swap mutants were produced at comparable or higher levels than 
the wild-type SboA peptide in the pETDuet system (see Appendix Table B.1). In several 
instances (12 out of 40), we observed no product from induction of a given mutant.  The variable 
or complete lack of production may happen for any number reasons.  Intrinsic destabilization of 
the given mutant peptide, its transcript causing degradation, unanticipated metabolic processing 
such as glutathionylation, other detoxifying post-translational modifications could lead to low or 
no production and  might cause the sactipeptide product to escape our isolation procedure for this 
system. We expected that post-translation installation of sactionine linkages would improve 
overall peptide stability. Therefore, in the analysis, instances of “no product” (Table 3.1) were 
actually interpreted as a weak proclivity of the enzyme to accept those substrates. However, it 
should be noted that these are the results of peptide expression under the current and reported in 
vivo conditions. It is reasonable to speculate that while expression of some mutants may be lower 
than wild-type, even production at these low levels has been improved by the presence of strong 
overexpression of the sactionine synthase relative to levels in the native producer. 
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3.4 Substrate Tolerance at Bridging Partners 
Several different amino acids, with different steric and electrochemical properties, appear 
at bridging partner residues with in sactipeptides. Even within subtilosin A, Phe and Thr appear 
at different positions, suggesting that the sactionine synthase, AlbA, might have some level of 
tolerance for different bridging partners. A set of alanine mutants at the three bridging partners of 
subtilosin A was tested in our E. coli expression system (Table 3.1a, entries 1, 5, and 10) and in 
all three Ala mutants, all three bridges were formed and confirmed by MS-MS showing that the 
site of modification remained the same, i.e. cross-linking occurred at the new Ala22, Ala28, or 
Ala31 residue. Marahiel and co-workers had reported a lack of production of F22A, T28A, and 
F31A mutants expressed in parallel with the native cluster in B. subtilis.
13
 However, in an E. coli 
heterologous expression system, these three mutants were well tolerated by the AlbA machinery, 
demonstrating a potential benefit of this approach.  Beyond alanine residues, only the +28 
position appeared particularly permissive to any other amino acid residue substitution. Thr28 
could also be substituted with Ser, Phe, and Asn and still be activated and incorporated into the 
resulting sactionine bridge. Meanwhile, Phe22 could be substituted with Met and still be 
processed to a sactionine bridge, but neither Ser nor Thr substitutions at this position yielded 
identifiable peptide product. Similarly, the F31S was processed to a three bridge product, but no 
product could be observed with Thr, Met, or Asn substitutions at this position.  Given the 
obvious promiscuity at the +28 residue, we wondered if there could be any bias for the native 
amino acid Thr. We therefore exchanged Thr28 with the upstream Ala27 to see if this would 
drive bridge formation toward the newly positioned Thr. This, however, was not the case and the 
sactionine bridge was instead formed at Ala28, suggesting minimal residue level control over 
steering modifications, at least at this position. 
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Figure 3.3.  Confirming bridge formation in mutant sactipeptides. a) Mechanism of sactionine 
fragmentation. b) MS/MS on modified “wild-type” SboA peptide from 50 rpm overnight culture. 
c) MS-MS on modified T27/A28 swap SboA mutant peptide from 50 rpm overnight culture. d) 
MS/MS on modified Δ Pro 18 SboA mutant peptide from 50 rpm overnight culture. Insets show 
[M+3H]
3+
 ion targeted in MS-MS. 
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3.5 Substrate Tolerance at Unmodified Positions 
The precursor peptides for subtilosin and the two sactipeptides that make up thuricin CD, 
Trn-α and Trn-β, have relatively high glycine content (22%, 26%, and 22% of non-cysteine 
residues respectively). We sought to find out whether substrate flexibility arising from these 
constitutive glycine residues was necessary to allow enzymatic modification by the sactionine 
synthase or if Cα-branching might drive other alternative bridging partners. An alanine scan of 
the three C-terminal glycine residues, Gly26, Gly29, and Gly32, demonstrated that these 
positions can tolerate at least small, sterically unhindered alanine side chains at these positions 
(Table 3.1a, entries 15−21). Besides modification occurring with these single mutations the 
same as WT modification, all three positions could be substituted with alanines at once, with no 
detriment to modified product formation. All products isolated from these mutation experiments 
formed three, complete sactionine bridges with the native residues of WT (Phe22, Thr28, and 
Phe31), suggesting that AlbA is at least somewhat indifferent to secondary structure or flexibility 
at these specific glycine residues. 
Subtilosin A has the largest loop of the known sactipeptides (eight amino acids compared 
to the seven in thuricin CD and the four in thurincin H), and none of these other known 
sactipeptides have prolines, much less two prolines,  in their designated loop regions. We 
therefore sought to determine whether Pro18 and/or Pro20 were necessary for inducing a turn 
and allowing AlbA to work on the sets of bridging residues (Table 3.1a, entries 22−27). Again, 
alanine scans at these two Pro positions demonstrated that AlbA was indifferent to the presence 
of prolines at these positions similar to the results seen in the glycine mutations.  However, 
complete deletion of Pro18 did appear to shift the bridging partner of Cys13 in SboA for the first 
time in our experiments (Table 3.1a, entry 25). Careful study and examination of the tandem 
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mass spec. data indicated that the Cys13 sactionine thioether is formed at the α carbon of the new 
Pro19 in isolates from this mutant while the locations of the other two sactionine bridges are 
conserved and not changed.  In contrast, deletion of Pro20 did not change the bridging partners 
of the cysteines involved in thioether bridge formation again (Table 3.1a, entry 26). Overall, 
these mutants demonstrated substrate promiscuity in regards to AlbA activity and suggest that 
the substrate-enzyme interactions may play a role in dictating the position of bridge formation. 
Alterations to the loop proline residues could also conceivably be expected to have an impact on 
stereochemistry, especially at the nearby Cys13−Phe21 sactionine linkage, but this a question for 
future investigations. 
3.6 Substrate Tolerance for Cysteine Placement 
Interestingly, subtilosin A has seemingly relaxed specificity for the bridging partner 
residues and is able to accept Ala, Gln, Met, Phe, Ser, and Thr residues at the bridging partners 
to varying degrees of success.  Therefore, two major issues can be probed with respect to 
cysteine placement: (1) the possibility of cysteines being moved and still form bridges and (2) 
what will the bridging partner residue be, if the cysteine is moved.  We set out to probe these 
issues with a series of 14 cysteine swap mutants: four swap mutants at both Cys4 and Cys7, five 
swap mutants at Cys13, and also a tandem mutant.  Under our heterologous expression 
conditions, described above, sactionine bridges at Cys4 and Cys7 seemed very resistant to 
changes in placement (Table 3.1a, entries 28−35).  Cys4 did tolerate a single move one residue 
toward the leader peptide (Table 3.1a, entry 30), but this move came at the expense of the 
formation of the remaining two sactionine bridges, which did not form in this product. Similarly, 
Cys7 could be swapped with Ser8 or Gly10, while still allowing formation of the sactionine 
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bridge at Cys4 (Table 3.1a, entries 33 and 35), but neither of the other two bridges were 
formed. 
In stark contrast to the Cys4 and Cys7 bridge placements, Cys13 proved remarkably 
tractable. Of the five positional swaps tested (Table 3.1, entries 36−40), only the Cys11/Ala13 
swap (entry 37) did not yield a fully modified three-bridge sactipeptide. Each placement of 
Cys13, either at the +10, + 12, + 14, or +15 positions within SboA, resulted in a sactionine 
linkage to the same bridging partner as the WT sactipeptide linkage (Phe22). Interestingly, the 
Gly10 position, which did not allow a swap with Cys7, is capable of tolerating a sactionine 
bridge when a +7 bridge is also formed in the final product (Table 3.1, entry 36). 
The relative success of the mutants that were tested may betray the order of AlbA-
catalyzed sactionine bridge formation in this E. coli, heterologous host. While the system does 
not appear to tolerate cysteine movement at the +4 and +7 positions, the third bridge at Cys13 
seems to tolerate a wide variety of movements.  This could be due to the first two sactionine 
bridges being formed quickly, allowing the rest of the peptide to reach a type of conformational 
equilibrium before the third bridge can be formed; further kinetic analysis and experiments of the 
bridge-forming reaction will be necessary to confirm this hypothesis. The formation of a bridge 
to Phe22 regardless of the position of the third cysteine indicates a degree of enzymatic control 
over regioselectivity. This control, however, is overridden in the case of Pro18 deletion, which 
suggests that this residue is critical in both the spacing and in the conformation of the loop. 
3.7 Unpublished Mutants Tested 
The 40 mutants tested and published were not the only mutants cloned and tested.  In 
Table 3.1b, another 31 mutants, designed to have 2, 3 or even 4 sactionine bridges, are listed 
with their changes and their preliminary results by LC-MS.  These mutants were designed to 
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have different secondary structure characteristics than the native sactipeptide.  The mutants were 
not included in the other table of mutants (Table 3.1a) due to the low quality of data obtained 
during the initial testing of production.  While some mutants (F22N and T28M, not listed) were 
not initially successfully cloned into out heterologous expression system, other mutants did not 
produce or simply gave inconclusive MS data after purification of the product from inclusion 
bodies.  Others mutant SboA peptides did produce and an initial run on the LC-MS gave an 
indication of the number of sactionine bridges or disulfides formed.  However, upon trypsin 
digestion, NEM modification, and injection onto the LC-MS to run tandem mass spectrometry, 
no product ions could be analyzed successfully.  This led us to the conclusion that while the 
mutants were produced, they were produced as such low levels that accurate determination of the 
bridging partners was impossible.  Low or no production could be due to a number of factors 
including intrinsic destabilization and degradation, unaccounted for metabolic processing, other 
detoxifying post-translational modifications.  These modifications might cause the sactipeptide 
product to escape our designed isolation procedure for this heterologous system. 
3.8 Incorporation of Unnatural Amino Acids into Sactipeptides 
Unnatural amino acids (UAAs) have been incorporated in a number of heterologously 
expressed RiPP natural products by amber codon suppression technology, including both the 
lantipeptides and the cyanobactins.
20,24−28
 In the case of the lantipeptides, UAAs allowed access 
to mutant lanitpeptides with improved potency and solubility. We anticipated that similar effects 
could be obtained with UAA incorporation into bioactive sactipeptides. UAA incorporation may 
also allow access to new chemistries from sactionine forming sactionine synthases: since the 
enzyme putatively generates a reactive radical intermediate, at the α carbon of the bridging 
residue , a specific placement of a radical trap or other reactive group on a bridging partner 
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amino acid side chain could allow side-tracking into alternative reactions. This would only be 
possible if the sactionine synthases prove permissive enough for UAAs at the bridging partner 
residue. We thus tested UAA incorporation via the orthogonal O-methyl tyrosine tRNA 
synthetase/tRNA (O-Me-Tyr) pair adapted from M. janaschii. 
Table 3.1b. Unpublished SboA mutant analysis  
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Figure 3.4.  Incorporation of unnatural amino acids (UAAs) into sactipeptides in E. coli. a) LC-
MS of isolate from F31O-Me-Tyr mutant, structure of O-Me-Tyr, and blow-up of [M+7H]
7+
 
envelope.(b) MS-MS of trypsinized F31O-Me-Tyr sactipeptide mutant. 
pUltra-O-Me-Tyr plasmid, replicated by an orthogonal pCDF origin of replication and 
bearing streptomycin resistance, was incorporated into BL21 (DE3) cells on top of pPH151 and a 
pETDuet-SboA-AlbA vector mutated to the amber stop codon (TAG) at Phe31. While we could 
observe unmodified peptide production/UAA incorporation at 200 rpm, this was accompanied by 
substantial amounts of truncation arising from disrupted translation at the newly incorporated 
TAG codon. No modified sactipeptide could be found at the lower, 50 rpm shake rate either. We 
therefore turned to the recently reported“TAGless” E. coli strain, C321.ΔA.exp, developed by 
Isaacs et al.
33
 In order to drive expression of our same pETDuet-SboA-AlbA, the λDE3 prophage 
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was integrated into C321.ΔA.exp. After these changes and subsequent growth under our 
optimized conditions, cyclic precursor peptide exhibiting fully modified cysteine thioether 
bridges at all three native positions (Figure 3.4) was produced. Tandem mass spec. confirmed 
the C4
S
-(O-Me−Tyr)Cα linkage at the newly installed UAA position. 
3.9 Design, production, and analysis of potential sactipeptide MDM2-p53 inhibitor 
With the proclivity of our heterologous expression system to accept changes made to the 
precursor peptide, we decided to test if grafting a known biologically relevant epitope onto a 
modified sactipeptide would result in a novel inhibitor or binder to a biologically important 
protein.  We decided to test whether a modified sactipeptide could inhibit the well-known 
protein-protein interaction (PPI) MDM2-p53.  We thought sactipeptide would be an attractive 
alternative to traditional approaches for targeting and disrupting PPIs due to their propensity for 
helical secondary structures and their overall larger, stable structure.
34,35 
These points can prove 
useful due to two facts.  The first is based on the multiple observations of helices participating in 
PPIs.
36
 While these helices can be present before or after the conformational change upon 
binding, helices are crucial in the interactions present MDM2-p53 interaction.  The second is the 
fact that PPIs usually encompass a large surface area, >2000 Å
2
.
37
 This area cannot be mediated 
efficiently by traditional small molecules unless it can mimic key residues (hot spots)
36, 38-41
, but 
a larger molecule such as a peptide should prove to be more beneficial in this regard by not only 
mimicking hot spots but also making other favored interactions throughout the hydrophobic 
pocket of the interaction.  Thus we sought to design sactipeptides specifically to mimic 
secondary motifs and hot spot residues crucial for binding in MDM2-p53 interaction and 
therefore creating a natural peptidomimetic. 
 
95 
 
 
Figure 3.5. Overview of proposed inhibitor SboA-2xMut.  a) Sequence of SboA-2xMut with 
mutated residues in green, corresponding to the Phe, Trp epitope inserted.  b-c) Mass spectrum of 
SboA-2xMut produced in pETDuet system. b was at 200 rpm while c was at 50 rpm.  The 
difference between the two mass spectrums is a loss of 2.0 atomic mass units (amu).  d) Mass 
spectrum of TEV-cleaved SboA-2xMut used in inhibition assays.  e) left-crystal structure of p53 
interacting with MDM2, right-proposed binding of SboA-2xMut to MDM2. 
Phe19 and Trp23 have been characterized as hot spot residues in the MDM2-p53 
interaction and thus make a suitable epitope to graft onto a sactipeptide.  We did this by mutating 
Ile24 and Ala27 to Phe and Trp respectively (Table 3.1b entry 41, and Figure 3.5).  The 
peptide was expressed and modified within our heterologous expression system as before and 
yielded a sactipeptide with only one sactionine linkage (Figure 3.5b and c).  The location of this 
bridge has yet to be determined but we decided to go on with our modified SboA-124F-A27W 
(referred to from now on as SboA-2xMut).  The 6xHis tag was removed by TEV protease and 
the peptide further purified by HPLC yielding the peptide that would be used in our inhibition 
assays (Figure 3.5d).   
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Figure 3.6.  Fluorescence Polarization assay of MDM2-p53 interaction.  a) FP curve showing 
p53 truncate (15-29) binding to MDM2 yielding a Kd of ~0.8 μM.  b) FP competition assay with 
unlabled-p53 truncate, nutlin3, and proposed inhibitor SboA-2xMut.  IC50 values are shown in 
the table below the graph.   
There are many ways to measure inhibition and binding in vitro and while several have 
been used to measure the inhibition of the p53-MDM2 interaction, fluorescence polarization (FP) 
and surface plasmon resonance (SPR) were used to measure the inhibitory affect that SboA-
2xMur has on the MDM2-p53 interaction.
42,43  
A MDM2 truncate (1-188) was expressed and 
purified from an adapted procedure
41
 as a 6xHIS-MBP fusion.  Both 5-(and-6)-
carboxytetramethylrhodamine-p53 (TAMRA-p53) and Biotin-p53 truncates (residues 15-29) 
were synthesized using a microwave peptide synthesizer using conventional Fmoc solid phase 
peptide synthesis (SPPS) (Experimental 3.11.7).  The TAMRA labeled peptide was used in the 
FP assays from an adapted procedure
41
, while the Biotin labeled peptide was used and bound to 
the streptavidin SPR chip for the SPR assays.
42
   In Figure 3.6 and 3.7, whether by FP or SPR, 
the results were the same.  Both assays show that MDM2 can bind to p53, a control to ensure 
proper folding of both the MDM2 truncate and the p53. Both the FP and SPR assays gave a 
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binding constant for p53 to MDM2 that corresponded well to literature values (~1 M).  We 
were also able to show that nutlin 3 inhibited binding of p53 to MDM2 in both assays, but our 
proposed inhibitor (SboA-2xMut) showed no binding or affect in either assay.  This could be due 
to only one sactionine bridge being formed in our heterologous expression system.  This could 
inhibit any meaningful secondary structure from forming and prevent the hot spot residues of 
Phe and Trp from adopting the proper orientation to interact with MDM2 in the p53 binding 
pocket. Another possibility is the size of SboA-2xMut compare to the p53 truncate. SboA-2xMut 
is over three times the size of the p53 truncate used in our study.  SboA-2xMut, once modified, 
may adopt a conformation that cannot access the p53 binding pocket due to its large size.  More 
testing and characterization of the system is required to fully realize the goal of sactipeptide 
inhibitor.  
3.10 Other Sactipeptide Systems: Thurincin H and 4BD1 
After seeing successful production and modification of variant subtilosin A sactipeptides, 
we believed that our system could be adapted for other known and predicted sactipeptides.  We 
attempted to produce one known sactipeptide system, Thurincin H (Figure 3.1b) and one 
predicted sactipeptide system from Bacillus thuringiensis serovar huazhongensis BGSC 4BD1 in 
our heterologous expression system and determine whether peptide could be produced and 
modified by their respective sactionine synthases.  A sactipeptide gene cluster has been 
bioinformatically predicted in Bacillus thuringiensis serovar huazhongensis BGSC 4BD1 
(Figure 3.8a) that houses two copies of its precursor peptide termed 4BD1sg and two predicted 
sactionine synthases belonging to the radical SAM superfamily of enzymes, named 4BD1-
rSAM1 and 4BD1-rSAM2.  This system is similar to Thurincin H in that the precursor peptide 
has four cysteines for a potential of four sactionine bridges (Figure 3.8b).  We were able to  
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Figure 3.7.  Surface Plasmon Resonance binding assays of MDM2-p53 interaction.  a) Curves 
showing p53 truncate (15-29) binding to MDM2 yielding a Kd of ~0.9 μM at equilibrium.  b) 
Curves showing nutlin3 is able to bind MDM2 and prevent p53 truncate binding reducing the 
response.  c) Curves showing the proposed inhibitor SboA-2xMut has no effect on MDM2-p53 
truncate binding. 
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isolate a product from the native producer whose mass corresponded to the precursor peptide of 
the cluster but with a loss of eight hydrogens.  These eight hydrogens correspond to a possible 
four sactionine bridges formed between the cysteine residues and their yet unidentified bridging 
partners.  This mass was able to be isolated in both the pellet and supernatant of the culture with 
a variety of truncates at the N-terminus (see Experimental 3.12.3 and Figure 3.8c-e).  We 
termed this isolated product 4BD1-NP for natural product.  Experiments are ongoing to determne 
the placement of the sactionine bridged positions by tandem mass spectrometry.  
 
Figure 3.8. Isolation of 4BD1 Natural Product (4BD1-NP).  a) Predicted sactipeptide gene 
cluster from Bacillus thuringiensis serovar huazhongensis BGSC 4BD1. b) Amino acid sequence 
of 4BD1sg with cysteines highlighted for formation of sactionine linkages.  c) Mass spectrum of 
4BD1-NP isolated from the cell pellet showing a range of N-terminal truncates and four 
sactionine linkages. d) Mass spectrum of 4BD1-NP isolated from the supernatant of the culture 
showing a range of N-terminal truncates and four sactionine linkages. e) Table of expected 
masses for potential truncates of 4BD1-NP forming four sactionine linkages. 
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Next, for both Thurincin H and 4BD1 satipeptide systems, we placed both their precursor 
peptides and their respective sactionine synthases into our Duet system as described in 
Experimental 3.12.1.  For Thurincin H, we followed a strategy similar to subtilosin A where the 
precursor peptide, ThnA, was 6xHis-tagged and placed in MCS1 of pETDuet-1 while the 
sactionine synthase, ThnB, was cloned into MCS2 without an affinity tag (Figure 3.9a).  For the 
4BD1 sactipeptide system, a second Duet plasmid was employed.  We found that by cloning the 
precursor peptide, 4BD1sg with a 6xHis-tag, into MCS1 of pETDuet-1 and cloning the predicted 
sactionine synthases 4BD1-rSAM1 and 4BD1-rSAM2 into MCS1 and 2 respectively of 
pRSFDuet-1 we were able to see production of the peptide (Figure 3.9b).  Both systems were 
transformed and expressed in systems containing the pPH151 corrector plasmid, just as the 
subtilosin A system described above.  However, unlike our previous system, both Thurincin H 
and the predicted 4BD1 sactipeptide system never yielded fully modified products.  During 
aerobic conditions, both peptides can be isolated with masses indicating two sactionine bridges 
or two disulfides (Figure 3.9a-d).  There are ongoing efforts to definitively answer if these are 
disulfides are true sactionine bridges, but being as these peptides were produced aerobically, 
disulfide bonds seem likely to be responsible for the corresponding four hydrogen loss.  Unlike 
our subtilosin A-Duet system, we were unable to see production of peptide at 50 rpm anaerobic 
conditions.  These systems may be less robust than the subtilosin A sactipeptide system and 
further optimization of expression conditions could remedy this production problem.  These 
systems show promise within our heterologous system and indicate our system can be adopted 
for producing other sactipeptide modified products.   
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Figure 3.9.  Duet systems cloned and expressed for Thurincin H and 4BD1 sactipeptides. a) 
Mass spectrum of 6xHis-tagged ThnA expressed from pETDuet at 200 rpm.  The insert shows 
the Duet construct used to produce the potential sactipeptde.  b) Table of expected masses for 
6xHis-ThnA modification. c) Mass spectrum of 6xHis-tagged 4BD1sg expressed from pETDuet 
at 200 rpm.  The insert shows the Duet constructs used to produce the potential sactipeptde.  d) 
Table of expected masses for 6xHis-4BD1sg modification.  
3.11 Summary and Discussion 
In summary, we have created a system for the heterologous expression of modified 
sactipeptide derivatives from subtilosin A in E. coli and demonstrated unexpected biosynthetic 
promiscuity of the sactionine synthetase, AlbA. We anticipate that a similar strategy could be 
utilized to access other predicted sactipeptides or else chemistry from the ever-widening library 
of rSAM enzymes in RiPP pathways.
44-46
 The pronounced promiscuity, especially in the loop 
region and at unmodified positions on the solvent-exposed exterior of the sactipeptide 
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macrocycle, could be exploited for the grafting of peptide epitopes as has been seen in lasso 
peptides and conotoxins, such as integrin binding motifs.  We did try and use our promiscuous 
heterologous expression system, to insert a biologically relevant epitope into our sactipeptide 
natural products.  While the production of a possible MDM2-p53 sactipeptide inhibitor did not 
yield a functioning peptide, it did indicate and show the potential for the production of natural 
peptidomimetics by our system. Moreover, we observed for the first time promiscuity with 
respect to sactionine bridge placement and, in specific instances, bridging partner selection. An 
expanded understanding of control over sactionine bridge placement could allow for the design 
of constrained sactipeptide conformations for display of peptide epitopes; as such, our E. coli 
expression system should facilitate such efforts. Results with sactionine bridge movement 
suggest interdependence between the positioning of these three bridges; this may further be 
compounded by the overall flexibility of the substrate. Therefore, many more modified 
sactipeptides may be possible from compound mutants that combine multiple mutations. Again, 
this is another place where the heterologous expression system may prove beneficial: based on 
the changes reported here, including the demonstrated mobility of the bridge partners, we 
estimate libraries far in excess of 10
12
 non-native subtilosin A analogs to be possible with use of 
the right system. This work suggests that sactipeptides systems are capable of producing vast 
libraries with significantly high structural complexity.  Finally we have also introduced unnatural 
amino acids (UAAs) into sactipeptides using stop-codon suppression technology, specifically at 
an otherwise less permissive bridging partner position. This demonstrates the robustness of UAA 
incorporation in our system and may open up new chemistry and new applications for unnatural 
sactipeptides. 
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3.12 Experimental 
3.12.1 Cloning and Generation Duet System for the Production of Sactipeptides 
LIC cloning precursor peptides genes into pMCSG7 
The precursor gene sboA was amplified from B. subtilis 168 genomic DNA by PCR using 
Phusion® High-Fidelity Master Mix with HF-buffer following the manufacturer’s manual. 
Primers 1 and 2 were used to accomplish this (see Table 3.3). The purified PCR product was 
phosphorylated with T4-PNK and then treated with T4-DNA Polymerase to create 
LICoverhangs.  In parallel, pMCSG7 was linearized with SspI and dephosphorylated with 
Antarctic Phosphatase (AP) and then treated with T4-DNA Polymerase to create LIC overhangs. 
Treated PCR product and vector were combined and transformed into One-Shot ® Top 10 cells. 
The plasmid was harvested from cells utilizing the GeneJET Plasmid Miniprep kit following the 
manual.  This process was repeated from cloning 4BD1sg and thnA in to pMCSG7 as well.  
4BD1sg was amplified from Bacillus thuringiensis serovar huazhongensis BGSC 4BD1 genomic 
DNA by PCR using primers 21 and 22 (See Table 3.3) while thnA was amplified from a codon 
optimized template obtained from Integrated DNA Technologies (Gene-Block 1, Table 3.3) 
using primers 23 and 24  (See Table 3.3). 
QuikChange Site-Directed Mutagenesis of His-sboA (pMCSG7-SboA) 
Site-directed mutagenesis of the His-sboA construct was performed following 
instructions from the QuikChange Site-Directed Mutagenesis kit (Agilent). Briefly, the 
pMCSG7-sboA plasmid was amplified with primers designed to incorporate desired mutations 
(see Table 3.3). Template plasmid was digested away using DpnI and mutant plasmid was 
transformed into One-Shot ® Top 10 cells. The mutant plasmids were harvested from cells by 
GeneJET Plasmid Miniprep kit. 
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Cloning of sactionine synthases (albA, thnB, 4BD1-rSAM1, and 4BD1-rSAM2) into multiple 
cloning sites (MCS1 or 2) of Duet plasmids 
The gene albA was amplified from B. subtilis 168 genomic DNA by PCR using 
Phusion® High-Fidelity Master Mix with HF-buffer following the manufacturer’s manual. 
Primers 19 and 20 were used to accomplish this (see Table 3.3). The purified PCR product and 
Duet plasmid (pETDuet-1 or pRSFDuet-1) were digested using NdeI and XhoI (MCS2). The 
purified digested plasmid was treated with AP and then combined with the purified digested PCR 
product in the presence of T4 ligase. The ligation was allowed to go overnight at 16 
o
C. After 
ligation, the T4 ligase was heat inactivated at 65 
o
C for 10 min before being transformed into 
One-Shot ® Top 10 cells. The plasmid was harvested from cells by GeneJET Plasmid Miniprep 
kit.  This process was repeated for the cloning of thnB, 4BD1-rSAM1, and 4BD1-rSAM2 into the 
Duet plasmids as well.  The gene thnB was amplified by PCR from a codon optimized template 
obtained from Integrated DNA Technologies (Gene-Block 2, Table 3.3) using primers 33 and 34 
(see Table 3.3), while both 4BD1-rSAM1, and 4BD1-rSAM2 were amplified from Bacillus 
thuringiensis serovar huazhongensis BGSC 4BD1 genmoic DNA by PCR using primers 29/30 
and 31/32 respectively (see Table 3.3).  thnB was placed in MCS2 of pETDuet-1.  4BD1-rSAM1 
was placed in MCS1 of pRSFDuet-1 using NcoI and NotI while 4BD1-rSAM2 was placed in 
MCS2 of pRSFDuet-1 with NdeI and XhoI after successful cloning of 4BD1-rSAM1. 
Cloning of His-precursor genes (pMCSG7-precursor gene) and mutant sboA into multiple 
cloning site 1 (MCS1) of Duet plasmids 
The construct His-sboA was amplified from the pMCSG7-sboA plasmid by PCR using 
Phusion® High-Fidelity Master Mix with HF-buffer following the manufacturer’s manual. 
Relevant primers are listed in Table 3.3 below. Primers 16, 17, and 18 were used to amplify 
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mutants from synthetic genes. The purified PCR product and Duet plasmid with albA in MCS2 
(pETDuet-1 or RSFDuet-1) were digested using NcoI and HindIII. The purified digested plasmid 
was treated with AP and then combined with the purified digested PCR product in the presence 
of T4 ligase. The ligation was allowed to incubate overnight at 16 
o
C. After ligation, the T4 
ligase was heat inactivated at 65 
o
C for 10 min before being transformed into One-Shot ® Top 10 
cells. The plasmid was harvested from cells by GeneJET Plasmid Miniprep kit.  The above 
process was used for His-thnA and His-4BD1sg into MCS1 of pETDuet-1.  Primers 27 and 28 
were used for His-thnA and Primers 25 and 26 were used for His-4BD1sg (see Table 3.3). 
Generation of mutant sactipeptide library 
All other mutants were purchased from General Biosystems. Mutants were based on the 
template: 5’- CAA TCC AAT GCG ATG AAA AAA GCT GTC ATT GTA GAA AAC AAA 
GGT TGT GCA ACA TGC TCG ATC GGA GCC GCT TGT CTA GTG GAC GGT CCT ATC 
CCT GAT TTT GAA ATT GCC GGT GCA ACA GGT CTA TTC GGT CTA TGG GGG TAA 
AAG CTT-3’. Swaps were generated by directly swapping the codons at the relevant positions. 
Alternatively, the following codons, adopted from other sites in sboA, were used for direct 
replacement of a native codon: Phe-TTT, Met-ATG, Ala-GCC, Ser-TCG, Thr-ACA, Asn-AAC. 
The mutant gene templates received from General Biosystems were then amplified using 
relevant primers (see Table 3.3). These purified PCR constructs were used as templates for the 
cloning into Duet-MCS1 described above. 
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Table 3.3. Plasmids, sites, and primers used in pETDuet-SboA-AlbA heterologous system 
LIC-plasmid pMCSG7 SspI 
MCS1-Duet pETDuet, RSFDuet NcoI, HindIII for all expcept 4BD1-rSAM1-MCS1, then use NotI 
MCS2-Duet pETDuet, RSFDuet NdeI, XhoI 
Primer 1 pMCSG7-SboA-F 5’-TAC TTC CAA TCC AAT GCG ATG AAA AAA GCT GTC ATT 
GTA GAA AAC AAA GG-3’ 
Primer 2 pMCSG7-SboA-R 5’-TTA TCC ACT TCC AAT GCG CTA TTA CCC CCA TAG ACC 
GAA TAG ACC T-3’ 
Primer 3 Quick-change-SboA-
C3/G4 swap-F 
5’-ATT GTA GAA AAC AAA TGT GGT GCA ACA TGC TCG ATC-
3’ 
Primer 4 Quick-change-SboA-
-C3/G4 swap-R 
5’-GAT CGA GCA TGT TGC ACC ACA TTT GTT TTC TAC AAT-3’ 
Primer 5 Quick-change-SboA-
-S7/C8 swap-F 
5’-AAA GGT TGT GCA ACA TCG TGC ATC GGA GCC GCT TGT-
3’ 
Primer 6 Quick-change-SboA-
-S7/C8 swap-R 
5’-ACA AGC GGC TCC GAT GCA CGA TGT TGC ACA ACC TTT-3’ 
Primer 7 Quick-change-SboA-
C12/A13 swap-F 
5’-TGC TCG ATC GGA GCC TGT GCT CTA GTG GAC GGT CCT-3’ 
Primer 8 Quick-change-SboA-
C12/A13 swap-F 
5’-AGG ACC GTC CAC TAG AGC ACA GGC TCC GAT CGA GCA-
3’ 
Primer 9 His-SboA-into Duet-
MCS1-F 
5’-GAT CGA TCC CAT GGG CAT GCA CCA TCA TCA TCA TCA 
TTC TT-3’ 
Primer 10 His-SboA-into Duet-
MCS1-R 
5’-GAT CGA TCA AGC TTT TAC CCC CAT AGA CCG AAT AGA 
CCT-3’ 
Primer 11 His-SboA-P18A into 
Duet-MCS1-R 
5’-GAT CGA TCA AGC TTT TAC CCC CAT AGA CCG AAT AGA 
CCT GTT GCA CCG GCA ATT TCA AAA TCA GCG ATA GGA 
CCG TC-3’ 
Primer 12 His-SboA-P20A into 
Duet-MCS1-R 
5’-GAT CGA TCA AGC TTT TAC CCC CAT AGA CCG AAT AGA 
CCT GTT GCA CCG GCA ATT TCA AAA TCA GGG ATA GCA 
CCG TC-3’ 
Primer 13 His-SboA-P18A and 
P20A into Duet-
MCS1-R 
5’-GAT CGA TCA AGC TTT TAC CCC CAT AGA CCG AAT AGA 
CCT GTT GCA CCG GCA ATT TCA AAA TCA GCG ATA GCA 
CCG TC-3’ 
Primer 14 His-SboA-F31TAG 
into Duet-MCS1-R 
5’-GAT CGT ACA AGC TTT TAC CCC CAT AGA CCC TAT AGA 
CCT GT-3’ 
Primer 15 SboA-add His into 
Duet-MCS1-F-
Library 
5’-GAT CGA TCC CAT GGG CAT GCA CCA TCA TCA TCA TCA 
TTC TTC TGG TGT AGA TCT GGG TAC CGA GAA CCT GTA CTT 
CCA ATC CAA TGC GAT GAA A-3’ 
107 
 
Primer 16 His-SboA-into Duet-
MCS1-F-Library 
5’-GAT CGA TCC CAT GGG CAT GCA CCA T-3’ 
Primer 17 His-SboA-into Duet-
MCS1-R-Library-1 
5’-GAT CGT ACA AGC TTT TAC CCC CAT AG-3’ 
Primer 18 His-SboA-into Duet-
MCS1-R-Library-2 
5’-GAT CGT ACA AGC TTT TAC CCC CA-3’ 
Primer 19 AlbA-into Duet-
MCS2-F 
5’-GAT CGA TCC ATA TGT TGT TTA TAG AGC AGA TGT TTC 
CAT-3’ 
Primer 20 AlbA-into Duet-
MCS2-R 
5’-GAT CGA TCC TCG AGC TAA ATA AGC TGG ACC ACG TCT 
TC-3’ 
Primer 21 pMCSG7-4BD1sg-F 5’-TAC TTC CAA TCC AAT GCG ATG GAA CCA ATT CAA CGT 
GA-3’ 
Primer 22 pMCSG7-4BD1sg-R 5’-TTA TCC ACT TCC AAT GCG CTA TTA ACC ATG TCC TCC 
AGC AT-3’ 
Primer 23 pMCSG7-ThnA-F 5’-TAC TTC CAA TCC AAT GCG ATG GAA ACA CCA GTA GTA 
CAA-3’ 
Primer 24 pMCSG7-ThnA-R 5’-TTA TCC ACT TCC AAT GCG CTA TTA GCT TGC AGT ACT 
AGC CCC TGT-3’ 
Primer 25 His-4BD1sg-into 
Duet-MCS1-F 
5’-GAT CGA TCC CAT GGG CAT GCA CCA TCA TCA TCA TCA 
TTC TT-3’ 
Primer 26 His-4BD1sg-into 
Duet-MCS1-R 
5’-GAT CGA TCA AGC TTT TAA CCA TGT CCT CCA GCA T-3’ 
Primer 27 His-ThnA-into Duet-
MCS1-F 
5’-GAT CGA TCC CAT GGG AAT GCA CCA TCA TCA TCA TCA 
TTC TTC TGG T-3’ 
Primer 28 His-ThnA-into Duet-
MCS1-R 
5’-GAT CGA TCA AGC TTT TAG CTT GCA GTA CTA GCC CCT 
GT-3’ 
Primer 29 4BD1-rSAM1 into 
Duet-MCS1-F 
5’-GAT CGA TCC CAT GGG CAT GCA AAC TGG TAC TGC TAA 
AG-3’ 
Primer 30 4BD1-rSAM1 into 
Duet-MCS1-R 
5’-GAT CGA TCG CGG CCG CTT ACA TAT TTA ATA TAT CAT-3’ 
Primer 31 4BD1-rSAM2 into 
Duet-MCS2-F 
5’-GAT CGA TCC ATA TGA TGT TCA TGA ATA AAT ACT T-3’ 
Primer 32 4BD1-rSAM2 into 
Duet-MCS2-R 
5’-GAT CGA TCC TCG AGT TAA GCA TAA GAG CAT AAT G-3’ 
Primer 33 ThnB into Duet-
MCS1-F 
5’-GAT CGA TCC ATA TGA TGA ATG GTT ACC TGT TTT GGA 
AGG AAA AAC TGG AAA TCC G-3’ 
Primer 34 ThnB into Duet-
MCS1-R 
5’-GAT CGA TCC TCG AGC TAA TTC TGA CCA ACC ATG AGT 
GGC TCT TT-3’ 
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Gene-Block 1 ThnA 5’-ATG GAA ACA CCA GTA GTA CAA CCA AGG GAT TGG ACT 
TGT TGG AGT TGC TTA GTA TGT GCA GCA TGT TCT GTG GAA 
TTA TTA AAT TTA GTT ACT GCG GCA ACA GGG GCT AGT ACT 
GCA AGC TAA -3’ 
Gene-Block 2 ThnB 5’-ATG AAT GGT TAC CTG TTT TGG AAG GAA AAA CTG GAA 
ATC CGC AAA TTT ACC TCT AAT TAC GAG AGC ATG CTG GTA 
GTT CAT AAA AAC CCT AAC GAA AGC GCA CCG ACC CTG 
AAG AAT GAG AAT ACG TTT ACG ATC AAC AAG ACG GCG 
ACC GAA ATC ATT GAA TTA ATT GAT GGC ACA AAG ACG 
TAC GGC CAA GTG GTG AGT TTT CTT TCA CTG AAA TAC TCC 
GAA GAT CCT ATC AGT ATT GAA AAG AAA CTG AAC GCC 
TTT CTT AAC AAC GTG TCC AAA GTG TAC AAC ATG AAT ATC 
GGC ACG CAA GAA GAA CCT ATT AAT GTT CCG GTG AAC 
CTG ATC GAG GAA CAG ACC ATT TAC CCA AAA GTG GCT 
AGC ATT GAG ATT ACA AAT CGC TGC AAC GTT CGT TGT CGC 
CAC TGC TAT GGG GAT TTC GGC GCG GTA AAA CCG AAG 
GTT ATG TCG CTG GAT CAG ATC AAA TCG CTT TTA GAT GAT 
CTG AAC AAC ATT GGA GTT AAA CTG ATC GAA CTG ACG 
GGC GGT GAT ATC ACT GTT CAC CCG AAT TTA AAA GAA ATC 
CTG CTG TAT GCC CTG AAT CTG GAT TTC AGC CAG ATT ACA 
TTA CTG ACA AAC GGT ATT GCC CTG AGT GAT AAA GTC ATG 
GAC ATT ATC ATT AAA AAC AAA AGT AAA ACT TTC GTC 
CAA ATT GAT ATG CAC TCT TTA GAT GAT AAC TAC CTG ACG 
TGG TTC TTC AAA GTA CCG AAC ACA CTG CAT AAA ATC 
AAA AAC AAT ATT ATG AAG TTG GCA GAA AAT GAC GTG 
CGT CTT CGT ATT GCT ACG ATC GTT ACC CAT CTG AAT GTT 
CAT GAA GTG GAA GAC ATC GCC GAA TGG GTT CAT AAC 
CTG GGC ATT GAT TCT ATC GGT GTG AGC CCG GTG ATC CCG 
ATG GGG CGC GCG CTG GGC TGC AGC GAC CTC TAT CTT 
AAC GAG GAA GAT GTC AAA ACC TAC GGC GAA GCT CTG 
TTA AAG ATT AAT AAG AAA TAT CCG AAA TTCG TCT CTT 
TAT ATG AGG GCG CTC GTG CAG AGA TTC GCA ATT GTG GTG 
CCA TCA CTA GTC ATA TTG TAA TCG CAC CGG ATG GCG 
AAA TTA AGA TGT GCA CTA TGC ATA GTC TGG ATG ATC TCA 
AAA ACT CCA TTG GTA ATG TGT TTG AAC AGA ACA TCA 
AAG ACA TTT ATG ATG AAA AAT TCA AGT ACA TCA ATG CCT 
TCT TTA ACC TGC AAG CTC CGC AGA TGG ATA GTG AAG AAT 
GCA AAG AGT GCG AAA ATA AGC GTT TCT GCA GTA CCT 
GCT TTT TGC GCA GTT TCA TTA AAG CGC AGG AAA TTG GCG 
ATA AAT GCA AAT GGT TCA AGA ACC ATG TGC CTG AAA 
TTA TCA AAG AGC CAC TCA TGG TTG GTC AGAAT TAG-3’ 
 
3.12.2 Expression and purification of sactipeptides from Duet System 
Production of cell lines and expression of sactipeptides from Duet system 
pPH151/BL21 DE3, Duet-sboA-alba/pPH-151/Bl21 DE3, and Duet-sboA-F31TAG-
alba/pPH151/pUltra-O-Me-Tyr-aaRS/TAGless DE3, pETDuet-thnA-thnB/pPH-151/Bl21 DE3, 
pETDuet-4BD1sg/pRSFDuet-4BD1-rSAM1,4BD1-rSAM2/pPH-151/Bl21 DE3 cell lines were 
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created by transforming plasmids into electrocompetent cells generated according to standard 
molecular biology protocols found in Green et al.
47
 The electroporation was carried out in a 
0.1cm cuvette, at 1.8 kV, 200 Ω, and 20 μFD.  His-tagged sactipeptides were heterologously 
expressed in E. coli (pPH151/BL21 DE3) cells in either 100 mL or 1 L of LB media. Media was 
supplemented with ampicillin (100 μg/mL) and chloramphenicol (34 μg/mL) and either 0.5 mL 
(100 mL grow-up) or 5 mL (1 L grow-up) of an overnight culture. Cultures are then grown at 37 
o
C and 200 rpm to an OD600~0.6-0.7, at which point IPTG was added to a final concentration of 
0.5 mM and the culture was grown at 18 
o
C for 22-24 hours. For unmodified peptides the shake 
was left at 200 rpm but for modified peptides the shake was dropped down to 50 rpm. 
Purification of His-tagged sactipeptides from inclusion bodies (IB) (100mL scale) 
Modified from Li et al.
29
 Cell pellet was suspended in 1 mL of Start Buffer (20 mM 
Nax(PO4)y pH=7.5, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and then sonicated. Cell 
debris was pelleted at 15,000 rpm, 4 
o
C, for 10 minutes. The supernatant was removed and the 
cell pellet was washed with 0.5 mL of IB Buffer (20 mM Nax(PO4)y pH=7.5, 6 M Guanidinium 
HCl, 500 mM NaCl, 50 mM imidazole) and vortexed to ensure the pellet was washed 
thoroughly. Cell debris was pelleted again and the supernatant was collected. Using HisPur
TM
 
Ni-NTA Spin Columns-0.2 mL (Thermo Scientific), the supernatant was incubated in contact 
with the resin for 30 minutes at a gentle shake at 4 
o
C. After incubation, the spin column was 
spun at 2000 x g for 2 minutes at 4 
o
C. The flow through was discarded and the resin washed 
twice with 0.4 mL of IB buffer twice while spinning and removing flow through. The resin was 
washed with 0.4 mL of water and then eluted with 0.3-0.4 mL of Elution Buffer (25 mM 
Tris/HCl pH=8.0, 150 mM NaCl, 500 mM imidazole). The elution was used as is in other 
experiments. 
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Purification of His-tagged sactipeptides from Duet system (1L scale) 
Modified from Li et al.
29
 Cell pellet was suspended in 30 mL of Start Buffer 
supplemented with 0.5 mL of 25 mg/mL T4 lysozyme and 0.5 mL of 150 mM PMSF and then 
incubated on ice for 10 minutes. The cell pellet was then sonicated. The cell pellet was pelleted 
at 15,000 rpm at 4 
o
C for 10 minutes. The supernatant was then removed and the pellet was 
washed and suspended in 30 mL of IB Buffer. The cell pellet was scrapped and broken up by 
spatula and using the vortexer. The cell debris was pelleted again and the supernatant collected 
and filtered through a 0.45 μm syringe filter. The flow through from the filter was then passed 
over a Ni
2+
 IMAC column (HISTrap
TM
 HP 5mL GE Healthcare) utilizing a FPLC (NGC-Quest-
10 Bio-Rad). The Ni
2+
 IMAC column was washed with 6 column volumes (CV) of IB Buffer 
and 2.5 CV of water. To elute the peptide off the Ni
2+
 IMAC column, a binary elution gradient of 
0-100% of Elution buffer (water the other solvent) over 10 CV was used. The peptide came off 
between 30-40% Elution Buffer. The elution was used as is in other experiments. 
3.12.3 Production and Extraction of 4BD1-Natural Product (NP) 
The 4BD1-natural product (4BD1-NP) sactipeptide was produced by inoculating 1 L of 
LB media with 1 mL of a previous overnight of Bacillus thuringiensis serovar huazhongensis 
BGSC 4BD1.  This culture was allowed to grow at 37 
o
C and 200 rpm overnight.  After ~24 
hours of growth, the cells were separated from the supernatant by centrifugation (5000 rpm, 4 
o
C, 
20 minutes) and the supernatant collected.  The natural product was extracted from the pellet 
with ~10 mL of methanol and breaking the pellet up with vigorous shaking and vortexing.  Then 
the methanol was allowed to incubate in contact with the pellet with gentle agitation at room 
temperature for two hours.  The cell debris was removed by centrifugation and the methanol 
supernatant collected.  The methanol supernatant was concentrated in a rotary evaporator and a 
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small sample was diluted and analyzed by mass spectrometry with the method listed below.  To 
the first supernatant collected (spent LB media), this was passed over a small C18-SepPak® Plus 
column (Waters, WAT023635) with the use of a syringe.   Once all the spent LB had been 
passed over the column and the flow-through discarded, the column was washed once with 10 
mL nuclease free water followed by elution of the natural product in 5 mL of methanol. A small 
sample was diluted and analyzed by mass spectrometry with the method listed below 
3.12.4 NEM Modification of free cysteines 
Used a procedure adapted from Thibodeaux et al.
48
 First, the sactipeptide solutions were 
changed to a pH~6.5-7 by the addition of HCl. Then the sactipeptide solutions were incubated 
with 16.67 mM TCEP at 25 
o
C and 500 rpm for 10 minutes. Then NEM (in ethanol) was added 
to a final concentration of 10 mM. The reaction was carried out at 37 
o
C and 500 rpm for 10 
minutes. 
3.12.5 Incorporation of unnatural amino acids into Duet System 
His-SboA-F31OMe-Tyr was heterologously expressed in E. coli (pPH151/pUltra-O-Me-
Tyr aaRS/TAGless DE3) cells. The C321.ΔA.exp cell line (https://www.addgene.org/49018/) 
was modified to allow expression of constructs via the T7 promoter. Site specific integration of 
λDE3 prophage was performed with λDE3 Lysogenization Kit (Novagen). Sactipeptide 
expression was carried out as above with the following exceptions: 1) media was supplemented 
with ampicillin (100 μg/mL) chloramphenicol (34 μg/mL) and spectinomycin (100 μg/mL); 2) in 
addition to IPTG, when OD600 reached 0.6, O-Me-Tyr in 0.1 M NaOH was added to a final 
concentration of 2 mM. To limit the amount of base added, minimal amounts were used to 
dissolve the unnatural amino acid (2 mL for a 100 mL culture, 15 mL for a 1 L culture). All other 
purification and analysis as above. 
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3.12.6 Characterization of sactipeptides by mass spectrometry 
Trypsin digestion of sactipeptide 
An aliquot of 300-600 μl of sactipeptide solution was digested by adding 2 μl of 10 
mg/ml trypsin in 0.1 mM HCl. The digestion was carried out at 37 
o
C and 500 rpm for 0.75-2 
hours. 800 μl of methanol was added and the solution was pelleted at 15,000 rpm and 4 oC for 5 
minutes. The supernatant was collected and the solvent removed by speed-vac till the volume 
was 100-200 μl. This solution was injected onto the LC-MS. 
LC-MS and MS-MS methods 
LC-MS analysis was performed on an Agilent 1200 HPLC system coupled to a 6520 
Accurate-Mass Q-TOF spectrometer with an electrospray ionization (ESI) source in positive ion 
mode. LC used a 2.1 mm x 50 mm Phenomenex® Kinetex C18 column (100 Å, 2.6 μm) with the 
gradient program described below. Water with 0.1 % formic acid (FA) was used as solvent A 
and acetonitrile with 0.1% FA was used as solvent B. Analytes were eluted directly into the MS 
and spectra were acquired in profile mode using a gas temperature of 350 
o
C and a fragmentor 
voltage of 250 V. 
Flow Rate 0.5 ml/min 
Post time 4 min 
Time (min) %B 
0.00 2 
2.00 2 
15.00 100 
16.00 100 
18.01 2 
 
When running tandem MS-MS, the +3 (Z) state of the trypsin digest product (K-6) was 
used as the target ion. A specific retention time for each ion was collected and used for the MS-
MS with a delta time of 0.5 min and an isolation width of 1.3 m/Z. When only one bridge was 
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produced, the +3 (Z) state of the trypsin digest product (K-6) of the doubly n-ethylmaleimide 
(NEM) modified product was targeted. A collision energy of 25-35 eV was used to obtain 
MS/MS spectra. 
3.12.7 Synthesis of p53
15-29 
and derivatives by Solid Phase Peptide Synthesis 
 All syntheses were carried out by microwave assisted solid-phase peptide synthesis 
(SPPS).  Unlabled-p53 truncate (aa. 15-29), N-terminal TAMRA- p53 truncate (aa. 15-29), and 
N-terminal Biotin- p53 truncate (aa. 15-29) were all synthesized for FP and SPR experiments.  
ChemMatrix solid support (0.47 mmol/g) on a 0.047 mmol scale was used.  The solid support 
was initially swollen in DMF (1.5 mL) for 20 min at 70 °C. Fmoc-Amino Acids-OH (0.5 M in 
DMF), 5,6 TAMRA-OH (0.5 M in DMF, VWR) or Biotin, free acid (0.5 M in DMF)  at 5.0 - 
10.0 equiv were coupled with HATU (0.2 M in DMF) at 6.86 equiv., and DIEA (0.2 M in DMF) 
at 14.0 equiv.  The reagents were added to the swollen resin in the above. The resulting 
suspension was heated under microwave irradiation for 5 min at 75 °C.  The reaction vessel is 
then drained and resin is thoroughly washed with DMF four times.  Removal of the Fmoc 
protecting group was accomplished after amino acid coupling using excess 20% piperidine.  20% 
piperidine was added to the reaction vessel and allowed to incubate at RT for 3 min with 
constant stirring. The reaction vessel was then drained, washed with DMF and excess 20% 
piperidine was again added and the reaction was incubated for another 10 min at RT. The 
reaction vessel was then drained and the resin thoroughly washed with DMF four times.  After 
washing the resin with DCM, the resin was dried and cleaved using the standard cleavage 
cocktail (TFA/TIPS/H2O, 95:2.5:2.5) to yield the fully deprotected peptides.  The peptides were 
concentrated by precipitation with cold diethyl ether.  Preparative HPLC was performed for 
purification of the p53
15-29 
peptide and its derivatives.  Relevant fractions were collected and 
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partially concentrated in a rotary evaporator, followed by flash freezing and lyophilization to 
obtain the purified solid product.  The identities were confirmed by LC-MS by the method 
described above. 
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CHAPTER 4 
PROBING THE PROMISCUITY OF RIPPS ENZYMES USING MRNA DISPLAY 
TECHNOLOGIES AND NEXT-GENERATION SEQUENCING 
 
4.1 Introduction 
From its initial conception and subsequent publication in 1997, mRNA display has 
become a robust in vitro selection method that has been used to select peptides and protein with 
designed and desired properties.
1-4
 The power of mRNA display has been exploited many times 
over its ~20 years as an in vitro selection and display technology.  It has been used to address 
and answer a wide range of complicated and diverse biochemical questions and problems.  Being 
as it is a natural extension of directed evolution and its high enrichment fidelity, mRNA display 
has been used to a) identify important residues required for protein binding and affinity and 
improve upon them, b) elucidate important enzyme-substrate interactions, c) identify ligands for 
receptors, d) identify drug-binding targets, and e) evolve novel protein sequences with unique 
enzymatic activities.
5-24
 mRNA display works by covalently linking the translated protein or 
peptide to the mRNA that encodes the amino acid sequence, essentially connecting genotype to 
phenotype.  The connection between the C-terminal portion of the polypeptide chain and the 3’-
end of the mRNA occurs because of a DNA linker that has been grafted onto the mRNA.  This 
DNA linker terminates in a puromycin moiety that mimics an aminoacyl tRNA.  During 
translation, the ribosome pauses at the RNA-DNA junction thus allowing the puromycin moiety 
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to enter the “A” site of the ribosome and form an amide bond with the growing polypeptide 
chain translated from the mRNA.  When using a library template, the result is the display of the 
entire compendium of all possible polypeptide sequences attached to its corresponding mRNA 
“barcode” used for the identification of library members.  After a selection process has been 
carried out (i.e. binding to a target), the “positive” selection members can separated from the 
“negative” selection members, reverse transcribed back into DNA, sequenced, and identified on 
a genomic level resulting in genomic and phenotypic information on what residues are important 
for what property is being selected.   
Compared to other display technologies (phage, yeast, ribosome, etc.), mRNA display 
and selection have several unique advantages that make it a compelling system for interrogating 
biological systems and questions.  In vivo steps in a selection procedure typically limit the size of 
the library that can be studied, resulting in low complexity compared to the completely in vitro 
mRNA display.  This can be due to low efficiency of transformation or transfecting the library 
cDNA into the organism of choice.  Phage display allows the complexity of the library to range 
from 10
9
-10
10
, while other cell-based selections (yeast-two hybrid, bacteria and yeast display) are 
limited to ~10
6
. 
25,26
 Unlike the previously mentioned systems, mRNA display is completely in 
vitro, allowing large libraries to be generated, on the order of 10
13
 unique members, reflecting 
the large diversity present within the proteome.  Another advantage of mRNA display is that 
each library sequence will be represented multiple times, allowing the greater likelihood of 
capturing rare sequences.  Rapid identification of these sequences is achieved due to the 
genotype and phenotype being covalently linked through the puromycin moiety.  mRNA display 
also allows greater flexibility in selection methods than other display methods due to it being an 
in vitro system.   By being an in vitro system, adjustments in cofactors (i.e. ATP), temperature, 
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metals (i.e. Mg
+2
), pH and detergents, which are useful in selection procedures, can be made to 
optimize selection and post-translational modifications if so desired.
5-7,27,28
 
Ribosomally-synthesized and post-translationally modified peptides (RiPPs) are a 
growing class of natural products that have garnered substantial attention because of their 
structural diversity and biological activities due to the enzymatic modifications changing the 
canonical amino acids into moieties not accessible by ribosomal synthesis.
29-32
 The biosynthesis 
of RiPPs involves leader peptide-directed enzymatic transformations on the core peptide which 
can be readily exploited for combinatorial biosynthesis and other applications.
33-37
  The 
biosynthetic enzymes and machinery that impart the desired modifications for activity are unique 
due to several properties they share.  First, most of these enzymes house a specialized 
recognition domain termed the RiPPs recognition element (RRE) that allows the RiPPs enzymes 
to recognize and coordinate to their intended peptide substrate.  This RRE recognizes specific 
amino acids and motifs present in the leader peptide of the precursor peptide.
38-45
 This gives 
RiPPs one of their most impressive abilities, their promiscuity within their own biosynthesis.  
Since the recognition of the peptide substrate happens due to the leader peptide-RRE interaction, 
the core peptide can be altered from its wild-type amino acid sequence and the enzymatic 
modifications still imparted on the altered core peptide.  While not every change is allowed, this 
system houses much more flexibility in the identity of its substrates than most enzymes could 
tolerate.
46-51
 This gives RiPPs the advantage of creating a wide range of distinct, yet similar 
peptides that can be tested and altered for specific activities or properties.  mRNA display 
happens to be uniquely compatible with RiPPs due to several factors.  RiPPs are genetically 
encoded and translated by the ribosome both of which are required by mRNA display.  Also, 
mRNA display can tolerate chemical post-translational modifications and has capability to test 
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libraries on the order of 10
12-13 
unique members giving a comprehensive study of the promiscuity 
of a certain RiPPs enzyme related to its substrate.    
We set out to accomplish two things using the powerful combination of mRNA display 
and RiPPs natural products (see Figure 4.1a).  The first was to tease out leader peptide 
requirements for binding to the RRE of two RiPPs enzymes, PaaA and TbtF.  PaaA is a RiPPs 
enzyme from the pantocin A biosynthesis pathway that catalyzes the double dehydration and 
decarboxylation of two glutamic acid residues in its precursor peptide PaaP (Figure 4.1b).  The 
structure of PaaA was solved in 2016 by Bowers and co-workers and a RRE motif can clearly be 
seen at the N-terminus of each one of the monomers present in the dimer.
52
 TbtF is an accessory 
protein in the biosynthesis of thiomuracin that acts as the recognition element for peptide and 
enzymatic modification (Figure 4.1b).  Although no structural information is known for TbtF, 
many biochemical analyses have been done to determine a) TbtF is required for full maturation 
of the precursor peptide, TbtA, into thiomuracin
53
 and b) TbtF binds to TbtA with a Kd of ~43 
nM and several residues within the leader peptide have been identified to be critical to binding 
by fluorescence polarization.
54
  If key residues of RRE binding could be identified, then chimeric 
leader peptides, leader peptides that allow the recognition of more than one RiPPs enzyme from 
different pathways, can be designed to allow the generation of hybrid-RiPPs natural products to 
be modified by more than one RiPP enzyme from more than one pathway, combining two 
distinct RiPPs pathways into one.
55
 The second was to fully probe the promiscuity of PaaA 
modification in regards to changes in PaaP.   While small libraries can give some sort of 
indication of RiPP enzyme biosynthetic promiscuity, the library size accomplished through 
mRNA display can give a completely picture of what residues are necessary for modification and 
what residues can be modified.  With mRNA display, a complete promiscuity profile can be 
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done on a single RiPPs enzyme in mere days.  This study will build upon the results gathered in 
Ghodge et al.
52
  
 
Figure 4.1. Overview of mRNA display combined with RiPPs.  a) Workflow of mRNA display 
to test enzymatic modification and binding to RiPPs enzymes. b) Two precursor peptides and 
their corresponding natural products used in this study.  The core peptides are highlighted in red 
that form the natural products to the left. 
4.2 Design of Targeted RiPP libraries for mRNA Display 
We started by designing DNA templates that house the T7 promoter (necessary for T7 
RNA polymerase), RBS (necessary for translation), precursor peptide of interest, and then a 
specialized spacer and annealing sequences (see Experimental 4.6.1 and Table 4.1).  The 
highly optimized and specialized annealing sequence is required to photo-crosslink to the DNA-
puromycin linker, which is used to attach the translated peptide off the mRNA.
56
 The precursor 
peptides of interest His-PaaP (used for PaaA activity), PaaP (used for PaaA binding) and TbtA 
(used for TbtF binding), were synthesized by Keck Oligonucleotide Synthesis facility at Yale 
School of Medicine, while the additional components were added by PCR and primers (see 
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Experimental 4.6.1 Table 4.1 and 4.2).  Since this is a pilot study, we decided to limit the 
complexity of the libraries we would use in our selections and not try the top level of library 
members, ~10
12-14
.  For both the PaaP based libraries, we used bioinformatics to predict 
important residues for both binding and activity of PaaP to its modifying enzyme PaaA (see 
Appendix C.1 and C.2). Based on these analyses, we decided to randomize codons Ile2, Leu7, 
Arg10, Ile11, Ser12, Asn18 (Figure 4.1b) to NNC, NNC, RVK, NNC, RVK, NNC respectively, 
where NNC represent a list of 15 amino acids ( A, C, D, F, G, H, I, L, N, P, R, S, T, V, Y) and 
RVK represents ( A, D, E, G, H, K, N, R, S, T) or charged hydrophilic amino acids.  In the 
codon annotation, N=any nucleotide (A, C, G or T), R= any purine (A or G), V= any nucleotide 
not T (A, C or G), and K= keto nucleotide (G or T).  The theoretical library complexity for PaaP 
is designed to contain 5,062,500 unique members.  For TbtA, we looked to a recent article by 
Zhang et al. where they measured the binding affinity of full length TbtA to two thiomuracin 
biosynthetic enzymes (TbtF and TbtD).
54
  They found three residues that when mutated to an 
alanine, severely impair binding affinity to both TbtF and TbtD.  We randomize the codons of 
these residues, Leu-29, Asp-26, and Phe-24 (Figure 4.1b) to NNC.  The theoretical library 
complexity for TbtA is designed to contain 3,375 unique members.  For both PaaP and TbtA, it 
was imperative that for the codons randomized, there was the possibility for the wild-type (WT) 
residues to be selected for again, since these residues were already selected for in nature and may 
have the best affinity or be required activity. Also there was no possibility of stop codons so the 
full length precursor peptide could be translated.  Using the NNC and RVK codons, we were 
able to lower the library complexity, include the WT residues in each randomized position, and 
prevent stop codons for terminating translation prematurely.  In parallel, the true WT peptide 
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constructs for His-PaaP, PaaP, and TbtA were made as radio-labeled controls to test conditions 
and selections. 
4.3 Creation of Displayed-Peptide Libraries 
All experimental detail is explained in Experimental sections 4.6.1, 4.6.3 and 4.6.4 but 
the entire process will be explained in brief here.  After the DNA template of the randomized 
precursor peptides were synthesized and delivered by Keck, the prerequisite additions (T7 
promoter, RBS, spacer, and annealing sequences) were added on using a series of primers and 
PCR reactions.  After the PCR reaction and gel purification, the DNA template was used in a 
transcription reaction using T7 RNA polymerase followed by a purification step using phenol: 
chloroform: isoamyl alcohol extraction.  After this purification, the mRNA was treated with 
DNaseI to remove the template DNA followed by another phenol: chloroform: isoamyl alcohol 
extraction and purification.  Now that the mRNA is clean, we connect the mRNA to a DNA-
Puromycin linker (P-linker).  This specialized linker was synthesized by standard oligonucleotide 
solid-phase synthesis (Experimental 4.6.2) to allow four things to happen 1) anneal, 
complementary, to the mRNA anneal sequence, 2) photo-crosslink through a [2+2] photo-
cycloaddition to one uracil nucleotide on the mRNA sequence and one O-Me-uracil nucleotide 
on the DNA-Puromycin linker, 3) has a region of poly-A sequence (A15) that facilitates the 
purification by Oligo-dT25 magnetic resin and 4) house the Puromycin moiety that will attach to 
the C-terminus of the peptide translated off the mRNA sequence (Figure 4.2a and b).  To 
connect the mRNA to the P-linker, an annealing program was run to allow the complementary 
sequences on the mRNA and linker to come together.  The annealing program was followed by 
the exposure to UV light (~365 nm) for 20 minutes.  UV exposure facilitates the [2+2] photo-
cycloaddition covalent attachment of the mRNA to the DNA puromycin linker.  This mRNA-
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DNA-Puromycin molecule was purified by LiCl precipitation.  The cross-linking efficiency was 
tested by 8% denaturing urea gel compared to the mRNA template (see Figure 4.2c).  The 
efficiency ranged anywhere from 20-50% mRNA cross-linked.  In Figure 4.2d, the crosslinking 
efficiency for the library constructs can be seen in order: PaaP, His-PaaP, TbtA. 
 
Figure 4.2.  Covalent attachment of DNA-Puromycin linker to mRNA. a) Pictorial 
representation of mRNA attachment to DNA-Puromycin linker (P-linker). b)  [2+2] photo-
cycloaddition covalent attachment between two uracil bases. c) Example 8% denaturing urea gel 
showing the shift from mRNA (-) to mRNA-DNA-Puromycin molecule (+). d) 8% denaturing 
urea gel showing crosslinking efficiency of library constructs, PaaP (left), His-PaaP (middle), 
TbtA (right). 
Using the mRNA-DNA-Puromycin as a template, the peptide was translated using the 
PURE in vitro translation system supplied by New England Biosciences (NEB).  For every 
reaction (25 μl), ~1.0-1.2 μg of template was used in the reaction.  If the desired molecule was to 
be radio-labeled, 
35
S-Met was used to incorporate into the peptide of interest.  After the 
translation, MgCl2 and KCl was added to allow the puromycin to enter the “A” site of the 
ribosome and attach to the C-terminus of the recently translated peptide.
2
 After the overnight salt 
incubation, the mRNA-DNA-Puromycin-Peptide fusion (display peptide) was purified by Oligo-
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dT25 magnetic resin and eluted in simple Tris buffer.  The purification results in the purified 
displayed peptide used in the mRNA display selection procedures (Figure 4.3). 
 
Figure 4.3.  Translation and purification of “display” peptide. a) Pictorial representation of 
display peptide. b) Oligo-dT25 purification of display peptide. c) Radio-labeled (
35
S), 8% SDS-
PAGE gel showing purified WT-display peptides that correspond to library constructs. 
4.4 Selection Procedures 
We decided to not protect the mRNA portion of the displayed peptide molecule by 
reverse transcription before selection because upon doing so, the gel bands in the radio-labeled 
gels became diffuse and low quality.  We tested thoroughly for RNase activity, included excess 
Murine RNase Inhibitor (0.5 U/μl), and we were satisfied by the quality of the data without the 
additional protection of the reverse transcription.  PaaA and TbtF were expressed and purified 
based on previously reported procedures but adapted to ensure the removal of RNases (see 
Experimental section 4.6.6).
52,53
 The selection procedures differed significantly between 
binding and activity and are discussed separately below (see Experimental section 4.6.5). 
4.4.1 PaaA Activity 
We used the display peptide His-PaaP and PaaA to test whether PaaA could modify a 
displayed peptide and what residue mutations from the above library criteria allow this 
modification. Using conditions set forth by Ghodge et al.
52
, His-PaaP displayed peptide was 
incubated with or without PaaA overnight at room temperature for 16-18 hours.  PaaA catalyzes 
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the double dehydration and decarboxylation of two glutamic acid residues in PaaP (Figure 4.4a). 
After overnight modification assay, GluC was added to cleave after the glutamic acids present in 
the peptide.  The beauty of PaaA is that upon modification of the glutamic acids, the side chains 
are no longer there or hidden and prevent GluC from cleaving the peptide and removing the 
6xHis peptide (Figure 4.4b) Then the modified, digested His-PaaP displayed peptide is 
incubated with Ni-NTA to allow any 6xHis tag still present to attach and bind to the resin.  After 
washing the resin, the bound displayed peptide is eluted off with high imidazole and heat.  This 
is the positive, selected peptides, meaning the mutations allowed modification by PaaA.  After 
elution, we used Superscript III to reverse transcribe the mRNA followed by PCR to create more 
of the selected DNA template (Figure 4.6c).  
By testing with radio-labeled, WT, His-PaaP, we can see a distinct difference between 
GluC digested PaaA treated vs non-treated display peptide.  In Figure 4.4c, a clear shift 
corresponding to the loss of the 6xHis tag and leader peptide of His-PaaP can be seen when 
comparing treated vs. non-treated with PaaA.  This is clear evidence that GluC cannot digest 
modified PaaP.  It is unlikely that all the displayed peptide is modified by PaaA, but these results 
show that is it possible for a RiPPs modifying enzyme to impart its modifications on a displayed 
peptide. 
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Figure 4.4.  Selection for PaaA activity. a) PaaP modification by PaaA. b) Pictorial 
representation of selection procedures for PaaA activity. c) Radio-labeled (
35
S), 8% SDS-PAGE 
gel showing shift from GluC digestion when not treated with PaaA. 
4.4.2 PaaA and TbtF Binding 
For binding assays, we had the 6xHis tags attached to PaaA (C-term) and TbtF (N-term 
with MBP) and not attached to the peptide substrate.  Initially, we incubated the displayed 
peptide substrate with its corresponding RiPPs enzyme.  After this “pre-binding” step, we 
incubated this peptide-bound-enzyme with Ni-NTA resin.  We removed the flow-through and 
washed the resin once with buffer.  To elute, we heat denatured at 95 
o
C in 1x reverse 
transcription (RT) buffer.  This is the positive, selected peptides, meaning the mutations allowed 
binding to the enzymes.  After elution, we used Superscript III to reverse transcribe the mRNA 
followed by PCR to create more of the selected DNA template (Figure 4.6.b).   
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By testing with radio-labeled, WT, PaaP and TbtA, binding to their respective RiPPs 
enzymes (PaaA and TbtF) can clearly be seen (Figure 4.5b and c).   In these radio-labeled gels, 
little to no displayed peptide can be seen in the flow-through and wash lanes, but the displayed 
peptide can clearly be seen coming off in the elution.  These gels show that displayed peptide can 
bind to its corresponding RiPPs enzymes.  These results open the door to testing binding affinity 
and leader peptide requirements for interacting and binding to their corresponding RRE present 
in these enzymes.  It has been shown by Roberts and co-workers that mRNA display can be used 
to determine binding kinetics which can be used and adapted for determining binding constants 
for leader peptides to RRE’s.23 
 
 
Figure 4.5. Selection for binding to RiPPs enzymes.  a) Pictorial representation of selection for 
binding to RiPPs enzymes. b) Radio-labeled (
35
S), 8% SDS-PAGE gel showing display-peptide 
(TbtA) binding and eluting with TbtF.  c) b) Radio-labeled (
35
S), 8% SDS-PAGE gel showing 
display-peptide (PaaP) binding and eluting with PaaA. 
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4.5 Summary and Discussion 
The next step after the reverse transcription and PCR would be to sequence the positive 
selected sequences that correspond to either modification or binding depending on the selection 
procedure (Figure 4.6).  Traditionally, the DNA sequences would be cloned into a blunt or TA-
TOPO vector and the insert sequenced normally by Sanger methods.
15,19-22
  This approach does 
not give a full depiction of the library until many round of selection and a great number of 
colonies sequenced.  Also, when we tried this approach, we received inconsistent data, namely 
partial reads and low quality data.  There is another approach using next-generation sequencing 
(high-throughput sequencing) to sequence the DNA that was amplified after selection, called 
amplicons.  Next-generation sequencing (NGS) has many advantages over traditional cloning 
and sequencing.
57
 First, there is no cloning, so poor cloning, ligation, and transformation 
efficiency are not a problem.  Second, the PCR product off the reverse transcription reaction is 
what is sent for sequencing, so there are no more necessary steps required by the scientist 
carrying out the selection.  Lastly, instead of getting one read of a sequence like in traditional 
Sanger sequencing, NGS gives millions of reads over the amplicons, allowing full coverage and 
quantitation, by percentage, of what is present in the amplicon.  Exact sequences, single-
nucleotide polymorphisms (SNPs), and mutations can all be detected at the same time through 
NGS.  More recently, NGS was used with mRNA display in a high-throughput manner to 
measure binding kinetics between a library of peptide and Bcl-xL protein.
23
 This was 
accomplished by adding on unique identifying barcodes and utilizing a Illumina
58
 HiSeq 2500 
platform to sequence the library.  This approach gave both the frequency and factional 
composition of their library, statistics valuable for knowing the complexity and make-up of your 
selected library.  We have planned on doing a similar NGS approach using the Illumina 
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technology and platform; however at the time of this writing, this has yet to be done.  We are 
actively pursuing NGS through GENEWIZ to perform NGS on the amplicons after selection, 
both binding and activity (Figure 4.6b and c).   
 
Figure 4.6. Reverse transcription and amplification of selected library members. a) Pictorial 
representation of workflow. b) Amplicons of selected members from PaaA and TbtF binding 
assays. c) Amplicon of selection from PaaA activity assay.  The sizes of the corresponding 
amplicons are: PaaP: 225 bp, His-PaaP: 258 bp, and TbtA: 282 bp. 
In the presented work, we have described a mRNA system for probing the promiscuity of 
the biosynthesis of a natural product class, RiPPs. We show that it is possible for displayed 
RiPPs to bind to their respective enzymes while attached to their genomic component, mRNA.  
We also show that it is indeed possible to impart RiPPs modifications onto a displayed RiPP 
precursor peptide and confirm that modification.  We also outline the procedures necessary to 
probe both the biosynthetic activity as well as binding affinity of RiPPs to their enzymes by 
mRNA display.  Sequencing, specifically NGS, is what remains to analyze the data collected 
after selection.  With this system, we believe it is possible to fully probe the biosynthetic 
promiscuity of a RiPP enzyme as well as to determine the leader peptide requirements necessary 
for binding to the RRE of the enzyme.  This can give valuable information on what residues are 
necessary and can be used to create chimeric leader peptides to combine separate and distinct 
RiPPs pathways into a single precursor peptide. 
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4.6 Experimental 
4.6.1 Design of DNA templates and mRNA transcription and photo-crosslinking 
The following tables describe the DNA prepared by Keck Oligonucleotide Synthesis 
facility at Yale School of Medicine and the primers prepared by Eton Bioscience. Also listed are 
the sequences to be added on by PCR to create the DNA templates for mRNA display.  Library 
codons are in bold and underlined.  The Universal RT primer was synthesized and prepared by 
Integrated DNA Technologies and where iSp9 is an internal triethylene glycol spacer prepared 
by them.  The template DNA was amplified from their respective templates (Table 4.1) by PCR 
using primers (Table 4.2) and Q5® High-Fidelity DNA Polymerase with Q5 Reaction Buffer 
following the manufacturer’s manual (New England Bioscience (NEB)).  The template DNA 
was purified by 2% agarose gel and then gel extracted following the manufacturer’s manual 
(Thermo Scientific GeneJET Gel Extraction Kit).  The template DNA was eluted in nuclease free 
water and used as is in the RNA transcription step. 
Table 4.1. DNA sequences used to create template DNA for mRNA display constructs. 
PaaP-WT 5’-CTT TAA GAA GGA GAT ATA CAT ATG ATC AAG TTC TCT ACT 
CTG TCT CAG CGC ATT TCT GCT ATC ACT GAA GAA AAT GCT ATG 
TAT ACC AAA GGT CAG GTT ATC GTC CTT AGC GGT TCT GGT GGT 
AGC GGT ATG-3’ 
His-PaaP-WT 5’-CAT CAT CAT GGT TCT TCT GGT ATG ATC AAG TTC TCT ACT CTG 
TCT CAG CGC ATT TCT GCT ATC ACT GAA GAA AAT GCT ATG TAT 
ACC AAA GGT CAG GTT ATC GTC CTT AGC GGT TCT GGT GGT AGC 
GGT ATG-3’ 
TbtA-WT 5’-CTT TAA GAA GGA GAT ATA CAT ATG GAC CTG AAT GAT CTG 
CCG ATG GAT GTT TTT GAA CTG GCA GAT AGC GGT GTT GCA GTT 
GAA AGC CTG ACC GCA GGT CAT GGT ATG ACC GAA GTT GGT GCA 
AGC TGT AAT TGC TTT TGT TAT ATT TGT TGT AGC TGC AGC AGC 
GCC-3’ 
PaaP-Lib 5’-CTT TAA GAA GGA GAT ATA CAT ATG NNC AAG TTC TCT ACT 
NNC TCT CAG RVK NNC RVK GCT ATC ACT GAA GAA NNC GCT ATG 
TAT ACC AAA GGT CAG GTT ATC GTC CTT AGC GGT TCT GGT GGT 
AGC GGT ATG-3’ 
His-PaaP-Lib 5’-CAT CAT CAT GGT TCT TCT GGT ATG NNC AAG TTC TCT ACT NNC 
TCT CAG RVK NNC RVK GCT ATC ACT GAA GAA NNC GCT ATG TAT 
ACC AAA GGT CAG GTT ATC GTC CTT AGC GGT TCT GGT GGT AGC 
GGT ATG-3’ 
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TbtA-Lib 5’-CTT TAA GAA GGA GAT ATA CAT ATG GAC CTG AAT GAT NNC 
CCG ATG NNC GTT NNC GAA CTG GCA GAT AGC GGT GTT GCA GTT 
GAA AGC CTG ACC GCA GGT CAT GGT ATG ACC GAA GTT GGT GCA 
AGC TGT AAT TGC TTT TGT TAT ATT TGT TGT AGC TGC AGC AGC 
GCC-3’ 
T7-Promoter (based on 
pMCSG7) 
5’-TAA TAC GAC TCA CTA TAG G-3’ 
RBS (based on pMCSG7) 5’-TAA CTT TAA GAA GGA G-3’ 
Spacer Sequence 5’-GGT TCT GGT GGT AGC GGT ATG GGA ATG TC-3’ 
Anneal Sequence 5’-CAC CGG CTA TTA A-3’ 
Total 5’ Addition (based 
on pMCSG7) 
5’-GAA ATT AAT ACG ACT CAC TAT AGG GGA ATT GTG AGC GGA 
TAA CAA TTC CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA 
GGA GAT ATA CAT-3’ 
Total 3’ Addition 
(Spacer+Anneal Seq.) 
5’-GGT TCT GGT GGT AGC GGT ATG GGA ATG TCC ACC GGC TAT 
TAA-3’ 
 
Table 4.2.  Primers used in mRNA display study 
Primer # Template Used Sequence 
Primer 1 PaaP-Fwd 1 and 
TbtA-Fwd 1 
5’-TTC CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA 
GAT ATA-3’ 
Primer 2 His-PaaP-Fwd-1 5’-TTC CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA 
GAT ATA CAT ATG CAC CAT CAT CAT CAT CAT GGT TCT TCT-3’ 
Primer 3 PaaP-Fwd 2 and 
His-PaaP-Fwd 2 
and TbtA-Fwd 2 
5’-GAA ATT AAT ACG ACT CAC TAT AGG GGA ATT GTG AGC 
GGA TAA CAA TTC CCC TCT AGA AAT-3’ 
Primer 4 TbtA-Rev-1 5’-TTA ATA GCC GGT GGA CAT TCC CAT ACC GCT ACC ACC 
AGA ACC GGC GCT GCT GCA GCT AC-3’ 
Primer 5 Universal Fwd 5’-GAA ATT AAT ACG ACT CAC TAT-3’ 
Primer 6 Universal Rev 5’-TTA ATA GCC GGT GGA CAT TCC-3’ 
Primer 7 Univeral RT 5’-TTT TTT TTT TTT TTT TTT TT/iSp9/G ACA TTC CCA TAC CGC 
TAC CAC CAG AAC C-3’ 
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Generation of RNA 
Following the manufacturer’s manual (NEB), RNA was created with T7 RNA 
Polymerase and precipitated out of the reaction solution (white solid) using MgCl2.  All reagents 
were nuclease free (both RNA and DNA).  The normal reaction consisted of: 
Water (nuclease free)   X to a volume of 250 μL 
10x RNA polymerase Buffer  25 μL 
25 mM rNTP’s   30 μL 
1 M MgCl2    3 μL 
1 M DTT    2.5 μL 
T7 RNA Polymerase (50 U/μL) 25 μL 
cDNA     Y to an amount of ~1.0 μg 
Total      250 μL 
 
The reaction was incubated at 37 
oC for 2 hrs. Then 18 μL of 0.5 M EDTA was added to 
suspend the RNA back in solution 
Purification of RNA 
RNA was purified using a standard Phenol: Chloroform: Isoamyl Alcohol extraction, 
keeping the aqueous layer.  Then to the ~500 μl of aqueous solution, 250 μl of 8 M LiCl was 
added to precipitate the RNA.  The solution was incubated at -20 
o
C for 0.5 hrs-overnight.  The 
RNA was pelleted out of solution by centrifugation at 4 
o
C, 15,000 rpm, for 30 minutes.  The 
supernatant was removed leaving a white pellet.  The white pellet was suspended in 85 ul of 
water and DNaseI treatment was carried out as follows: 
RNA solution   85 μL 
10x DNaseI Buffer  10 μL 
DNaseI (2 U/μL)    5 μL 
Total:             100 μL 
 
The solution was incubated at 37 
o
C for 2.5 hrs.  Purification was done as before and the 
RNA was suspended in 100 μL of nuclease free water.  
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4.6.2 Synthesis of DNA-Puromycin Linker (P-linker) 
Synthesis of the DNA-Puromycin (P-linker) was accomplished by standard solid-phase 
phosphoramidite chemistry using an Applied Biosystems 392/394 biosystems DNA/RNA 
Synthesizer with Software API.  All reagents and building blocks were purchased from Glen 
Research.  The overall sequence of the P-linker is as follows: 5’-Psoralen(C6)-
(UAGCCGGUC)2’OMe-RNA-dA15-C9C9-(ACC)RNA-Puromycin-3’, where dA15 is a DNA spacer 
of 15 adenosines and C9 is Spacer Phosphoramidite 9.  Detritylation was achieved with use of 
3% trifluoroacetic acid (TFA) in dichloromethane (DCM).  Activation of the phorphoramidite 
building block for coupling used 0.45M 
1
H-tetrazole in acetonitrile.  To prevent branching and 
missing nucleotides, capping of any un-coupled phosphoramidite building blocks was achieved 
using both acetic anhydride/pyridine/tetrahydrofuran(THF) in a 1:1:8 ratio and 16% N-
methylimidazole in THF.  Prior to the next coupling, the phosphite-triester (P(III)) formed in the 
previous coupling step must be converted to the more stable P(V) species.  This is achieved by 
iodine oxidation in the presence of water and pyridine using 0.02M iodine in THF/pyridine/water 
in a ratio of 70:20:10.   This converts the backbone into a protected-phosphate DNA backbone.  
Then the deprotection and coupling cycle continues.  For our coupling procedures the following 
steps were used to couple each building block.  The steps were modified from 0.1 μM RNA 
standard coupling procedure from ABI 392/394.   
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Step Time (seconds) 
Acetonitrile Wash 30 
Trityl-deprotection 50 
Coupling (Tetrazole+ Base) 720 
Capping (Capping solution A and B) 30 
Oxidizing 45 
Reverse Flush (to remove reagents) 10 
 
The building blocks were dissolved in acetonitrile (anhydrous) to a final concentration of 
0.1M and the starting solid support was Puromycin-CPG (1 μmole scale).  All couplings were 
done in an inert (argon gas) atmosphere under anhydrous conditions.  The trityl-deprotection was 
monitored by detecting the release of the chromophore trityl cation at absorbance of 498 nm.  If 
average deprotection count was > 90% the synthesis was allowed to proceed forward without 
change or restarting.  Once Psoralen(C6) was added, light was avoided with the use of foil.  
Cleavage and deprotection was accomplished with 1 mL of ethanolic ammonium hydroxide (3 
parts ammonium hydroxide to 1 part 100% ethanol.  The solution was passed over the column 4-
5 times and then allowed to incubate in contact with the resin at room temperature for 24 hours.  
After deprotection and cleavage, the solution was collected and resin washed with 0.25 mL of 
RNase free water and combined with the precious supernatant.  The solution was further dried 
under vacuum with the use of a speed-vac with no heat.  This was to remove as much ammonium 
hydroxide, ethanol, and water as possible and to yield a white solid.  Further deprotection was 
carried out to remove the 2’-t-butyl-dimethylsilyl groups (Ultramild TBDMS) from the RNA 
bases added in P-linker sequence.  The white solid was dissolved/suspended in 0.5 mL of 
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anhydrous dimethyl sulfoxide (DMSO) by heating the solution at 65 
o
C for 5 minutes.  Add 125 
μL of triethylamine trihydrofluoride (TEA.3HF) and heat at 65 oC, 750 rpm mix, for 2 ½ hours. 
After, the solution was cooled at -20 
oC for 3 minutes followed by the addition of 25 μL of 3 M 
sodium acetate and 1 mL of 1-butanol.  The solution was then incubated at -80 
o
C for 1 hour.  
The P-linker solid was then pelleted at 4 
o
C at 15,000 rpm for 10 minutes.  A white pellet formed 
at the bottom of the tube and the supernatant was removed.  The pellet was washed twice with 
0.75 mL of 100% ethanol repeating the pelleting step above and removing the supernatant.  The 
pellet was further dried under vacuum using a speed-vac with no heat for 30 minutes.  The P-
linker solid was dissolved/suspended in nuclease free water and loading dye and loaded onto a 
preparatory-20% denaturing urea gel.  Before loading, the gel was pre-warmed at 200 V (6 
watts) for 45 minutes.  The gel after loading was ran at 250 V (6 watts) for 2 hours.  The loading 
dye used held xylene cyanol FF (XCFF) dye which runs at ~28 bp in a 20% denaturing urea gel.  
Therefore XCFF was used as a ladder being the P-linker is 31 bp.  Also, the P-linker was 
detected, without over exposure, with UV-light.  With the addition of the Psoralen(C6), the band 
is bright blue.  The band was cut and removed from the gel, mashed to pieces/powder and 1x TE 
(10 mM Tris-HCl pH=7.5, 1 mM EDTA) added in a ratio of 3 mL for every 0.5 grams of gel.  
The gel solution was vortexed vigorously and then frozen at -80 
o
C for 15 minutes or until frozen 
solid.  The frozen solution was thawed in a water bath (42 
o
C) for 10 minutes followed by being 
wrapped in foil and place on rotary shaker overnight at room temperature.  After overnight 
extraction, the gel pieces were pelleted and the supernatant removed and collected.  The 
supernatant was filtered through a 0.22 μm filter to remove any other solid.  The volume of the 
supernatant was reduced by the removal of water with 1:1 butanol extraction.  Briefly, the 
butanol was added, shaken for 30 seconds and then pelleted at 4000 rpm, room temperature, for 
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two minutes and the top layer removed.  This was repeated until the bottom layer, the layer with 
the P-linker, was ~ 1 mL.  Next, 3 M sodium acetate (pH=5.2) was added to a final concentrate 
of 0.3M.  Then 2 mL of ice cold 100% ethanol was added followed by incubation at -20 
o
C for 
30minutes.  When the sodium acetate was added, the solution turned white and cloudy, but when 
the ethanol was added, the solution turned clear and colorless again.  After incubation at -20 
o
C, 
the P-linker was pelleted at 4 
o
C, 15,000 rpm, for 20 minutes.  A white pellet formed at the 
bottom of the tube and the supernatant was removed.  The pellet was washed with 70%, ice cold, 
ethanol and the pelleted the same way above.  To further dry the pellet, the pellet was dried 
under vacuum using a speed-vac without heat.  The pellet was suspended in nuclease free water.  
Purity was tested by diagnostic 20% denaturing urea gel and nanodrop UV-vis measurements.  
The final concentration of the P-linker solution was designed to be ~150 μM.  The overall yield 
of the P-linker synthesis was calculated to be 6.4% from a 1.0 μmole scale. 
4.6.3 Preparation of puromycin-fused mRNA libraries 
A reaction solution was made to perform a UV-crosslink between the RNA of interest 
and the DNA-Puromycin linker (P-linker).  All reagents were nuclease free (both RNA and 
DNA).  The solution contained: 
1 M HEPES     5 μL 
2 M KCl   12 μL 
P-linker    Z μL (~5.6 μM) 
RNA     Y μL (~1.0 μM) 
Water (nuclease free)   X μL (final volume 250 μl) 
Total:    250 μl 
 
The solution was split into 5 x 50 μl reactions.  An anneal program, in a thermocycler, 
was ran starting at 85 
o
C and dropping 0.5 
o
C every 30 seconds, finally holding at 25 
o
C for 3 
minutes.  After anneal program is finished, the reaction solution was exposed to UV light (~365 
nm) for 20 minutes in cold room (4 
o
C).  After UV crosslink was formed, the reactions were 
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combined and 118 μL of 8 M LiCl was added.  The reaction was incubated overnight at -20 oC.  
After the overnight incubation at -20 
o
C, the RNA-DNA-Puromycin construct was pelleted by 
centrifugation at 4 
o
C, 15,000 rpm, for 30 minutes.  A pellet formed, and the supernatant was 
removed.  The pellet was washed twice with 0.5 mL of 75% ethanol.  Once all supernatant was 
removed from the wash, the pellet was suspended in 50 μL of nuclease water. 
4.6.4 PURE System Translation of Displayed Peptide Libraries 
Expression of Display Molecules using PURE System 
Expression was done according to the manufacturer’s manual (NEB) that comes with the 
PURExpress® In Vitro Protein Synthesis Kit.  All reagents were nuclease free (both RNA and 
DNA).  The reaction is as follows and scales linearly: 
Solution A    10 μL 
Solution B    7.5 μL 
Water     X (final volume 25 μL) 
Murine RNase Inh. (40 U/μL) 1 μL 
35
S-Met (if desired)   1 μL 
Template     Y (~1-2 μg of RNA) 
Total:     25 μL 
 
The solution was incubated at 37 
o
C for 3 hours followed by incubation at 4 
o
C for 5 
minutes to halt translation.  After expression a salt incubation was performed by adding 2 μL of 
1M MgCl2 and 11 μL of 2M KCl (final concentrations: ~50 mM and ~580 mM respectively. The 
reaction was incubated at room temp for 30 minutes then -20 
o
C overnight. 
Purification of Display Molecules by Oligo-dT25 Magnetic Beads 
Purification was done according to the manufacturer’s manual (NEB) that comes with 
Oligo dT25 Magnetic Beads and magnetic separation rack.  The buffer used were as follows: 
Lysis/Binding Buffer (20 mM Tris-HCl pH=7.5, 500 mM LiCl, 0.5% LiDS, 100 mM EDTA, 5 
mM DTT), Wash Buffer I (20 mM Tris-HCl pH=7.5, 500 mM LiCl, 0.1% LiDS, 1 mM EDTA, 5 
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mM DTT), Wash Buffer II (20 mM Tris-HCl pH=7.5, 500 mM LiCl, 1 mM EDTA), Low Salt 
Buffer (20 mM Tris-HCl pH=7.5, 200 mM LiCl, 1 mM EDTA), and Elution Buffer (20 mM 
Tris-HCl pH=7.5).  Briefly, the Oligo-dT25 resin was equilibrated and washed with lysis buffer.  
For purification, the amount of resin used is roughly the same volume as the translation reaction.  
Lysis buffer was added in a 1:1 ratio to that of the translation reaction and vortexed briefly.  Add 
the translation reaction with lysis buffer to the resin and incubate at room temperature for 30 
minutes with light mixing.  The supernatant was removed with magnetic separation rack, 
followed by washing (with one translation reaction volume) the resin twice with Wash Buffer I, 
twice with Wash Buffer II, and once with Low Salt Buffer with removal of the supernatant after 
each wash.  The display molecule was eluted in Elution Buffer twice with 0.5 x translation 
reaction volumes after heating the elution buffer and resin at 70 
o
C, 500 rpm, for 2 minutes.  The 
elutions are combined, cooled and used as is in the selection procedures. 
4.6.5 In vitro selection methods and Reverse Transcription/PCR 
PaaA or TbtF Binding Assays 
The binding assays were the same for either peptide-protein interactions tested except for 
the buffers used.  PaaA used the buffer 50 mM HEPES at pH= 7~8 tested by pH paper, 0.01% 
Triton X-100, 0.5 mM TCEP, and 0.5 U/μL of murine RNase inhibitor while TbtF used the 
buffer 50 mM HEPES at pH= 7~8 tested by pH paper, 300 mM NaCl, 2.5% glycerol, 0.01% 
Triton X-100, 0.5 mM TCEP, and 0.5 U/μL of murine RNase inhibitor.  Protein (20 μM) was 
incubated in buffer with 25 μL of purified display molecule in a total of 40 μL.  This solution 
was allowed to incubate at 4 
o
C in end-over-end mixer for one hour (pre-bind).  As the 
incubation was happing, 40 μL of a 50% slurry of NuviaTM IMAC resin from Bio-rad was 
prepared and washed with the corresponding buffer above.  The resin was spun down at 2000 x g 
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at 4 
o
C for 2 minutes.  The resin was washed twice with the buffer before all the supernatant was 
removed, leaving 20 μL of resin.  To the equilibrated resin, the pre-binding solution was added, 
followed by further incubation at 4 
o
C in end-over-end mixer for 1 ½ hours.  After the 
incubation, the resin and supernatant (flow-through (FT)) were separated by centrifugation at 
2000 x g at 4 
oC for 2 minutes.  The resin was washed twice with 40 μL of the corresponding 
buffer while the supernatant (Wash) was collected as previously stated above.  The display-
molecule bound to protein was eluted by adding 40 μL of 1x reverse transcription (RT), 1st strand 
buffer (50 mM Tris-HCl pH= 8.3, 75 mM KCl, 3 mM MgCl2 and heating the resin and solution 
at 95 
o
C for 5 minutes.  The supernatant (Elution) was collected as previously stated above. 
PaaA Activity Assays 
PaaA activity and modification assays were adapted from Ghodge et al.  The buffer used 
in the activity assay was 50 mM HEPES at pH= 7~8 tested by pH paper, 0.01% Triton X-100, 
0.5 mM TCEP, 10 mM MgCl2, 4 mM ATP,  and 0.5 U/μL of murine RNase inhibitor.  20 μM of 
PaaA was incubated with 25 μL of purified display molecule in a total volume of 50 μL.  The 
reaction was vortex briefly to mix and then allowed to incubate at room temperature without 
further mixing for 16-18 hours overnight.  Following the modification, 0.5 μL of endoproteinase 
GluC (500 U/mL) was added to the previous reaction and incubated at 37 
o
C, 500 rpm, for 2 
hours.  After the modification and digestion reactions, Ni-NTA selection was achieved as stated 
above with PaaA binding assays.  The differences are 50 μL volumes, 25 μL of resin, the wash 
buffer was the original binding buffer with 50 mM imidazole while the elution buffer was the 
original binding buffer with 500 mM imidazole.  A single incubation time of one hour was used 
to bind the 6xHis tag to the Nuvia
TM
 IMAC resin. 
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Reverse Transcription (RT) /PCR amplification of selection 
The following procedures were used with all samples after selection.  SuperScript™ III 
First-Strand Synthesis System from Invirtogen
TM
 was used to preform reverse transcription 
following the procedures laid out in the manufacturer’s manual. All reagents were nuclease free 
(both RNA and DNA).  Briefly the following reactions were made to carry out the reverse 
transcription: 
Part I 
Universal RT Primer (100 μM) 0.5 μL 
Water        0 μL 
10 mM dNTP’s      1 μL 
Template (from selection)           11.5 μL 
Total:      13 μL 
 
Part II 
5x 1
st
 Strand Buffer       4 μL 
Water         1 μL 
100 mM DTT        1 μL 
Superscript III (200 U/μL)       1 μL 
Total (once added to Part I)    20 μL 
 
Part I was heated at 65 
o
C for 5 minutes then incubated on ice for 1 minute.  Next Part II 
was added to part I and then incubated at the following temperatures using a thermocycler: 55 
o
C 
for 1 hour, 75 
o
C for 15 minutes, and 4 
o
C for 5 minutes.  This was followed by the addition of 
0.4 μL of 5 U/μL of RNase H.  This was incubated at 37 oC for 20 minutes.  This gave back the 
complementary piece of DNA corresponding to the RNA selected.  Amplification of the DNA 
was achieved using Taq DNA Polymerase with Standard Taq Buffer following the 
manufacturer’s manual using the universal forward and reverse primers in Table 4.2.  The DNA 
was purified by 2% agarose gel and then gel extracted following the manufacturer’s manual 
(Thermo Scientific GeneJET Gel Extraction Kit).  The template DNA was eluted in nuclease free 
water and used as is. 
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4.6.6 Protein Expression and purification of PaaA and TbtF 
PaaA 
This procedure was adapted from Ghodge et al.
52
 Buffers were steri-filterd and made 
with DEPC treated water while the Ni
2+
 IMAC column was stripped and regenerated before use.  
PaaA (from paaA-pET28b, C-terminal 6xHis tag) was expressed in BL21 (DE3) E. coli cells in 
LB medium containing 40 μg/mL kanamycin.  Cells were grown at 37 °C until an OD600 of 0.5 
was attained, at which point the temperature was lowered to 18°C. At an OD600 of 0.8, protein 
expression was induced with the addition of 0.1 mM isopropyl-1-thio-D-galactopyranoside 
(IPTG) and incubated overnight at 18 °C. Cells were collected and pelleted by centrifugation. 
Cell pellets were suspended in Buffer A (20 mM Tris, pH=7.5, 30 mM imidazole, 300 mM 
NaCl, 5% Glycerol, 1 mM DTT) supplemented with 0.5 mL of 25 mg/mL T4 lysozyme, 0.5 mL 
of 150 mM PMSF, 80 μl of DNaseI (1u/μl), one tablet of PierceTM Protease Inhibitor Tablets 
(EDTA Free from Thermo Scientific), and then incubated on ice for 10 minutes.  The cell pellet 
was then sonicated.  The lysate was clarified by centrifugation at 15,000 rpm at 4 
o
C for 15 
minutes.  The supernatant was collected and filtered through a 0.45 μm syringe filter.  The flow 
through from the filter was then passed over a Ni
2+
 IMAC column (HISTrap
TM
 HP 5mL GE 
Healthcare) coupled to an FPLC (NGC-Quest-10 Bio-Rad).  The Ni
2+
 IMAC column was 
washed with 5 column volumes (CV) of Buffer A.  Protein was eluted with Buffer B (20 mM 
Tris, pH=7.5, 500 mM imidazole, 300 mM NaCl, 5% glycerol, 1 mM DTT) in a gradient of 0-
14% B over 2 CV, 14-14% B over 2 CV, and then 14-100% B over 10 CV.    Purity of eluted 
fractions was assessed by SDS-PAGE. Purest fractions were combined and concentrated in a 
30,000 MWCO filter in an Amicon stirred cell.  The concentrated protein was then exchanged 
into 50 mM HEPES, pH=7.5, 150 mM NaCl, 5% glycerol, and 1 mM DTT by passage over a 
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Sephadex
TM
 PD-10 column (GE Healthcare).  The protein concentration was estimated by A280 
using an extinction coefficient of 0.988 mg•mL-1•AU-1. 
TbtF 
This procedure was adapted from Hudson et al.
53
 Buffers were steri-filterd and made with 
DEPC treated water while the Ni
2+
 IMAC column was stripped and regenerated before use.  TbtF 
(from pMCSG9-tbtF, N-terminal 6xHis-MBP tag) was expressed in BL21 (DE3) E. coli cells in 
LB medium containing 100 μg/mL ampicillin.  Cells were grown at 37 °C until an OD600 of 0.6 
was attained, at which point the temperature was lowered to 18°C and protein expression was 
induced with the addition of 0.2 mM IPTG and incubated overnight at 18 °C. Cells were 
collected and pelleted by centrifugation. Cell pellets were suspended in Buffer A (50 mM Tris, 
pH=7.5, 150 mM NaCl, 2.5% Glycerol, 0.1% Trition X-100) supplemented with 0.5 mL of 25 
mg/mL T4 lysozyme, 0.5 mL of 150 mM PMSF, 80 μl of DNaseI (1u/μl), one tablet of PierceTM 
Protease Inhibitor Tablets (EDTA Free from Thermo Scientific), and then incubated on ice for 
10 minutes.  The cell pellet was then sonicated.  The lysate was clarified by centrifugation at 
15,000 rpm at 4 
oC for 15 minutes.  The supernatant was collected and filtered through a 0.45 μm 
syringe filter.  The flow through from the filter was then passed over a Ni
2+
 IMAC column 
(HISTrap
TM
 HP 5mL GE Healthcare) coupled to an FPLC (NGC-Quest-10 Bio-Rad).  The Ni
2+
 
IMAC column was washed with 5 column volumes (CV) of Buffer B (50 mM Tris, pH=7.5, 400 
mM NaCl, 2.5% Glycerol, 50 mM imidazole).  Protein was eluted with Buffer C (50 mM Tris, 
pH=7.5, 300 mM NaCl, 2.5% Glycerol, 500 mM imidazole) in a gradient of 0-9% B over 2 CV, 
9-9% B over 2 CV, and then 9-100% B over 10 CV.    Purity of eluted fractions was assessed by 
SDS-PAGE. Purest fractions were combined and concentrated in a 30,000 MWCO filter in an 
Amicon stirred cell.  The concentrated protein was then exchanged into 50 mM Tris, pH=7.5, 
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300 mM NaCl, and 2.5% Glycerol by passage over a SephadexTM PD-10 column (GE 
Healthcare).  The protein concentration was estimated by A280 using an extinction coefficient of 
0.96 mg•mL-1•AU-1. 
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CHAPTER 5 
CONCLUSION 
 
By studying RiPPs biosynthetic enzymes and their innate tendency toward accepting 
changes to the core peptide, we have opened the door to creating, studying, and designing 
peptide natural product libraries for the creation of novel therapeutics based in nature.  By 
focusing on the RiPPs class of natural products and sactipeptides, we have biochemically and 
structurally characterized a sactionine synthase and reported the first crystal structure of its kind, 
developed a heterologous platform for the production of sactipeptides to study the promiscuity of 
sactionine synthases outside their native producers, and developed an in vitro system for 
studying RiPPs biosynthetic promiscuity on a large scale using mRNA display. 
In the presented work, we detailed the structure of a sactionine synthase, CteB from C. 
thermocellum ATCC 27405 and biochemically characterize its activity on its thermocellin 
precursor peptide.  CteB installs a single sactionine bridge between Cys32 and Thr37 within the 
precursor peptide.  The CteB structure represents the first structure of a sactionine synthase and 
PqqE-like enzyme.  It houses three distinct domains: a wHTH domain that corresponds to the 
RRE that binds to the leader peptide portion of the precursor peptide, a conserved SAM 
activating domain, and a new SPASM  domain motif that houses two auxiliary [4Fe-4S] clusters, 
one of which displays a single open coordination site (Aux I).  The crystal structure provide 
insights into the enzymatic mechanism of sactionine bridge formation and evidence for the role 
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of SPASM auxiliary clusters in direct substrate ligation and potential activation required to 
facilitate product formation. 
We have also developed a heterologous expression system for the production of 
sactipeptide derivatives of subtilosin A in E. coli.  Using this system we demonstrated 
unexpected biosynthetic promiscuity of the sactionine synthase AlbA.  We found there was great 
promiscuity especially in the loop region and at unmodified positions on the solvent-exposed 
exterior of the peptide macrocycle and we hypothesize that this could be exploited for the 
grafting of peptide epitopes (i.e. integrin binding motifs) as has been seen in lasso peptides and 
conotoxins.  We have also introduced nonproteinogenic amino acids into sactipeptides using 
stop-codon suppression technology, specifically at a bridging partner position. This demonstrates 
the robustness of UAA incorporation in our system and may open up new chemistry and new 
applications for unnatural sactipeptides. 
Furthermore, we have developed a system that combines RiPPs natural products and 
mRNA display to test their respective biosynthetic promiscuity on a large scale and in a high-
throughput manner.  Specifically, we used the pantocin A precursor peptide and modifying 
enzyme, PaaP and PaaA respectively, to test the biosynthetic promiscuity of PaaA in regards to 
six different randomized positions.  We also used this system as well as the thiomuracin 
precursor peptide and binding protein, TbtA and TbtF respectively, to test binding efficacy and 
to select for the best possible binders with respect to binding to the RRE domain.  This system 
can revolutionize the way RiPPs promiscuity is studied and lead the way to making natural 
product peptide libraries which can be selected for different properties and activities. 
With the leaps and advances of next-generation sequencing, the pool for unknown and 
attractive natural products grows.  Natural products are attractive lead molecules for novel 
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therapeutics due to their complex structures and their inherent biological activities.  RiPPs, with 
their unique access to modified chemistries and privileged scaffolds can be mined for even more 
lead molecules and modified by their promiscuous enzymes allowing further optimization of 
activity and properties.  By studying these enzymes and combining RiPPs with mRNA display, 
testing and optimizing these peptide products can lead to novel therapeutics for today’s most 
pressing and troubling diseases. 
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APPENDIX A. SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 2 
Figure A.1.  Radical cleavage of SAM by CteB and variants.  In black is the extracted ion 
chromatogram (EIC) of SAM (399.1445) and in red is the EIC of the 5’-deoxyadensosine 
(252.1091) product formed by radical cleavage of SAM. 
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Figures A.2. Peptide Modification Assays-CteB Variants. In black is the mass spec 
chromatogram of the SNA-CteA construct without CteB.  In red is the mass spec chromatogram 
of the SNA-CteA construct treated with CteB or its variants.   
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Figures A.3. Peptide Modification Assays-CteA Variants. In black is the mass spec 
chromatogram of the SNA-CteA or its variants without CteB.  In red is the mass spec 
chromatogram of the SNA-CteA or its variants treated with CteB. 
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Table A.1. Crystallography Table: Data collection and refinement statistics 
 
 CteB+SAM+CteA 
(M1-C21) anomalous
1
 
CteB+SAM+CteA 
(M1-C21) 
2
 
CteB+SAM
3 
Data collection    
Wavelength (Å) 1.3776 1.0781 1.0333 
Space group P21212 P21212 P1 
Cell dimensions    
    α, β, γ (°) 90, 90, 90 90, 90, 90 83.09, 73.31, 66.63 
    a, b, c (Å) 69.74, 154.02, 51.93 68.92, 153.77, 51.82 51.93, 50.36, 81.36 
Resolution (Å) 30.00-2.21 (2.33-2.21) 28.6-2.04 (2.11-2.04) 30.0-2.7 (2.79 – 2.70) 
Redundancy 14.0 (14.2) 4.5 (3.9) 1.8 (1.7) 
Completeness (%) 99.9 (100.0) 98.0 (89.4) 97.0 (90.0) 
<I /I> 21.0 (3.7) 10.47 (2.16) 6.56 (1.73) 
Wilson B-factor (Å
2
)  38.29  
Rmerge 0.088 (0.708) 0.06768 (0.506) 0.060 (0.423) 
Rmeasure 0.103 (0.758) 0.07639 (0.585) 0.0855 (0.604) 
CC1/2 0.999 (0.970) 0.997 (0.817) 0.994 (0.910) 
Refinement    
Resolution (Å)  30.0-2.04 30.0-2.70 
No. reflections  158251 (12163) 23100 (2125) 
Rwork / Rfree  0.2047/0.2343 0.2400/0.2481 
No. atoms  3794 6762 
    Protein  3622 6698 
    Ligand/ion  26 53 
Water  146 11 
B-factors (Å
2
)    
    Protein  57.4 78.6 
    Ligand/ion  44.8 70.9 
    Water  52.4 60.8 
R.m.s. deviations    
    Bond lengths (Å)  0.006 0.021 
    Bond angles ()  1.580 1.970 
Ramachandran analysis    
    Favored (%)  98 98 
    Allowed (%)  2 2.1 
    Outliers (%)  0 0.12 
1
Data collected at LRL-CAT beamline 31-ID-G 
2
Data collected at LS-CAT beamline 21-ID-D 
3
Data collected at GM/CA-CAT beamline 23-ID-D 
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Figure A.4.  Size Exclusion Chromatography of TEV cleaved CteB crystals. For this SEC, 
crystals were combined and passed over the size exclusion column in the same manner as before. 
This shows that CteB can form an intermolecular disulfide bond in the crystal packing. 
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Figure A.5.  Size Exclusion Chromatography of TEV cleaved CteB.  Whether the substrate is 
present or not, the data suggests that CteB is a monomer.  The data is in good agreeance with the 
standards as well. 
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Figure A.6.  Non-reducing, denaturing SDS-Page Gel of CteB.  CteB (after size-exclusion 
without DTT) at 35 μM in mixed with varying ratios of 10 mM GSH (reduced 
glutathione):GSSG (oxidized glutathione). CteB cannot form a disulfide-linked dimer in 
solution. CteB monomer is ~54.68 kDa. 
 
 
 
 
Figure A.7.  Non-reducing, denaturing SDS-Page Gel of CteA-CteB Complex.  Incubating CteA 
and CteB in solutions with varying ratios of GSH (reduced glutathione): GSSG (oxidized 
glutathione) shows that a CteA-CteB complex is forming and not a dimer of CteB. CteB 
monomer is ~54.68 kDa and the CteA-CteB complex is ~59.86 kDa. 
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Figure A.8. Location of possible disulfide bond between symmetry mates of CteB.  a) Overall 
structure of CteB+SAM+CteA 21mer showing the 2-fold symmetry axis (red ellipse) between 
two molecules of CteB from adjacent asymmetric units.  The red circle denotes an area of weak 
electron density that connects the two symmetry mates.  b) Zoomed in view of the red circle.  
The electron density (2Fo-Fc is shown in green) is weak in this area with a break (dashed lines) 
between residue Q333 and I337.  An area of density connects the symmetry mates where C336 
should be located.  
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Figure A.9. Structural comparison CteB to anSME.  a) Residues 90-449 CteB (colored as in 
Figure 2.3) overlaid with anSME (gray, 4K38).  Despite sharing only 20 % sequence identity, 
CteB and anSME overlay with and R.M.S.D of 2.52 Å.  b)  Active site of CteB showing SAM 
(grey sticks) bound to the RS cluster along with absolutely conserved amino acids (shown as 
sticks and colored by domain location as in a) found in the active site based on proximity to the 
overlaid peptide substrate (grey, Kp18Cys) of anSME from the pdb 4K38.  His-363 occupies the 
same location as the active site base Asp-277 (blue) of anSME.  The role of the remaining 
residues are likely hydrogen bonding interactions for proper orientation of the peptide substrate.  
c) SAM binding interactions with CteB. d)  Overlay of SPASM domains from CteB (orange) and 
anSME (gray, 4K38).  The overall secondary structural elements (R.M.S.D. of 2.3 Å) are highly 
conserved between these domains despite the difference in cluster coordination and substrate 
sequences. 
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Figure A.10. Fe edge anomalous difference electron density map. The Fe anomalous difference 
electron density map (brown mesh) contoured at 4.0σ.  SAM is shown in grey sticks with a 
simulated annealing omit composite map (2F
o
-F
c
) contoured to 1.5 σ. 
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Figure A.11.  Structural Alignment of CteB+SAM+CteA and Apo-CteB. Using Pymol, 
structural alignments were created between CteB+SAM+CteA and apo-CteB monomers.  In 
color is the CteA bound-CteB monomer while in gray is the apo-CteB monomer.  An overall 
alignment (residues 1-450) created a C RMSD of 1.318 Å
2
 while an active site alignment 
(residues 76-450) created a C RMSD of 1.279 Å
2
.    
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Figure A.12.  Sequence Similarity Network of rSAM-Pfam (PF04055).  Acquired by using the 
online EFI-Enzyme Similarity Tool (http://efi.igb.illinois.edu/efi-est/stepa.php).
1
 Used the 
following parameters: E-value: -5, Alignment score of 40, 200-500 amino acids in length, 40% 
identity.  Important rSAM enzymes marked by a big red square and labeled. 
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Figure A.13. Alignment of characterized radical SAM enzymes.  Alignment was generated 
using MUSCLE with default parameters.  100% similarity = red, 75% similarity = blue, 50% 
similarity = gray.  Black arrows point to cysteines that ligate the SAM 4Fe-4S center. Red arrows 
point to seven cysteine motif that corresponds to the SPASM domain in CteB. 
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Figure A.14. Alignment of characterized sactionine synthases. Alignment was generated using 
MUSCLE with default parameters.  100% similarity = red, 75% similarity = blue, 50% similarity 
= gray.  Red arrows point to seven cysteine motif that corresponds to the SPASM domain. 
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Figure A.15. SPASM Domain Logo Analysis of SCIFF radical SAM maturases (IPR024025).  
An analysis of the SPASM domain of SCIFF radical SAM maturases that contain relevant 
cysteines that ligate 4Fe-4S centers.  An alignment was generated using MUSCLE with default 
parameters with all members of the protein family IPR024025 (952 sequences).  From this 
alignment, the SPASM domain was located and the sequences were imported to WebLogo 
software (internet version 3)
2,3
 to create the sequence logos below.  The cysteines labeled 
represent the cysteines found in CteB and their respective locations in the CteB protein sequence. 
Cysteines 344, 362, and 413 ligate AuxI while cysteines 400, 403, 409, and 432 ligate AuxII in 
the CteB structure. 
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Figure A.16. Comparison of anSME and CteB active site volumes. (a and b) Calculated volumes 
for anSME (PDB 4K36) and CteB, respectively, were generated using the 3Vee, volume 
calculator (http://3vee.molmovdb.org).
4
 The settings were: grid resolution-low, small probe-2.0, 
and big probe-9.0 
 
a  anSME- Calculated vol.= 1760Å3                              b  CteB- Calculated vol.= 2997 Å3 
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Figure A.17. Secondary Structure Prediction of CteA.  Jpred was ran for a secondary structure 
prediction for CteA.  It concurs with the presence of a helical region in the peptide present in the 
model. Green arrows indicate predicted -strands while red tubes indicate predicted -helices. 
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Figure A.18. Full Model of CteA bound to CteB. a) Model depicting a possible interaction of 
CteA with CteB using the parameters described in Experimental Section 2.7.8.  CteB is colored 
as in Figure 2.3 while CteA is in yellow.  Two lowest energy conformations are depicted here for 
CteA. b)  Zoom in on the active site of the model.  This shows CteA-C32 ligating the open 
coordination site in Aux I while CteA-T37 is in close proximity to SAM. 
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APPENDIX B. SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 3 
Figure B.1-B.27. Mass spectrometry (spec.) and tandem mass spec. analysis for the 
determination of bridging partner residues. 
 
 
174 
 
 
175 
 
 
176 
 
 
177 
 
 
178 
 
 
179 
 
 
180 
 
 
181 
 
 
182 
 
 
183 
 
 
184 
 
 
185 
 
 
186 
 
 
Figure B.28. 12%-SDS-PAGE gel showing increased expression of AlbA in vector pETDuet-
SboA-AlbA with corrector plasmid pPH151 in BL21 cells.  Time points shown at 0 and 20 hours 
of induction with 0.5 mM IPTG. 
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Figure B.29. UV comparison of the natural product subtilosin A vs. the wild-type (WT) and 
several mutants produced in the pETDuet system at 50 rpm.  The UV was monitored at 220 nm. 
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Table B.1. List of mutants made and produced in this study.  Additional columns show the area 
under the curves of the EICs and their respected ratios with respect to (w.r.t.) the wild-type (WT) 
EIC.  EICs shown in Figures B.30-B.59. 
 
 
 
 
 
189 
 
 
190 
 
 
191 
 
 
192 
 
 
193 
 
 
194 
 
APPENDIX C. SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 4 
Figure C.1. Alignment of PaaP and its homologs. Alignment was generated using MUSCLE 
with default parameters.  100% similarity = red, 75% similarity = blue, 50% similarity = gray.   
 
 
Figure C.2. Logo Analysis of Alignment above. From the alignment, the sequences were 
imported to WebLogo software (internet version 3)
1,2
 to create the sequence logos below. 
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